<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Multiple sclerosis - Wikipedia, the free encyclopedia</title>
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />
<meta name="generator" content="MediaWiki 1.23wmf18" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Multiple_sclerosis" />
<link rel="apple-touch-icon" href="//bits.wikimedia.org/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="//bits.wikimedia.org/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="http://en.wikipedia.org/wiki/Multiple_sclerosis" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.ui.button%7Cskins.common.interface%7Cskins.vector.styles&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: enwiki:resourceloader:filter:minify-css:7:3904d24a08aa08f6a68dc338f9be277e */</style>

<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Multiple_sclerosis","wgTitle":"Multiple sclerosis","wgCurRevisionId":600986501,"wgRevisionId":600986501,"wgArticleId":50603,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Pages containing cite templates with deprecated parameters","Use dmy dates from March 2014","Wikipedia indefinitely semi-protected pages","Articles with Open Directory Project links","Featured articles","Multiple sclerosis","Epstein–Barr virus-associated diseases"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Multiple_sclerosis","wgIsProbablyEditable":false,"wgRestrictionEdit":["autoconfirmed"],"wgRestrictionMove":["autoconfirmed"],"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"templateEditor":false,"templates":false,"preview":false,"previewDialog":false,"publish":false,"toc":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"isPageWatched":false,"magnifyClipIconURL":"//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png","pageLanguageCode":"en","pageLanguageDir":"ltr","svgMaxSize":2048},"wikilove-recipient":"","wikilove-anon":0,"wgGuidedTourHelpGuiderUrl":"Help:Guided tours/guider","wgFlowTermsOfUseEdit":"By saving changes, you agree to our \u003Ca class=\"external text\" href=\"//wikimediafoundation.org/wiki/Terms_of_use\"\u003ETerms of Use\u003C/a\u003E and agree to irrevocably release your text under the \u003Ca rel=\"nofollow\" class=\"external text\" href=\"//creativecommons.org/licenses/by-sa/3.0\"\u003ECC BY-SA 3.0 License\u003C/a\u003E and \u003Ca class=\"external text\" href=\"//en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License\"\u003EGFDL\u003C/a\u003E","wgULSAcceptLanguageList":["en-us"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q8277"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function(){mw.user.options.set({"ccmeonemails":0,"cols":80,"date":"default","diffonly":0,"disablemail":0,"editfont":"default","editondblclick":0,"editsectiononrightclick":0,"enotifminoredits":0,"enotifrevealaddr":0,"enotifusertalkpages":1,"enotifwatchlistpages":0,"extendwatchlist":0,"fancysig":0,"forceeditsummary":0,"gender":"unknown","hideminor":0,"hidepatrolled":0,"imagesize":2,"math":0,"minordefault":0,"newpageshidepatrolled":0,"nickname":"","norollbackdiff":0,"numberheadings":0,"previewonfirst":0,"previewontop":1,"rcdays":7,"rclimit":50,"rememberpassword":0,"rows":25,"showhiddencats":false,"shownumberswatching":1,"showtoolbar":1,"skin":"vector","stubthreshold":0,"thumbsize":4,"underline":2,"uselivepreview":0,"usenewrc":0,"watchcreations":1,"watchdefault":0,"watchdeletion":0,"watchlistdays":3,"watchlisthideanons":0,"watchlisthidebots":0,"watchlisthideliu":0,"watchlisthideminor":0,"watchlisthideown":0,"watchlisthidepatrolled":0,"watchmoves":0,
"wllimit":250,"useeditwarning":1,"prefershttps":1,"flaggedrevssimpleui":1,"flaggedrevsstable":0,"flaggedrevseditdiffs":true,"flaggedrevsviewdiffs":false,"usebetatoolbar":1,"usebetatoolbar-cgd":1,"visualeditor-enable":0,"visualeditor-enable-experimental":0,"visualeditor-enable-mwmath":0,"visualeditor-betatempdisable":0,"wikilove-enabled":1,"echo-subscriptions-web-page-review":true,"echo-subscriptions-email-page-review":false,"ep_showtoplink":false,"ep_bulkdelorgs":false,"ep_bulkdelcourses":true,"ep_showdyk":true,"echo-subscriptions-web-education-program":true,"echo-subscriptions-email-education-program":false,"echo-notify-show-link":true,"echo-show-alert":true,"echo-email-frequency":0,"echo-email-format":"html","echo-subscriptions-email-system":true,"echo-subscriptions-web-system":true,"echo-subscriptions-email-other":false,"echo-subscriptions-web-other":true,"echo-subscriptions-email-edit-user-talk":false,"echo-subscriptions-web-edit-user-talk":true,"echo-subscriptions-email-reverted":
false,"echo-subscriptions-web-reverted":true,"echo-subscriptions-email-article-linked":false,"echo-subscriptions-web-article-linked":false,"echo-subscriptions-email-mention":false,"echo-subscriptions-web-mention":true,"echo-subscriptions-web-edit-thank":true,"echo-subscriptions-email-edit-thank":false,"echo-subscriptions-web-flow-discussion":true,"echo-subscriptions-email-flow-discussion":false,"gettingstarted-task-toolbar-show-intro":true,"uls-preferences":"","language":"en","variant-gan":"gan","variant-iu":"iu","variant-kk":"kk","variant-ku":"ku","variant-shi":"shi","variant-sr":"sr","variant-tg":"tg","variant-uz":"uz","variant-zh":"zh","searchNs0":true,"searchNs1":false,"searchNs2":false,"searchNs3":false,"searchNs4":false,"searchNs5":false,"searchNs6":false,"searchNs7":false,"searchNs8":false,"searchNs9":false,"searchNs10":false,"searchNs11":false,"searchNs12":false,"searchNs13":false,"searchNs14":false,"searchNs15":false,"searchNs100":false,"searchNs101":false,"searchNs108":false,
"searchNs109":false,"searchNs118":false,"searchNs119":false,"searchNs446":false,"searchNs447":false,"searchNs710":false,"searchNs711":false,"searchNs828":false,"searchNs829":false,"gadget-teahouse":1,"gadget-ReferenceTooltips":1,"gadget-DRN-wizard":1,"gadget-charinsert":1,"gadget-mySandbox":1,"variant":"en"});},{},{});mw.loader.implement("user.tokens",function(){mw.user.tokens.set({"editToken":"+\\","patrolToken":false,"watchToken":false});},{},{});
/* cache key: enwiki:resourceloader:filter:minify-js:7:0378eace27e3aee431624f77f4809281 */
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","wikibase.client.init","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" /><!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static-1.23wmf18/skins/vector/csshover.min.htc")}</style><![endif]--></head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Multiple_sclerosis skin-vector action-view vector-animateLayout">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="mw-js-message" style="display:none;"></div>
						<div id="siteNotice"><!-- CentralNotice --></div>
						<h1 id="firstHeading" class="firstHeading" lang="en"><span dir="auto">Multiple sclerosis</span></h1>
			<div id="bodyContent">
								<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-navigation">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="metadata topicon nopopups" id="protected-icon" style="display:none; right:55px;"><a href="/wiki/Wikipedia:Protection_policy#semi" title="This article is semi-protected indefinitely in response to an ongoing high risk of vandalism."><img alt="Page semi-protected" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/20px-Padlock-silver.svg.png" width="20" height="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/30px-Padlock-silver.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/40px-Padlock-silver.svg.png 2x" /></a></div>
<table class="infobox" cellspacing="3" style="border-spacing:3px;width:22em;">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey;">Multiple sclerosis</th>
</tr>
<tr>
<td colspan="2" style="text-align:center;"><i>Classification and external resources</i></td>
</tr>
<tr>
<td colspan="2" style="text-align:center;"><a href="/wiki/File:MS_Demyelinisation_CD68_10xv2.jpg" class="image"><img alt="MS Demyelinisation CD68 10xv2.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/59/MS_Demyelinisation_CD68_10xv2.jpg/230px-MS_Demyelinisation_CD68_10xv2.jpg" width="230" height="171" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/59/MS_Demyelinisation_CD68_10xv2.jpg/345px-MS_Demyelinisation_CD68_10xv2.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/59/MS_Demyelinisation_CD68_10xv2.jpg/460px-MS_Demyelinisation_CD68_10xv2.jpg 2x" /></a><br />
<div>Demyelination by MS. The <a href="/wiki/CD68" title="CD68">CD68</a> colored tissue shows several <a href="/wiki/Macrophage" title="Macrophage">macrophages</a> in the area of the lesion. Original scale 1:100</div>
</td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a href="/wiki/ICD-10_Chapter_G" title="ICD-10 Chapter G" class="mw-redirect">G</a><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2010/en#/G35">35</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=340">340</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/OMIM" title="OMIM" class="mw-redirect">OMIM</a></th>
<td><a rel="nofollow" class="external text" href="http://omim.org/entry/126200">126200</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb8412.htm">8412</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000737.htm">000737</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/neuro/topic228.htm">neuro/228</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/oph/topic179.htm#">oph/179</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/emerg/topic321.htm#">emerg/321</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/pmr/topic82.htm#">pmr/82</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/radio/topic461.htm#">radio/461</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&amp;term=D009103">D009103</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/GeneReviews" title="GeneReviews">GeneReviews</a></th>
<td class="plainlist">
<ul>
<li><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/books/NBK1316/">Overview</a></li>
</ul>
</td>
</tr>
</table>
<p><b>Multiple sclerosis</b> (<b>MS</b>), also known as <b>disseminated sclerosis</b> or <b>encephalomyelitis disseminata</b>, is an <a href="/wiki/Inflammation" title="Inflammation">inflammatory</a> disease in which the <a href="/wiki/Myelin_sheaths" title="Myelin sheaths" class="mw-redirect">insulating covers</a> of <a href="/wiki/Neurons" title="Neurons" class="mw-redirect">nerve cells</a> in the <a href="/wiki/Human_brain" title="Human brain">brain</a> and <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a> are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of <a href="/wiki/Medical_sign" title="Medical sign">signs</a> and <a href="/wiki/Symptom" title="Symptom">symptoms</a>,<sup id="cite_ref-pmid18970977_1-0" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid11955556_2-0" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> including physical, <a href="/wiki/Cognitive_disability" title="Cognitive disability" class="mw-redirect">mental</a>,<sup id="cite_ref-pmid11955556_2-1" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> and sometimes psychiatric problems.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span>[</span>3<span>]</span></a></sup> MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms).<sup id="cite_ref-pmid8780061_4-0" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup> Between attacks, symptoms may go away completely; however, permanent neurological problems often occur, especially as the disease advances.<sup id="cite_ref-pmid8780061_4-1" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup></p>
<p>While the cause is not clear, the underlying mechanism is thought to be either <a href="/wiki/Autoimmune_disease" title="Autoimmune disease">destruction by the immune system</a> or failure of the <a href="/wiki/Myelin" title="Myelin">myelin</a>-producing cells.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup> Proposed causes for this include <a href="/wiki/Genetics" title="Genetics">genetics</a> and environmental factors such as <a href="/wiki/Infection" title="Infection">infections</a>.<sup id="cite_ref-pmid11955556_2-2" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-pmid17444504_6-0" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup> MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.</p>
<p>There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks.<sup id="cite_ref-pmid11955556_2-3" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> Medications used to treat MS while modestly effective can have adverse effects and be poorly tolerated. Many people pursue alternative treatments, despite a lack of evidence. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks.<sup id="cite_ref-pmid8017890_7-0" class="reference"><a href="#cite_note-pmid8017890-7"><span>[</span>7<span>]</span></a></sup> <a href="/wiki/Life_expectancy" title="Life expectancy">Life expectancy</a> is 5 to 10 years lower than that of an unaffected population.<sup id="cite_ref-pmid18970977_1-1" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<p>As of 2008, between 2 and 2.5 million people are affected globally with rates varying widely in different regions of the world and among different populations.<sup id="cite_ref-Atlas2008_8-0" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup> The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men.<sup id="cite_ref-Milo2010_9-0" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> The name <i>multiple sclerosis</i> refers to scars (sclerae—better known as plaques or lesions) in particular in the <a href="/wiki/White_matter" title="White matter">white matter</a> of the brain and spinal cord.<sup id="cite_ref-Charcot1_10-0" class="reference"><a href="#cite_note-Charcot1-10"><span>[</span>10<span>]</span></a></sup> MS was first described in 1868 by <a href="/wiki/Jean-Martin_Charcot" title="Jean-Martin Charcot">Jean-Martin Charcot</a>.<sup id="cite_ref-Charcot1_10-1" class="reference"><a href="#cite_note-Charcot1-10"><span>[</span>10<span>]</span></a></sup> A number of new treatments and diagnostic methods are under development.</p>
<div class="toclimit-3">
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Signs_and_symptoms"><span class="tocnumber">1</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Causes"><span class="tocnumber">2</span> <span class="toctext">Causes</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Geography"><span class="tocnumber">2.1</span> <span class="toctext">Geography</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Genetics"><span class="tocnumber">2.2</span> <span class="toctext">Genetics</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Infectious_agents"><span class="tocnumber">2.3</span> <span class="toctext">Infectious agents</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Other"><span class="tocnumber">2.4</span> <span class="toctext">Other</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Lesions"><span class="tocnumber">3.1</span> <span class="toctext">Lesions</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Inflammation"><span class="tocnumber">3.2</span> <span class="toctext">Inflammation</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Blood.E2.80.93brain_barrier"><span class="tocnumber">3.3</span> <span class="toctext">Blood–brain barrier</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#Clinical_courses"><span class="tocnumber">4.1</span> <span class="toctext">Clinical courses</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-13"><a href="#Management"><span class="tocnumber">5</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-14"><a href="#Acute_attacks"><span class="tocnumber">5.1</span> <span class="toctext">Acute attacks</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Disease-modifying_treatments"><span class="tocnumber">5.2</span> <span class="toctext">Disease-modifying treatments</span></a>
<ul>
<li class="toclevel-3 tocsection-16"><a href="#Relapsing_remitting_multiple_sclerosis"><span class="tocnumber">5.2.1</span> <span class="toctext">Relapsing remitting multiple sclerosis</span></a></li>
<li class="toclevel-3 tocsection-17"><a href="#Progressive_multiple_sclerosis"><span class="tocnumber">5.2.2</span> <span class="toctext">Progressive multiple sclerosis</span></a></li>
<li class="toclevel-3 tocsection-18"><a href="#Adverse_effects"><span class="tocnumber">5.2.3</span> <span class="toctext">Adverse effects</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-19"><a href="#Associated_symptoms"><span class="tocnumber">5.3</span> <span class="toctext">Associated symptoms</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Alternative_treatments"><span class="tocnumber">5.4</span> <span class="toctext">Alternative treatments</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-21"><a href="#Prognosis"><span class="tocnumber">6</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1 tocsection-22"><a href="#Epidemiology"><span class="tocnumber">7</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-23"><a href="#History"><span class="tocnumber">8</span> <span class="toctext">History</span></a>
<ul>
<li class="toclevel-2 tocsection-24"><a href="#Medical_discovery"><span class="tocnumber">8.1</span> <span class="toctext">Medical discovery</span></a></li>
<li class="toclevel-2 tocsection-25"><a href="#Historical_cases"><span class="tocnumber">8.2</span> <span class="toctext">Historical cases</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-26"><a href="#Research"><span class="tocnumber">9</span> <span class="toctext">Research</span></a>
<ul>
<li class="toclevel-2 tocsection-27"><a href="#Medications"><span class="tocnumber">9.1</span> <span class="toctext">Medications</span></a></li>
<li class="toclevel-2 tocsection-28"><a href="#Disease_biomarkers"><span class="tocnumber">9.2</span> <span class="toctext">Disease biomarkers</span></a></li>
<li class="toclevel-2 tocsection-29"><a href="#Chronic_cerebrospinal_venous_insufficiency"><span class="tocnumber">9.3</span> <span class="toctext">Chronic cerebrospinal venous insufficiency</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-30"><a href="#See_also"><span class="tocnumber">10</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-31"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-32"><a href="#Further_reading"><span class="tocnumber">12</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-33"><a href="#External_links"><span class="tocnumber">13</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span></h2>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Multiple_sclerosis_signs_and_symptoms" title="Multiple sclerosis signs and symptoms">Multiple sclerosis signs and symptoms</a></div>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Symptoms_of_multiple_sclerosis.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/bf/Symptoms_of_multiple_sclerosis.svg/220px-Symptoms_of_multiple_sclerosis.svg.png" width="220" height="335" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/bf/Symptoms_of_multiple_sclerosis.svg/330px-Symptoms_of_multiple_sclerosis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bf/Symptoms_of_multiple_sclerosis.svg/440px-Symptoms_of_multiple_sclerosis.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Symptoms_of_multiple_sclerosis.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Main symptoms of multiple sclerosis</div>
</div>
</div>
<p>A person with MS can have almost any neurological symptom or sign; with <a href="/wiki/Autonomic_nervous_system" title="Autonomic nervous system">autonomic</a>, visual, motor, and sensory problems being the most common.<sup id="cite_ref-pmid18970977_1-2" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> The specific symptoms are determined by the locations of the lesions within the nervous system, and may include <a href="/wiki/Hypoesthesia" title="Hypoesthesia">loss of sensitivity</a> or <a href="/wiki/Paresthesia" title="Paresthesia">changes in sensation</a> such as tingling, pins and needles or numbness, muscle weakness, <a href="/wiki/Clonus" title="Clonus">very pronounced reflexes</a>, <a href="/wiki/Muscle_spasms" title="Muscle spasms" class="mw-redirect">muscle spasms</a>, or difficulty in moving; difficulties with coordination and balance (<a href="/wiki/Ataxia" title="Ataxia">ataxia</a>); <a href="/wiki/Dysarthria" title="Dysarthria">problems with speech</a> or <a href="/wiki/Dysphagia" title="Dysphagia">swallowing</a>, visual problems (<a href="/wiki/Nystagmus" title="Nystagmus">nystagmus</a>, <a href="/wiki/Optic_neuritis" title="Optic neuritis">optic neuritis</a> or <a href="/wiki/Diplopia" title="Diplopia">double vision</a>), <a href="/wiki/Fatigue_(physical)" title="Fatigue (physical)" class="mw-redirect">feeling tired</a>, <a href="/wiki/Acute_pain" title="Acute pain" class="mw-redirect">acute</a> or <a href="/wiki/Chronic_pain" title="Chronic pain">chronic pain</a>, and bladder and bowel difficulties, among others.<sup id="cite_ref-pmid18970977_1-3" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Difficulties thinking and emotional problems such as <a href="/wiki/Clinical_depression" title="Clinical depression" class="mw-redirect">depression</a> or <a href="/wiki/Labile_affect" title="Labile affect" class="mw-redirect">unstable mood</a> are also common.<sup id="cite_ref-pmid18970977_1-4" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> <a href="/wiki/Uhthoff%27s_phenomenon" title="Uhthoff's phenomenon">Uhthoff's phenomenon</a>, a worsening of symptoms due to exposure to higher than usual temperatures, and <a href="/wiki/Lhermitte%27s_sign" title="Lhermitte's sign">Lhermitte's sign</a>, an electrical sensation that runs down the back when bending the neck, are particularly characteristic of MS.<sup id="cite_ref-pmid18970977_1-5" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> The main measure of disability and severity is the <a href="/wiki/Expanded_disability_status_scale" title="Expanded disability status scale" class="mw-redirect">expanded disability status scale</a> (EDSS), with other measures such as the <a href="/wiki/Multiple_sclerosis_functional_composite" title="Multiple sclerosis functional composite">multiple sclerosis functional composite</a> being increasingly used in research.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-pmid10467378_12-0" class="reference"><a href="#cite_note-pmid10467378-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-pmid12356200_13-0" class="reference"><a href="#cite_note-pmid12356200-13"><span>[</span>13<span>]</span></a></sup></p>
<p>The condition begins in 85% of cases as a clinically isolated syndrome over a number of days with 45% having motor or sensory problems, 20% having optic neuritis, and 10% having symptoms related to <a href="/wiki/Brainstem" title="Brainstem">brainstem</a> dysfunction, while the remaining 25% have more than one of the previous difficulties.<sup id="cite_ref-Tsang2011_14-0" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> The course of symptoms occurs in two main patterns initially: either as episodes of sudden worsening that last a few days to months (called <a href="/wiki/Relapse" title="Relapse">relapses</a>, exacerbations, bouts, attacks, or flare-ups) followed by improvement (85% of cases) or as a gradual worsening over time without periods of recovery (10-15% of cases).<sup id="cite_ref-Milo2010_9-1" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> A combination of these two patterns may also occur<sup id="cite_ref-pmid8780061_4-2" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup> or people may start in a relapsing and remitting course that then becomes progressive later on.<sup id="cite_ref-Milo2010_9-2" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> Relapses are usually not predictable, occurring without warning.<sup id="cite_ref-pmid18970977_1-6" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Exacerbations rarely occur more frequently than twice per year.<sup id="cite_ref-pmid18970977_1-7" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Some relapses, however, are preceded by common triggers and they occur more frequently during spring and summer.<sup id="cite_ref-pmid16804331_15-0" class="reference"><a href="#cite_note-pmid16804331-15"><span>[</span>15<span>]</span></a></sup> Similarly, viral infections such as the <a href="/wiki/Common_cold" title="Common cold">common cold</a>, <a href="/wiki/Influenza" title="Influenza">influenza</a>, or <a href="/wiki/Gastroenteritis" title="Gastroenteritis">gastroenteritis</a> increase their risk.<sup id="cite_ref-pmid18970977_1-8" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> <a href="/wiki/Stress_(medicine)" title="Stress (medicine)" class="mw-redirect">Stress</a> may also trigger an attack.<sup id="cite_ref-pmid17439878_16-0" class="reference"><a href="#cite_note-pmid17439878-16"><span>[</span>16<span>]</span></a></sup> Women with MS <a href="/wiki/Intercurrent_disease_in_pregnancy" title="Intercurrent disease in pregnancy">who become pregnant</a> experience less relapses; however, during the first months after delivery the risk increases.<sup id="cite_ref-pmid18970977_1-9" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Overall, pregnancy does not seem to influence long-term disability.<sup id="cite_ref-pmid18970977_1-10" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Many events have not been found to affect relapse rates including vaccination, breast feeding,<sup id="cite_ref-pmid18970977_1-11" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> physical trauma,<sup id="cite_ref-pmid11205361_17-0" class="reference"><a href="#cite_note-pmid11205361-17"><span>[</span>17<span>]</span></a></sup> and Uhthoff's phenomenon.<sup id="cite_ref-pmid16804331_15-1" class="reference"><a href="#cite_note-pmid16804331-15"><span>[</span>15<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Causes">Causes</span></h2>
<p>The cause of MS is unknown; however, it is believed to occur as a result of some combination of environmental factors such as infectious agents and genetics.<sup id="cite_ref-pmid18970977_1-12" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Theories try to combine the data into likely explanations, but none has proved definitive. While there are a number of environmental risk factors and although some are partly modifiable, further research is needed to determine whether their elimination can prevent MS.<sup id="cite_ref-pmid15556803_18-0" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Geography">Geography</span></h3>
<p>MS is more common in people who live farther from the <a href="/wiki/Equator" title="Equator">equator</a>, although exceptions exist.<sup id="cite_ref-pmid18970977_1-13" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid18606967_19-0" class="reference"><a href="#cite_note-pmid18606967-19"><span>[</span>19<span>]</span></a></sup> These exceptions include ethnic groups that are at low risk far from the equator such as the <a href="/wiki/Sami_people" title="Sami people">Samis</a>, <a href="/wiki/Indigenous_peoples_of_the_Americas" title="Indigenous peoples of the Americas">Amerindians</a>, Canadian <a href="/wiki/Hutterite" title="Hutterite">Hutterites</a>, New Zealand <a href="/wiki/M%C4%81ori_people" title="Māori people">Māori</a>,<sup id="cite_ref-pmid12127652_20-0" class="reference"><a href="#cite_note-pmid12127652-20"><span>[</span>20<span>]</span></a></sup> and Canada's <a href="/wiki/Inuit" title="Inuit">Inuit</a>,<sup id="cite_ref-Milo2010_9-3" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> as well as groups that have a relatively high risk close to the equator such as <a href="/wiki/Sardinians" title="Sardinians" class="mw-redirect">Sardinians</a>,<sup id="cite_ref-Milo2010_9-4" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> <a href="/wiki/Palestinians" title="Palestinians" class="mw-redirect">Palestinians</a> and <a href="/wiki/Parsis" title="Parsis" class="mw-redirect">Parsis</a>.<sup id="cite_ref-pmid12127652_20-1" class="reference"><a href="#cite_note-pmid12127652-20"><span>[</span>20<span>]</span></a></sup> The cause of this geographical pattern is not clear.<sup id="cite_ref-Milo2010_9-5" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> While the north-south gradient of incidence is decreasing,<sup id="cite_ref-pmid18606967_19-1" class="reference"><a href="#cite_note-pmid18606967-19"><span>[</span>19<span>]</span></a></sup> as of 2010 it is still present.<sup id="cite_ref-Milo2010_9-6" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup></p>
<p>MS is more common in regions with northern European populations<sup id="cite_ref-pmid18970977_1-14" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> and the geographic variation may simply reflect the global distribution of these high-risk populations.<sup id="cite_ref-Milo2010_9-7" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> Decreased sunlight exposure resulting in decreased <a href="/wiki/Vitamin_D" title="Vitamin D">vitamin D</a> production has also been put forward as an explanation.<sup id="cite_ref-pmid17492755_21-0" class="reference"><a href="#cite_note-pmid17492755-21"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-pmid20494325_22-0" class="reference"><a href="#cite_note-pmid20494325-22"><span>[</span>22<span>]</span></a></sup> A relationship between season of birth and MS lends support to this idea, with fewer people born in the northern hemisphere in November as compared to May being affected later in life.<sup id="cite_ref-pmid19897699_23-0" class="reference"><a href="#cite_note-pmid19897699-23"><span>[</span>23<span>]</span></a></sup> Environmental factors may play a role during childhood, with several studies finding that people who move to a different region of the world before the age of 15 acquire the new region's risk to MS. If migration takes place after age 15, however, the person retains the risk of his home country.<sup id="cite_ref-pmid18970977_1-15" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid15556803_18-1" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup> There is some evidence that the effect of moving may still apply to people older than 15.<sup id="cite_ref-pmid18970977_1-16" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Genetics">Genetics</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:HLA.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/7/77/HLA.svg/220px-HLA.svg.png" width="220" height="416" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/7/77/HLA.svg/330px-HLA.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/77/HLA.svg/440px-HLA.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:HLA.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
HLA region of Chromosome&#160;6. Changes in this area increase the probability of getting MS.</div>
</div>
</div>
<p>MS is not considered a <a href="/wiki/Hereditary" title="Hereditary" class="mw-redirect">hereditary</a> disease; however, a number of <a href="/wiki/Genetics" title="Genetics">genetic variations</a> have been shown to increase the risk.<sup id="cite_ref-pmid14747002_24-0" class="reference"><a href="#cite_note-pmid14747002-24"><span>[</span>24<span>]</span></a></sup> The probability is higher in relatives of an affected person, with a greater risk among those more closely related.<sup id="cite_ref-pmid11955556_2-4" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> In <a href="/wiki/Identical_twins" title="Identical twins" class="mw-redirect">identical twins</a> both are affected about 30% of the time, while around 5% for non-identical twins and 2.5% of siblings are affected with a lower percentage of half-siblings.<sup id="cite_ref-pmid18970977_1-17" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid11955556_2-5" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-25" class="reference"><a href="#cite_note-25"><span>[</span>25<span>]</span></a></sup> If both parents are affected the risk in their children is 10 times that of the general population.<sup id="cite_ref-Milo2010_9-8" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> MS is also more common in some ethnic groups than others.<sup id="cite_ref-pmid11603614_26-0" class="reference"><a href="#cite_note-pmid11603614-26"><span>[</span>26<span>]</span></a></sup></p>
<p>Specific <a href="/wiki/Gene" title="Gene">genes</a> that have been linked with MS include differences in the <a href="/wiki/Human_leukocyte_antigen" title="Human leukocyte antigen">human leukocyte antigen</a> (HLA) system—a group of genes on <a href="/wiki/Chromosome" title="Chromosome">chromosome</a> <a href="/wiki/Chromosome_6_(human)" title="Chromosome 6 (human)">6</a> that serves as the <a href="/wiki/Major_histocompatibility_complex" title="Major histocompatibility complex">major histocompatibility complex</a> (MHC).<sup id="cite_ref-pmid18970977_1-18" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> That changes in the HLA region are related to susceptibility has been known for over thirty years,<sup id="cite_ref-pmid21247752_27-0" class="reference"><a href="#cite_note-pmid21247752-27"><span>[</span>27<span>]</span></a></sup> and additionally this same region has been implicated in the development of other autoimmune diseases such as <a href="/wiki/Diabetes_type_I" title="Diabetes type I" class="mw-redirect">diabetes type I</a> and <a href="/wiki/Systemic_lupus_erythematosus" title="Systemic lupus erythematosus">systemic lupus erythematosus</a>.<sup id="cite_ref-pmid21247752_27-1" class="reference"><a href="#cite_note-pmid21247752-27"><span>[</span>27<span>]</span></a></sup> The most consistent finding is the association between multiple sclerosis and <a href="/wiki/Allele" title="Allele">alleles</a> of the MHC defined as <a href="/wiki/HLA-DR15" title="HLA-DR15">DR15</a> and <a href="/wiki/HLA-DQ6" title="HLA-DQ6">DQ6</a>.<sup id="cite_ref-pmid18970977_1-19" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Other loci have shown a protective effect, such as <a href="/wiki/HLA-C554" title="HLA-C554" class="mw-redirect">HLA-C554</a> and <a href="/wiki/HLA-DRB1" title="HLA-DRB1">HLA-DRB1</a>*11.<sup id="cite_ref-pmid18970977_1-20" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Overall, it has been estimated that HLA changes account for between 20 and 60% of the <a href="/wiki/Genetic_predisposition" title="Genetic predisposition">genetic predisposition</a>.<sup id="cite_ref-pmid21247752_27-2" class="reference"><a href="#cite_note-pmid21247752-27"><span>[</span>27<span>]</span></a></sup> Modern genetic methods (<a href="/wiki/Genome-wide_association_study" title="Genome-wide association study">genome-wide association studies</a>) have discovered at least twelve other genes outside the HLA <a href="/wiki/Locus_(genetics)" title="Locus (genetics)">locus</a> that modestly increase the probability of MS.<sup id="cite_ref-pmid21247752_27-3" class="reference"><a href="#cite_note-pmid21247752-27"><span>[</span>27<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Infectious_agents">Infectious agents</span></h3>
<p>Many <a href="/wiki/Microbes" title="Microbes" class="mw-redirect">microbes</a> have been proposed as triggers of MS, but none have been confirmed.<sup id="cite_ref-pmid11955556_2-6" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> Moving at an early age from one location in the world to another alters a person's subsequent risk of MS.<sup id="cite_ref-pmid17444504_6-1" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup> An explanation for this could be that some kind of infection, produced by a widespread microbe rather than a rare one, is related to the disease.<sup id="cite_ref-pmid17444504_6-2" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup> Proposed mechanisms include the <a href="/wiki/Hygiene_hypothesis" title="Hygiene hypothesis">hygiene hypothesis</a> and the prevalence hypothesis. The hygiene hypothesis proposes that exposure to certain infectious agents early in life is protective, the disease being a response to a late encounter with such agents.<sup id="cite_ref-pmid18970977_1-21" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> The prevalence hypothesis proposes that the disease is due to an infectious agent more common in regions where MS is common and where in most individuals it causes an ongoing infection without symptoms. Only in a few cases and after many years does it cause demyelination.<sup id="cite_ref-pmid17444504_6-3" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-pmid8269393_28-0" class="reference"><a href="#cite_note-pmid8269393-28"><span>[</span>28<span>]</span></a></sup> The hygiene hypothesis has received more support than the prevalence hypothesis.<sup id="cite_ref-pmid17444504_6-4" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup></p>
<p>Evidence for a virus as a cause include: the presence of <a href="/wiki/Oligoclonal_bands" title="Oligoclonal bands" class="mw-redirect">oligoclonal bands</a> in the brain and cerebrospinal fluid of most people with MS, the association of several viruses with human demyelination <a href="/wiki/Encephalomyelitis" title="Encephalomyelitis">encephalomyelitis</a>, and the occurrence of demyelination in animals caused by some viral infection.<sup id="cite_ref-pmid15721830_29-0" class="reference"><a href="#cite_note-pmid15721830-29"><span>[</span>29<span>]</span></a></sup> <a href="/wiki/Human_herpes_virus" title="Human herpes virus" class="mw-redirect">Human herpes viruses</a> are a candidate group of viruses. Individuals having never been infected by the <a href="/wiki/Epstein-Barr" title="Epstein-Barr" class="mw-redirect">Epstein-Barr</a> virus are at a reduced risk of getting MS, whereas those infected as young adults are at a greater risk than those having had it at a younger age.<sup id="cite_ref-pmid18970977_1-22" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid17444504_6-5" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup> Although some consider that this goes against the hygiene hypothesis, since the non-infected have probably experienced a more hygienic upbringing,<sup id="cite_ref-pmid17444504_6-6" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup> others believe that there is no contradiction, since it is a first encounter with the causative virus relatively late in life that is the trigger for the disease.<sup id="cite_ref-pmid18970977_1-23" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Other diseases that may be related include <a href="/wiki/Measles" title="Measles">measles</a>, <a href="/wiki/Mumps" title="Mumps">mumps</a> and <a href="/wiki/Rubella" title="Rubella">rubella</a>.<sup id="cite_ref-pmid18970977_1-24" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Other">Other</span></h3>
<p><a href="/wiki/Tobacco_smoking" title="Tobacco smoking">Smoking</a> has been shown to be an independent risk factor for MS.<sup id="cite_ref-pmid17492755_21-1" class="reference"><a href="#cite_note-pmid17492755-21"><span>[</span>21<span>]</span></a></sup> <a href="/wiki/Stress_(biological)" title="Stress (biological)" class="mw-redirect">Stress</a> may be a risk factor although the evidence to support this is weak.<sup id="cite_ref-pmid15556803_18-2" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup> Association with occupational exposures and <a href="/wiki/Toxin" title="Toxin">toxins</a>—mainly <a href="/wiki/Solvent" title="Solvent">solvents</a>—has been evaluated, but no clear conclusions have been reached.<sup id="cite_ref-pmid15556803_18-3" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup> <a href="/wiki/Vaccin" title="Vaccin" class="mw-redirect">Vaccinations</a> were studied as causal factors; however, most studies show no association.<sup id="cite_ref-pmid15556803_18-4" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup> Several other possible risk factors, such as <a href="/wiki/Diet_(nutrition)" title="Diet (nutrition)">diet</a> and <a href="/wiki/Hormone" title="Hormone">hormone</a> intake, have been looked at; however, evidence on their relation with the disease is "sparse and unpersuasive".<sup id="cite_ref-pmid17492755_21-2" class="reference"><a href="#cite_note-pmid17492755-21"><span>[</span>21<span>]</span></a></sup> <a href="/wiki/Gout" title="Gout">Gout</a> occurs less than would be expected and lower levels of <a href="/wiki/Uric_acid" title="Uric acid">uric acid</a> have been found in people with MS. This has led to the theory that uric acid is protective, although its exact importance remains unknown.<sup id="cite_ref-pmid18219824_30-0" class="reference"><a href="#cite_note-pmid18219824-30"><span>[</span>30<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h2>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Pathophysiology_of_multiple_sclerosis" title="Pathophysiology of multiple sclerosis">Pathophysiology of multiple sclerosis</a></div>
<p>The three main characteristics of MS are the formation of lesions in the <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> (also called plaques), inflammation, and the destruction of <a href="/wiki/Myelin_sheath" title="Myelin sheath" class="mw-redirect">myelin sheaths</a> of neurons. These features interact in a complex and not yet fully understood manner to produce the breakdown of nerve tissue and in turn the signs and symptoms of the disease.<sup id="cite_ref-pmid18970977_1-25" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Additionally MS is believed to be an <a href="/wiki/Immune-mediated_inflammatory_diseases" title="Immune-mediated inflammatory diseases">immune-mediated</a> disorder that develops from an interaction of the individual's genetics and as yet unidentified environmental causes.<sup id="cite_ref-pmid11955556_2-7" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> Damage is believed to be caused, at least in part, by attack on the nervous system by a person's own immune system.<sup id="cite_ref-pmid18970977_1-26" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Lesions">Lesions</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:MS_Demyelinisation_KB_10x.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e4/MS_Demyelinisation_KB_10x.jpg/220px-MS_Demyelinisation_KB_10x.jpg" width="220" height="163" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e4/MS_Demyelinisation_KB_10x.jpg/330px-MS_Demyelinisation_KB_10x.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e4/MS_Demyelinisation_KB_10x.jpg/440px-MS_Demyelinisation_KB_10x.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:MS_Demyelinisation_KB_10x.jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Demyelination in MS. On Klüver-Barrera myelin staining, decoloration in the area of the lesion can be appreciated (Original scale 1:100)</div>
</div>
</div>
<p>The name <i>multiple sclerosis</i> refers to the scars (sclerae – better known as plaques or lesions) that form in the nervous system. These lesions most commonly affect the <a href="/wiki/White_matter" title="White matter">white matter</a> in the <a href="/wiki/Optic_nerve" title="Optic nerve">optic nerve</a>, <a href="/wiki/Brain_stem" title="Brain stem" class="mw-redirect">brain stem</a>, <a href="/wiki/Basal_ganglia" title="Basal ganglia">basal ganglia</a>, and <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a>, or white matter tracts close to the lateral <a href="/wiki/Ventricular_system" title="Ventricular system">ventricles</a>.<sup id="cite_ref-pmid18970977_1-27" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> The function of white matter cells is to carry signals between <a href="/wiki/Grey_matter" title="Grey matter">grey matter</a> areas, where the processing is done, and the rest of the body. The <a href="/wiki/Peripheral_nervous_system" title="Peripheral nervous system">peripheral nervous system</a> is rarely involved.<sup id="cite_ref-pmid11955556_2-8" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup></p>
<p>To be specific, MS involves the loss of <a href="/wiki/Oligodendrocyte" title="Oligodendrocyte">oligodendrocytes</a>, the cells responsible for creating and maintaining a fatty layer—known as the <a href="/wiki/Myelin" title="Myelin">myelin</a> sheath—which helps the neurons carry <a href="/wiki/Action_potential" title="Action potential">electrical signals</a> (action potentials).<sup id="cite_ref-pmid18970977_1-28" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> This results in a thinning or complete loss of myelin and, as the disease advances, the breakdown of the <a href="/wiki/Axons" title="Axons" class="mw-redirect">axons</a> of neurons. When the myelin is lost, a neuron can no longer effectively conduct electrical signals.<sup id="cite_ref-pmid11955556_2-9" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> A repair process, called <a href="/wiki/Remyelination" title="Remyelination">remyelination</a>, takes place in early phases of the disease, but the oligodendrocytes are unable to completely rebuild the cell's myelin sheath.<sup id="cite_ref-pmid17531860_31-0" class="reference"><a href="#cite_note-pmid17531860-31"><span>[</span>31<span>]</span></a></sup> Repeated attacks lead to successively less effective remyelinations, until a scar-like plaque is built up around the damaged axons.<sup id="cite_ref-pmid17531860_31-1" class="reference"><a href="#cite_note-pmid17531860-31"><span>[</span>31<span>]</span></a></sup> These scars are the origin of the symptoms and during an attack <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> (MRI) often shows more than ten new plaques.<sup id="cite_ref-pmid18970977_1-29" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> This could indicate that there is a number of lesions below which the brain is capable of repairing itself without producing noticeable consequences.<sup id="cite_ref-pmid18970977_1-30" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Another process involved in the creation of lesions is an abnormal <a href="/wiki/Astrocytosis" title="Astrocytosis" class="mw-redirect">increase in the number of astrocytes</a> due to the destruction of nearby neurons.<sup id="cite_ref-pmid18970977_1-31" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> A number of <a href="/wiki/Pathophysiology_of_multiple_sclerosis#Demyelination_patterns" title="Pathophysiology of multiple sclerosis">lesion patterns</a> have been described.<sup id="cite_ref-pmid17351524_32-0" class="reference"><a href="#cite_note-pmid17351524-32"><span>[</span>32<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Inflammation">Inflammation</span></h3>
<p>Apart from demyelination, the other sign of the disease is <a href="/wiki/Inflammation" title="Inflammation">inflammation</a>. Fitting with an <a href="/wiki/Immunological" title="Immunological" class="mw-redirect">immunological</a> explanation, the inflammatory process is caused by <a href="/wiki/T_cell" title="T cell">T cells</a>, a kind of <a href="/wiki/Lymphocyte" title="Lymphocyte">lymphocyte</a> that plays an important role in the body's defenses.<sup id="cite_ref-pmid11955556_2-10" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> T cells gain entry into the brain via disruptions in the <a href="/wiki/Blood%E2%80%93brain_barrier" title="Blood–brain barrier">blood–brain barrier</a>. The T cells recognize myelin as foreign and attack it, explaining why these cells are also called "autoreactive lymphocytes".<sup id="cite_ref-pmid18970977_1-32" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<p>The attack of myelin starts inflammatory processes, which triggers other immune cells and the release of soluble factors like <a href="/wiki/Cytokine" title="Cytokine">cytokines</a> and <a href="/wiki/Antibodies" title="Antibodies" class="mw-redirect">antibodies</a>. Further breakdown of the blood–brain barrier, in turn cause a number of other damaging effects such as <a href="/wiki/Edema" title="Edema">swelling</a>, activation of <a href="/wiki/Macrophages" title="Macrophages" class="mw-redirect">macrophages</a>, and more activation of cytokines and other destructive proteins.<sup id="cite_ref-pmid11955556_2-11" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> Inflammation can potentially reduce transmission of information between neurons in at least three ways.<sup id="cite_ref-pmid18970977_1-33" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> The soluble factors released might stop neurotransmission by intact neurons. These factors could lead to or enhance the loss of myelin, or they may cause the axon to break down completely.<sup id="cite_ref-pmid18970977_1-34" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Blood.E2.80.93brain_barrier">Blood–brain barrier</span></h3>
<p>The <a href="/wiki/Blood%E2%80%93brain_barrier" title="Blood–brain barrier">blood–brain barrier</a> is a part of the <a href="/wiki/Capillary" title="Capillary">capillary</a> system that prevents the entry of T cells into the central nervous system. It may become permeable to these types of cells secondary to an infection by a virus or bacteria. After it repairs itself, typically once the infection has cleared, T cells may remain trapped inside the brain.<sup id="cite_ref-pmid11955556_2-12" class="reference"><a href="#cite_note-pmid11955556-2"><span>[</span>2<span>]</span></a></sup> <a href="/wiki/Gadolinium" title="Gadolinium">Gadolinium</a> cannot cross a normal BBB and, therefore, Gadolinium-enhanced MRI is used to show BBB breakdowns.<sup id="cite_ref-pmid23088946_33-0" class="reference"><a href="#cite_note-pmid23088946-33"><span>[</span>33<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Monthly_multiple_sclerosis_anim_cropped_no_text.gif" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Monthly_multiple_sclerosis_anim_cropped_no_text.gif/220px-Monthly_multiple_sclerosis_anim_cropped_no_text.gif" width="220" height="243" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/6/6c/Monthly_multiple_sclerosis_anim_cropped_no_text.gif 1.5x, //upload.wikimedia.org/wikipedia/commons/6/6c/Monthly_multiple_sclerosis_anim_cropped_no_text.gif 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Monthly_multiple_sclerosis_anim_cropped_no_text.gif" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Animation showing dissemination of brain lesions in time and space as demonstrated by monthly MRI studies along a year</div>
</div>
</div>
<p>Multiple sclerosis is typically diagnosed based on the presenting signs and symptoms, in combination with supporting <a href="/wiki/Medical_imaging" title="Medical imaging">medical imaging</a> and laboratory testing.<sup id="cite_ref-Tsang2011_14-1" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> It can be difficult to confirm, especially early on, since the signs and symptoms may be similar to those of other medical problems.<sup id="cite_ref-pmid18970977_1-35" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid11794488_34-0" class="reference"><a href="#cite_note-pmid11794488-34"><span>[</span>34<span>]</span></a></sup> The <a href="/wiki/McDonald_criteria" title="McDonald criteria">McDonald criteria</a>, which focus on clinical, laboratory, and radiologic evidence of lesions at different times and in different areas, is the most commonly used method of diagnosis<sup id="cite_ref-Atlas2008_8-1" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup> with the <a href="/wiki/Schumacher_criteria" title="Schumacher criteria">Schumacher</a> and <a href="/wiki/Poser_criteria" title="Poser criteria">Poser criteria</a> being of mostly historical significance.<sup id="cite_ref-pmid15177763_35-0" class="reference"><a href="#cite_note-pmid15177763-35"><span>[</span>35<span>]</span></a></sup> While the above criteria allow for a non-invasive diagnosis, some state that the only definitive proof is an <a href="/wiki/Autopsy" title="Autopsy">autopsy</a> or biopsy where lesions typical of MS are detected.<sup id="cite_ref-pmid18970977_1-36" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid11456302_36-0" class="reference"><a href="#cite_note-pmid11456302-36"><span>[</span>36<span>]</span></a></sup><sup id="cite_ref-pmid16283615_37-0" class="reference"><a href="#cite_note-pmid16283615-37"><span>[</span>37<span>]</span></a></sup></p>
<p>Clinical data alone may be sufficient for a diagnosis of MS if an individual has had separate episodes of neurologic symptoms characteristic of the disease.<sup id="cite_ref-pmid11456302_36-1" class="reference"><a href="#cite_note-pmid11456302-36"><span>[</span>36<span>]</span></a></sup> In those who seek medical attention after only one attack, other testing is needed for the diagnosis. The most commonly used diagnostic tools are <a href="/wiki/Neuroimaging" title="Neuroimaging">neuroimaging</a>, analysis of <a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">cerebrospinal fluid</a> and <a href="/wiki/Evoked_potential" title="Evoked potential">evoked potentials</a>. <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">Magnetic resonance imaging</a> of the brain and spine may show areas of demyelination (lesions or plaques). <a href="/wiki/Gadolinium" title="Gadolinium">Gadolinium</a> can be administered <a href="/wiki/Intravenous" title="Intravenous" class="mw-redirect">intravenously</a> as a <a href="/wiki/Contrast_agent" title="Contrast agent" class="mw-redirect">contrast agent</a> to highlight active plaques and, by elimination, demonstrate the existence of historical lesions not associated with symptoms at the moment of the evaluation.<sup id="cite_ref-pmid11456302_36-2" class="reference"><a href="#cite_note-pmid11456302-36"><span>[</span>36<span>]</span></a></sup><sup id="cite_ref-pmid18256986_38-0" class="reference"><a href="#cite_note-pmid18256986-38"><span>[</span>38<span>]</span></a></sup> Testing of <a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">cerebrospinal fluid</a> obtained from a <a href="/wiki/Lumbar_puncture" title="Lumbar puncture">lumbar puncture</a> can provide evidence of chronic <a href="/wiki/Inflammation" title="Inflammation">inflammation</a> in the central nervous system. The cerebrospinal fluid is tested for <a href="/wiki/Oligoclonal_band" title="Oligoclonal band">oligoclonal bands</a> of IgG on <a href="/wiki/Electrophoresis" title="Electrophoresis">electrophoresis</a>, which are inflammation markers found in 75–85% of people with MS.<sup id="cite_ref-pmid11456302_36-3" class="reference"><a href="#cite_note-pmid11456302-36"><span>[</span>36<span>]</span></a></sup><sup id="cite_ref-pmid16945427_39-0" class="reference"><a href="#cite_note-pmid16945427-39"><span>[</span>39<span>]</span></a></sup> The nervous system in MS may respond less actively to stimulation of the <a href="/wiki/Optic_nerve" title="Optic nerve">optic nerve</a> and <a href="/wiki/Sensory_neuron" title="Sensory neuron">sensory nerves</a> due to demyelination of such pathways. These brain responses can be examined using <a href="/wiki/Visual_evoked_potential" title="Visual evoked potential" class="mw-redirect">visual</a>- and sensory-<a href="/wiki/Evoked_potential" title="Evoked potential">evoked potentials</a>.<sup id="cite_ref-pmid10802774_40-0" class="reference"><a href="#cite_note-pmid10802774-40"><span>[</span>40<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Clinical_courses">Clinical courses</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:302px;"><a href="/wiki/File:Ms_progression_types.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/3c/Ms_progression_types.svg/300px-Ms_progression_types.svg.png" width="300" height="322" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/3c/Ms_progression_types.svg/450px-Ms_progression_types.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/3c/Ms_progression_types.svg/600px-Ms_progression_types.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Ms_progression_types.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Progression of MS subtypes</div>
</div>
</div>
<p>Several subtypes, or patterns of progression, have been described. Subtypes use the past course of the disease in an attempt to <a href="/wiki/Predict" title="Predict" class="mw-redirect">predict</a> the future course. They are important not only for prognosis but also for treatment decisions. In 1996, the United States <a href="/wiki/National_Multiple_Sclerosis_Society" title="National Multiple Sclerosis Society">National Multiple Sclerosis Society</a> described four clinical courses:<sup id="cite_ref-pmid8780061_4-3" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup></p>
<ol>
<li>relapsing remitting</li>
<li>secondary progressive</li>
<li>primary progressive</li>
<li>progressive relapsing.</li>
</ol>
<p>The relapsing-remitting subtype is characterized by unpredictable relapses followed by periods of months to years of relative quiet (<a href="/wiki/Remission_(medicine)" title="Remission (medicine)" class="mw-redirect">remission</a>) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave <a href="/wiki/Sequelae" title="Sequelae" class="mw-redirect">problems</a>, the latter in about 40% of attacks and being more common the longer a person has had the disease.<sup id="cite_ref-pmid18970977_1-37" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Tsang2011_14-2" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> This describes the initial course of 80% of individuals with MS.<sup id="cite_ref-pmid18970977_1-38" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> When deficits always resolve between attacks, this is sometimes referred to as <i>benign MS</i>,<sup id="cite_ref-pmid18219812_41-0" class="reference"><a href="#cite_note-pmid18219812-41"><span>[</span>41<span>]</span></a></sup> although people will still build up some degree of disability in the long term.<sup id="cite_ref-pmid18970977_1-39" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> On the other hand, the term <i><a href="/wiki/Malignant_multiple_sclerosis" title="Malignant multiple sclerosis">malignant multiple sclerosis</a></i> is used to describe people with MS having reached significant level of disability in a short period of time.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup> The relapsing-remitting subtype usually begins with a <a href="/wiki/Clinically_isolated_syndrome" title="Clinically isolated syndrome">clinically isolated syndrome</a> (CIS). In CIS, a person has an attack suggestive of <a href="/wiki/Demyelination" title="Demyelination" class="mw-redirect">demyelination</a>, but does not fulfill the criteria for multiple sclerosis.<sup id="cite_ref-pmid18970977_1-40" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid15847841_43-0" class="reference"><a href="#cite_note-pmid15847841-43"><span>[</span>43<span>]</span></a></sup> 30 to 70% of persons experiencing CIS later develop MS.<sup id="cite_ref-pmid15847841_43-1" class="reference"><a href="#cite_note-pmid15847841-43"><span>[</span>43<span>]</span></a></sup></p>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Nerve.nida.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/3e/Nerve.nida.jpg/220px-Nerve.nida.jpg" width="220" height="279" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/3/3e/Nerve.nida.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/3/3e/Nerve.nida.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Nerve.nida.jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Nerve axon with myelin sheath</div>
</div>
</div>
<p>Secondary progressive MS occurs in around 65% of those with initial relapsing-remitting MS, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission.<sup id="cite_ref-pmid18970977_1-41" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid8780061_4-4" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup> Occasional relapses and minor remissions may appear.<sup id="cite_ref-pmid8780061_4-5" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup> The most common length of time between disease onset and conversion from relapsing-remitting to secondary progressive MS is 19&#160;years.<sup id="cite_ref-pmid16545751_44-0" class="reference"><a href="#cite_note-pmid16545751-44"><span>[</span>44<span>]</span></a></sup> The primary progressive subtype occurs in approximately 10–20% of individuals, with no remission after the initial symptoms.<sup id="cite_ref-Tsang2011_14-3" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-pmid17884680_45-0" class="reference"><a href="#cite_note-pmid17884680-45"><span>[</span>45<span>]</span></a></sup> It is characterized by progression of disability from onset, with no, or only occasional and minor, remissions and improvements.<sup id="cite_ref-pmid8780061_4-6" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup> The usual age of onset for the primary progressive subtype is later than of the relapsing-remitting subtype. It is similar to the age that secondary progressive usually begins in relapsing-remitting MS, around 40 years of age.<sup id="cite_ref-pmid18970977_1-42" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Progressive relapsing MS describes those individuals who, from onset, have a steady neurologic decline but also have clear superimposed attacks. This is the least common of all subtypes.<sup id="cite_ref-pmid8780061_4-7" class="reference"><a href="#cite_note-pmid8780061-4"><span>[</span>4<span>]</span></a></sup></p>
<p><a href="/wiki/Idiopathic_inflammatory_demyelinating_diseases" title="Idiopathic inflammatory demyelinating diseases" class="mw-redirect">Unusual types of MS</a> have been described; these include <a href="/wiki/Devic%27s_disease" title="Devic's disease" class="mw-redirect">Devic's disease</a>, <a href="/wiki/Balo_concentric_sclerosis" title="Balo concentric sclerosis">Balo concentric sclerosis</a>, <a href="/wiki/Diffuse_myelinoclastic_sclerosis" title="Diffuse myelinoclastic sclerosis">Schilder's diffuse sclerosis</a>, and <a href="/wiki/Marburg_multiple_sclerosis" title="Marburg multiple sclerosis">Marburg multiple sclerosis</a>. There is debate on whether they are MS variants or different diseases.<sup id="cite_ref-pmid15727225_46-0" class="reference"><a href="#cite_note-pmid15727225-46"><span>[</span>46<span>]</span></a></sup> Multiple sclerosis behaves differently in children, taking more time to reach the progressive stage.<sup id="cite_ref-pmid18970977_1-43" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Nevertheless, they still reach it at a lower average age than adults usually do.<sup id="cite_ref-pmid18970977_1-44" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Management">Management</span></h2>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Management_of_multiple_sclerosis" title="Management of multiple sclerosis">Management of multiple sclerosis</a></div>
<p>Although there is no known cure for multiple sclerosis, several therapies have proven helpful. The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS have several <a href="/wiki/Adverse_effect_(medicine)" title="Adverse effect (medicine)" class="mw-redirect">adverse effects</a>. <a href="/wiki/Alternative_medicine" title="Alternative medicine">Alternative treatments</a> are pursued by some people, despite the shortage of supporting evidence.</p>
<h3><span class="mw-headline" id="Acute_attacks">Acute attacks</span></h3>
<p>During symptomatic attacks, administration of high doses of <a href="/wiki/Intravenous_therapy" title="Intravenous therapy">intravenous</a> <a href="/wiki/Corticosteroid" title="Corticosteroid">corticosteroids</a>, such as <a href="/wiki/Methylprednisolone" title="Methylprednisolone">methylprednisolone</a>, is the usual therapy,<sup id="cite_ref-pmid18970977_1-45" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> with oral corticosteroids seeming to have a similar efficacy and safety profile.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span>[</span>47<span>]</span></a></sup> Although, in general, effective in the short term for relieving symptoms, corticosteroid treatments do not appear to have a significant impact on long-term recovery.<sup id="cite_ref-RCOP_acute_48-0" class="reference"><a href="#cite_note-RCOP_acute-48"><span>[</span>48<span>]</span></a></sup> The consequences of severe attacks that do not respond to corticosteroids might be treatable by <a href="/wiki/Plasmapheresis" title="Plasmapheresis">plasmapheresis</a>.<sup id="cite_ref-pmid18970977_1-46" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Disease-modifying_treatments">Disease-modifying treatments</span></h3>
<h4><span class="mw-headline" id="Relapsing_remitting_multiple_sclerosis">Relapsing remitting multiple sclerosis</span></h4>
<p>Eight disease-modifying treatments have been approved by regulatory agencies for relapsing-remitting multiple sclerosis (RRMS) including: <a href="/wiki/Interferon_beta-1a" title="Interferon beta-1a" class="mw-redirect">interferon beta-1a</a>, <a href="/wiki/Interferon_beta-1b" title="Interferon beta-1b" class="mw-redirect">interferon beta-1b</a>, <a href="/wiki/Glatiramer_acetate" title="Glatiramer acetate">glatiramer acetate</a>, <a href="/wiki/Mitoxantrone" title="Mitoxantrone">mitoxantrone</a>, <a href="/wiki/Natalizumab" title="Natalizumab">natalizumab</a>, <a href="/wiki/Fingolimod" title="Fingolimod">fingolimod</a>,<sup id="cite_ref-He2012_49-0" class="reference"><a href="#cite_note-He2012-49"><span>[</span>49<span>]</span></a></sup> <a href="/wiki/Teriflunomide" title="Teriflunomide">teriflunomide</a><sup id="cite_ref-Aubagio_50-0" class="reference"><a href="#cite_note-Aubagio-50"><span>[</span>50<span>]</span></a></sup> and <a href="/wiki/Dimethyl_fumarate" title="Dimethyl fumarate">dimethyl fumarate</a>.<sup id="cite_ref-fumarate_51-0" class="reference"><a href="#cite_note-fumarate-51"><span>[</span>51<span>]</span></a></sup> Their cost effectiveness as of 2012 is unclear.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup></p>
<p>In RRMS they are modestly effective at decreasing the number of attacks.<sup id="cite_ref-He2012_49-1" class="reference"><a href="#cite_note-He2012-49"><span>[</span>49<span>]</span></a></sup> The interferons and glatiramer acetate are first-line treatments<sup id="cite_ref-Tsang2011_14-4" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> and are roughly equivalent, reducing relapses by approximately 30%.<sup id="cite_ref-Hassan2011_53-0" class="reference"><a href="#cite_note-Hassan2011-53"><span>[</span>53<span>]</span></a></sup> Early-initiated long-term therapy is safe and improves outcomes.<sup id="cite_ref-pmid21205679_54-0" class="reference"><a href="#cite_note-pmid21205679-54"><span>[</span>54<span>]</span></a></sup><sup id="cite_ref-pmid22284996_55-0" class="reference"><a href="#cite_note-pmid22284996-55"><span>[</span>55<span>]</span></a></sup> Natalizumab reduces the relapse rate more than first-line agents; however, due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments<sup id="cite_ref-Tsang2011_14-5" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> or with severe disease.<sup id="cite_ref-Hassan2011_53-1" class="reference"><a href="#cite_note-Hassan2011-53"><span>[</span>53<span>]</span></a></sup> Mitoxantrone, whose use is limited by severe adverse effects, is a third-line option for those who do not respond to other medications.<sup id="cite_ref-Tsang2011_14-6" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> Treatment of clinically isolated syndrome (CIS) with <a href="/wiki/Interferon" title="Interferon">interferons</a> decreases the chance of progressing to clinical MS.<sup id="cite_ref-pmid18970977_1-47" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid21205678_56-0" class="reference"><a href="#cite_note-pmid21205678-56"><span>[</span>56<span>]</span></a></sup> Efficacy of interferons and glatiramer acetate in children has been estimated to be roughly equivalent to that of adults.<sup id="cite_ref-pmid22642799_57-0" class="reference"><a href="#cite_note-pmid22642799-57"><span>[</span>57<span>]</span></a></sup> The role of some of the newer agents such as fingolimod, teriflunomide, and dimethyl fumarate, as of 2011, is not yet entirely clear.<sup id="cite_ref-pmid22014437_58-0" class="reference"><a href="#cite_note-pmid22014437-58"><span>[</span>58<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Progressive_multiple_sclerosis">Progressive multiple sclerosis</span></h4>
<p>No treatment has been shown to change the course of primary progressive MS<sup id="cite_ref-Tsang2011_14-7" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup> and as of 2011 only one medication, mitoxantrone, has been approved for secondary progressive MS.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup> In this population tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years.<sup id="cite_ref-CochMit2013_60-0" class="reference"><a href="#cite_note-CochMit2013-60"><span>[</span>60<span>]</span></a></sup><sup id="cite_ref-61" class="reference"><a href="#cite_note-61"><span>[</span>61<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Adverse_effects">Adverse effects</span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Copaxone_Injection_Site_Reaction.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a0/Copaxone_Injection_Site_Reaction.JPG/220px-Copaxone_Injection_Site_Reaction.JPG" width="220" height="318" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/a/a0/Copaxone_Injection_Site_Reaction.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/a/a0/Copaxone_Injection_Site_Reaction.JPG 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Copaxone_Injection_Site_Reaction.JPG" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Irritation zone after injection of glatiramer acetate.</div>
</div>
</div>
<p>The disease-modifying treatments have several adverse effects. One of the most common is irritation at the injection site for glatiramer acetate and the interferons (up to 90% with subcutaneous injections and 33% with intramuscular injections).<sup id="cite_ref-Balak2012_62-0" class="reference"><a href="#cite_note-Balak2012-62"><span>[</span>62<span>]</span></a></sup> Over time, a visible dent at the injection site, due to the local destruction of fat tissue, known as <a href="/wiki/Lipoatrophy" title="Lipoatrophy">lipoatrophy</a>, may develop.<sup id="cite_ref-Balak2012_62-1" class="reference"><a href="#cite_note-Balak2012-62"><span>[</span>62<span>]</span></a></sup> Interferons may produce <a href="/wiki/Flu-like_symptoms" title="Flu-like symptoms" class="mw-redirect">flu-like symptoms</a>;<sup id="cite_ref-pmid17131933_63-0" class="reference"><a href="#cite_note-pmid17131933-63"><span>[</span>63<span>]</span></a></sup> some people taking glatiramer experience a post-injection reaction with flushing, chest tightness, heart palpitations, breathlessness, and anxiety, which usually lasts less than thirty minutes.<sup id="cite_ref-pmid14974077_64-0" class="reference"><a href="#cite_note-pmid14974077-64"><span>[</span>64<span>]</span></a></sup> More dangerous but much less common are <a href="/wiki/Hepatotoxicity" title="Hepatotoxicity">liver damage</a> from interferons,<sup id="cite_ref-pmid15592724_65-0" class="reference"><a href="#cite_note-pmid15592724-65"><span>[</span>65<span>]</span></a></sup> <a href="/wiki/Systolic_dysfunction" title="Systolic dysfunction" class="mw-redirect">systolic dysfunction</a> (12%), <a href="/wiki/Infertility" title="Infertility">infertility</a>, and <a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">acute myeloid leukemia</a> (0.8%) from mitoxantrone,<sup id="cite_ref-CochMit2013_60-1" class="reference"><a href="#cite_note-CochMit2013-60"><span>[</span>60<span>]</span></a></sup><sup id="cite_ref-pmid19882365_66-0" class="reference"><a href="#cite_note-pmid19882365-66"><span>[</span>66<span>]</span></a></sup> and <a href="/wiki/Progressive_multifocal_leukoencephalopathy" title="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</a> occurring with natalizumab (occurring in 1 in 600 people treated).<sup id="cite_ref-Tsang2011_14-8" class="reference"><a href="#cite_note-Tsang2011-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-67" class="reference"><a href="#cite_note-67"><span>[</span>67<span>]</span></a></sup></p>
<p>Fingolimod may give rise to <a href="/wiki/Hypertension" title="Hypertension">hypertension</a> and <a href="/wiki/Bradycardia" title="Bradycardia">bradycardia</a>, <a href="/wiki/Macular_edema" title="Macular edema">macular edema</a>, elevated liver enzymes or a <a href="/wiki/Lymphopenia" title="Lymphopenia" class="mw-redirect">reduction in lymphocyte levels</a>.<sup id="cite_ref-pmid22014437_58-1" class="reference"><a href="#cite_note-pmid22014437-58"><span>[</span>58<span>]</span></a></sup> Tentative evidence supports the short term safety of teriflunomide, with common side effects including: headaches, fatigue, nausea, hair loss, and limb pain.<sup id="cite_ref-He2012_49-2" class="reference"><a href="#cite_note-He2012-49"><span>[</span>49<span>]</span></a></sup> There have also been reports of liver failure and PML with its use and it is <a href="/wiki/Teratology" title="Teratology">dangerous for fetal development</a>.<sup id="cite_ref-pmid22014437_58-2" class="reference"><a href="#cite_note-pmid22014437-58"><span>[</span>58<span>]</span></a></sup> Most common side effects of dimethyl fumarate are flushing and gastrointestinal problems.<sup id="cite_ref-fumarate_51-1" class="reference"><a href="#cite_note-fumarate-51"><span>[</span>51<span>]</span></a></sup><sup id="cite_ref-pmid22014437_58-3" class="reference"><a href="#cite_note-pmid22014437-58"><span>[</span>58<span>]</span></a></sup> While dimethyl fumarate may lead to a <a href="/wiki/Neutropenia" title="Neutropenia">reduction in the white blood cell count</a> there were no reported cases of opportunistic infections during trials.<sup id="cite_ref-fumarateNDA_68-0" class="reference"><a href="#cite_note-fumarateNDA-68"><span>[</span>68<span>]</span></a></sup><sup id="cite_ref-pmid22224673_69-0" class="reference"><a href="#cite_note-pmid22224673-69"><span>[</span>69<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Associated_symptoms">Associated symptoms</span></h3>
<p>Both medications and <a href="/wiki/Neurorehabilitation" title="Neurorehabilitation">neurorehabilitation</a> have been shown to improve some symptoms, though neither changes the course of the disease.<sup id="cite_ref-pmid16168933_70-0" class="reference"><a href="#cite_note-pmid16168933-70"><span>[</span>70<span>]</span></a></sup> Some symptoms have a good response to medication, such as an unstable bladder and spasticity, while others are little changed.<sup id="cite_ref-pmid18970977_1-48" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> For neurologic problems, a <a href="/wiki/Multidisciplinary" title="Multidisciplinary" class="mw-redirect">multidisciplinary</a> approach is important for improving quality of life; however, it is difficult to specify a 'core team' as many different health services may be needed at different points in time.<sup id="cite_ref-pmid18970977_1-49" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Multidisciplinary rehabilitation programs increase activity and participation of people with MS but do not influence impairment level.<sup id="cite_ref-pmid17443610_71-0" class="reference"><a href="#cite_note-pmid17443610-71"><span>[</span>71<span>]</span></a></sup> There is limited evidence for the overall efficacy of individual therapeutic disciplines,<sup id="cite_ref-pmid15859525_72-0" class="reference"><a href="#cite_note-pmid15859525-72"><span>[</span>72<span>]</span></a></sup><sup id="cite_ref-pmid15859525_72-1" class="reference"><a href="#cite_note-pmid15859525-72"><span>[</span>72<span>]</span></a></sup><sup id="cite_ref-pmid12917976_73-0" class="reference"><a href="#cite_note-pmid12917976-73"><span>[</span>73<span>]</span></a></sup> though there is good evidence that specific approaches, such as exercise,<sup id="cite_ref-pmid17482708_74-0" class="reference"><a href="#cite_note-pmid17482708-74"><span>[</span>74<span>]</span></a></sup><sup id="cite_ref-75" class="reference"><a href="#cite_note-75"><span>[</span>75<span>]</span></a></sup> and psychology therapies, in particular <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">cognitive behavioral approaches</a> are effective.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76"><span>[</span>76<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Alternative_treatments">Alternative treatments</span></h3>
<p>Over 50% of people with MS may use <a href="/wiki/Complementary_and_alternative_medicine" title="Complementary and alternative medicine" class="mw-redirect">complementary and alternative medicine</a>, although percentages vary depending on how alternative medicine is defined.<sup id="cite_ref-pmid16420779_77-0" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup> The evidence for the effectiveness for such treatments in most cases is weak or absent.<sup id="cite_ref-pmid16420779_77-1" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup><sup id="cite_ref-pmid19222053_78-0" class="reference"><a href="#cite_note-pmid19222053-78"><span>[</span>78<span>]</span></a></sup> While there is tentative evidence that vitamin D may be useful, evidence is insufficient for a definitive conclusion.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79"><span>[</span>79<span>]</span></a></sup> Treatments of unproven benefit used by people with MS include: dietary supplementation and regimens,<sup id="cite_ref-pmid16420779_77-2" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup><sup id="cite_ref-pmid17253500_80-0" class="reference"><a href="#cite_note-pmid17253500-80"><span>[</span>80<span>]</span></a></sup><sup id="cite_ref-pmid21965673_81-0" class="reference"><a href="#cite_note-pmid21965673-81"><span>[</span>81<span>]</span></a></sup> <a href="/wiki/Relaxation_technique" title="Relaxation technique">relaxation techniques</a> such as <a href="/wiki/Yoga" title="Yoga">yoga</a>,<sup id="cite_ref-pmid16420779_77-3" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup> <a href="/wiki/Herbal_medicine" title="Herbal medicine" class="mw-redirect">herbal medicine</a> (including <a href="/wiki/Medical_cannabis" title="Medical cannabis">medical cannabis</a>),<sup id="cite_ref-pmid16420779_77-4" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup><sup id="cite_ref-82" class="reference"><a href="#cite_note-82"><span>[</span>82<span>]</span></a></sup> <a href="/wiki/Hyperbaric_oxygen_therapy" title="Hyperbaric oxygen therapy" class="mw-redirect">hyperbaric oxygen therapy</a>,<sup id="cite_ref-pmid14974004_83-0" class="reference"><a href="#cite_note-pmid14974004-83"><span>[</span>83<span>]</span></a></sup> <a href="/wiki/Helminthic_therapy" title="Helminthic therapy">self-infection with hookworms</a>, <a href="/wiki/Reflexology" title="Reflexology">reflexology</a> and <a href="/wiki/Acupuncture" title="Acupuncture">acupuncture</a>.<sup id="cite_ref-pmid16420779_77-5" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup><sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>84<span>]</span></a></sup> Regarding the characteristics of users, they are more frequently women, have had MS for a longer time, tend to be more disabled and have lower levels of satisfaction with conventional healthcare.<sup id="cite_ref-pmid16420779_77-6" class="reference"><a href="#cite_note-pmid16420779-77"><span>[</span>77<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg/220px-Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg.png" width="220" height="97" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg/330px-Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg/440px-Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Multiple_sclerosis_world_map_-_DALY_-_WHO2004.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/Disability-adjusted_life_year" title="Disability-adjusted life year">Disability-adjusted life year</a> for multiple sclerosis per 100,000&#160;inhabitants in 2004
<div>
<table style="width: 100%; background-color:transparent;table-layout:fixed; border:none; border-spacing:0;" role="presentation">
<tr style="vertical-align: top;">
<td>
<div style="margin-right:20px;">
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #b3b3b3; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;no data</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffff65; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;&lt;13</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #fff200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;13–16</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffdc00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;16–19</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffc600; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;19–22</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffb000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;22–25</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff9a00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;25–28</div>
</div>
</td>
<td>
<div style="margin-right: 20px;">
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff8400; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;28–31</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff6e00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;31–34</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff5800; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;34–37</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff4200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;37–40</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff2c00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;40–43</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #cb0000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;&gt;43</div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div>
<p>The expected future course of the disease depends on the subtype of the disease; the individual's sex, age, and initial symptoms; and the degree of <a href="/wiki/Disability" title="Disability">disability</a> the person has.<sup id="cite_ref-pmid8017890_7-1" class="reference"><a href="#cite_note-pmid8017890-7"><span>[</span>7<span>]</span></a></sup> Female sex, relapsing-remitting subtype, optic neuritis or sensory symptoms at onset, few attacks in the initial years and especially early age at onset, are associated with a better course.<sup id="cite_ref-pmid8017890_7-2" class="reference"><a href="#cite_note-pmid8017890-7"><span>[</span>7<span>]</span></a></sup><sup id="cite_ref-pmid3495637_85-0" class="reference"><a href="#cite_note-pmid3495637-85"><span>[</span>85<span>]</span></a></sup></p>
<p>The average life expectancy is 30 years from onset, which is 5 to 10 years lower than that of unaffected people.<sup id="cite_ref-pmid18970977_1-50" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Almost 40% of people with MS reach the seventh decade of life.<sup id="cite_ref-pmid3495637_85-1" class="reference"><a href="#cite_note-pmid3495637-85"><span>[</span>85<span>]</span></a></sup> Nevertheless, two-thirds of the deaths are directly related to the consequences of the disease.<sup id="cite_ref-pmid18970977_1-51" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> <a href="/wiki/Suicide" title="Suicide">Suicide</a> is more common, while infections and other complications are especially dangerous for the more disabled.<sup id="cite_ref-pmid18970977_1-52" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Although most people lose the ability to walk before death, 90% are capable of independent walking at 10 years from onset, and 75% at 15 years.<sup id="cite_ref-pmid3495637_85-2" class="reference"><a href="#cite_note-pmid3495637-85"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-pmid11321195_86-0" class="reference"><a href="#cite_note-pmid11321195-86"><span>[</span>86<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span></h2>
<p>The number of people with MS, as of 2010, is 2–2.5&#160;million (approximately 30 per 100,000) globally, with rates varying widely in different regions.<sup id="cite_ref-Atlas2008_8-2" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Milo2010_9-9" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> It is estimated to have resulted in 18,000 deaths that year.<sup id="cite_ref-Loz2012_87-0" class="reference"><a href="#cite_note-Loz2012-87"><span>[</span>87<span>]</span></a></sup> In Africa rates are less than 0.5 per 100,000, while they are 2.8 per 100,000 in South East Asia, 8.3 per 100,000 in the Americas, and 80 per 100,000 in Europe.<sup id="cite_ref-Atlas2008_8-3" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup> Rates surpass 200 per 100,000 in certain populations of Northern European descent.<sup id="cite_ref-Milo2010_9-10" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> The number of new cases that develop per year is about 2.5 per 100,000.<sup id="cite_ref-Atlas2008_8-4" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup></p>
<p>Rates of MS appear to be increasing, this however may be explained simply by better diagnosis.<sup id="cite_ref-Milo2010_9-11" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> Studies on populational and geographical patterns have been common<sup id="cite_ref-pmid8269393_28-1" class="reference"><a href="#cite_note-pmid8269393-28"><span>[</span>28<span>]</span></a></sup> and have led to a number of theories about the cause.<sup id="cite_ref-pmid17444504_6-7" class="reference"><a href="#cite_note-pmid17444504-6"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-pmid15556803_18-5" class="reference"><a href="#cite_note-pmid15556803-18"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-pmid17492755_21-3" class="reference"><a href="#cite_note-pmid17492755-21"><span>[</span>21<span>]</span></a></sup></p>
<p>MS usually appears in adults in their late twenties or early thirties but it can rarely start in childhood and after 50 years of age.<sup id="cite_ref-Atlas2008_8-5" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Milo2010_9-12" class="reference"><a href="#cite_note-Milo2010-9"><span>[</span>9<span>]</span></a></sup> The primary progressive subtype is more common in people in their fifties.<sup id="cite_ref-pmid17884680_45-1" class="reference"><a href="#cite_note-pmid17884680-45"><span>[</span>45<span>]</span></a></sup> Similar to many autoimmune disorders, the disease is more common in women, and the trend may be increasing.<sup id="cite_ref-pmid18970977_1-53" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-pmid18606967_19-2" class="reference"><a href="#cite_note-pmid18606967-19"><span>[</span>19<span>]</span></a></sup> As of 2008, globally it is about two times more common in women than in men.<sup id="cite_ref-Atlas2008_8-6" class="reference"><a href="#cite_note-Atlas2008-8"><span>[</span>8<span>]</span></a></sup> In children, it is even more common in females than males,<sup id="cite_ref-pmid18970977_1-54" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> while in people over fifty, it affects males and females almost equally.<sup id="cite_ref-pmid17884680_45-2" class="reference"><a href="#cite_note-pmid17884680-45"><span>[</span>45<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span></h2>
<h3><span class="mw-headline" id="Medical_discovery">Medical discovery</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Carswell-Multiple_Sclerosis2.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e5/Carswell-Multiple_Sclerosis2.jpg/220px-Carswell-Multiple_Sclerosis2.jpg" width="220" height="309" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/e/e5/Carswell-Multiple_Sclerosis2.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/e/e5/Carswell-Multiple_Sclerosis2.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Carswell-Multiple_Sclerosis2.jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Detail of Carswell's drawing of MS lesions in the <a href="/wiki/Brain_stem" title="Brain stem" class="mw-redirect">brain stem</a> and <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a> (1838)</div>
</div>
</div>
<p>The French <a href="/wiki/Neurologist" title="Neurologist" class="mw-redirect">neurologist</a> <a href="/wiki/Jean-Martin_Charcot" title="Jean-Martin Charcot">Jean-Martin Charcot</a> (1825–1893) was the first person to recognize multiple sclerosis as a distinct disease in 1868.<sup id="cite_ref-pmid3066846_88-0" class="reference"><a href="#cite_note-pmid3066846-88"><span>[</span>88<span>]</span></a></sup> Summarizing previous reports and adding his own clinical and pathological observations, Charcot called the disease <i>sclerose en plaques</i>. The three signs of MS now known as <a href="/wiki/Charcot%27s_triad_1" title="Charcot's triad 1" class="mw-redirect">Charcot's triad 1</a> are <a href="/wiki/Nystagmus" title="Nystagmus">nystagmus</a>, <a href="/wiki/Intention_tremor" title="Intention tremor">intention tremor</a>, and <a href="/wiki/Telegraphic_speech" title="Telegraphic speech">telegraphic speech</a> (scanning speech), though these are not unique to MS. Charcot also observed cognition changes, describing his patients as having a "marked enfeeblement of the memory" and "conceptions that formed slowly".<sup id="cite_ref-Charcot1_10-2" class="reference"><a href="#cite_note-Charcot1-10"><span>[</span>10<span>]</span></a></sup></p>
<p>Before Charcot, <a href="/wiki/Robert_Carswell_(pathologist)" title="Robert Carswell (pathologist)">Robert Carswell</a> (1793–1857), a British professor of <a href="/wiki/Pathology" title="Pathology">pathology</a>, and <a href="/wiki/Jean_Cruveilhier" title="Jean Cruveilhier">Jean Cruveilhier</a> (1791–1873), a French professor of pathologic anatomy, had described and illustrated many of the disease's clinical details, but did not identify it as a separate disease.<sup id="cite_ref-pmid3066846_88-1" class="reference"><a href="#cite_note-pmid3066846-88"><span>[</span>88<span>]</span></a></sup> Specifically, Carswell described the injuries he found as "a remarkable lesion of the spinal cord accompanied with atrophy".<sup id="cite_ref-pmid18970977_1-55" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup> Under the microscope, Swiss pathologist <a href="/wiki/Georg_Eduard_Rindfleisch" title="Georg Eduard Rindfleisch" class="mw-redirect">Georg Eduard Rindfleisch</a> (1836–1908) noted in 1863 that the inflammation-associated lesions were distributed around blood vessels.<sup id="cite_ref-pmid10603616_89-0" class="reference"><a href="#cite_note-pmid10603616-89"><span>[</span>89<span>]</span></a></sup><sup id="cite_ref-90" class="reference"><a href="#cite_note-90"><span>[</span>90<span>]</span></a></sup> During the 20th century theories about the cause and pathogenesis were developed and effective treatments began to appear in 1990s.<sup id="cite_ref-pmid18970977_1-56" class="reference"><a href="#cite_note-pmid18970977-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Historical_cases">Historical cases</span></h3>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Animal_locomotion._Plate_541_(Boston_Public_Library).jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/85/Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg/220px-Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg" width="220" height="129" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/85/Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg/330px-Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/85/Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg/440px-Animal_locomotion._Plate_541_%28Boston_Public_Library%29.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Animal_locomotion._Plate_541_(Boston_Public_Library).jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Photographic study of locomotion of a MS female patient with walking difficulties created in 1887 by <a href="/wiki/Muybridge" title="Muybridge" class="mw-redirect">Muybridge</a></div>
</div>
</div>
<p>There are several historical accounts of people who lived before or shortly after the disease was described by Charcot and probably had MS.</p>
<p>A young woman called Halldora who lived in <a href="/wiki/Iceland" title="Iceland">Iceland</a> around 1200 suddenly lost her vision and mobility but, after praying to the saints, recovered them seven days after. <a href="/wiki/Saint_Lidwina" title="Saint Lidwina" class="mw-redirect">Saint Lidwina</a> of <a href="/wiki/Schiedam" title="Schiedam">Schiedam</a> (1380–1433), a <a href="/wiki/Netherlands" title="Netherlands">Dutch</a> <a href="/wiki/Nun" title="Nun">nun</a>, may be one of the first clearly identifiable people with MS. From the age of 16 until her death at 53, she had intermittent pain, weakness of the legs, and vision loss—symptoms typical of MS.<sup id="cite_ref-pmid390966_91-0" class="reference"><a href="#cite_note-pmid390966-91"><span>[</span>91<span>]</span></a></sup> Both cases have led to the proposal of a "Viking gene" hypothesis for the dissemination of the disease.<sup id="cite_ref-pmid16479124_92-0" class="reference"><a href="#cite_note-pmid16479124-92"><span>[</span>92<span>]</span></a></sup></p>
<p><a href="/wiki/Augustus_d%27Este" title="Augustus d'Este">Augustus Frederick d'Este</a> (1794–1848), son of <a href="/wiki/Prince_Augustus_Frederick,_Duke_of_Sussex" title="Prince Augustus Frederick, Duke of Sussex">Prince Augustus Frederick, Duke of Sussex</a> and <a href="/wiki/Lady_Augusta_Murray" title="Lady Augusta Murray">Lady Augusta Murray</a> and the grandson of <a href="/wiki/George_III_of_the_United_Kingdom" title="George III of the United Kingdom">George&#160;III of the United Kingdom</a>, almost certainly had MS. D'Este left a detailed diary describing his 22 years living with the disease. His diary began in 1822 and ended in 1846, although it remained unknown until 1948. His symptoms began at age 28 with a sudden transient visual loss (<a href="/wiki/Amaurosis_fugax" title="Amaurosis fugax">amaurosis fugax</a>) after the funeral of a friend. During the course of his disease, he developed weakness of the legs, clumsiness of the hands, numbness, dizziness, bladder disturbances, and <a href="/wiki/Erectile_dysfunction" title="Erectile dysfunction">erectile dysfunction</a>. In 1844, he began to use a wheelchair. Despite his illness, he kept an optimistic view of life.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93"><span>[</span>93<span>]</span></a></sup><sup id="cite_ref-pmid16103678_94-0" class="reference"><a href="#cite_note-pmid16103678-94"><span>[</span>94<span>]</span></a></sup> Another early account of MS was kept by the British diarist <a href="/wiki/W._N._P._Barbellion" title="W. N. P. Barbellion">W. N. P. Barbellion</a>, <a href="/wiki/Nom-de-plume" title="Nom-de-plume" class="mw-redirect">nom-de-plume</a> of Bruce Frederick Cummings (1889–1919), who maintained a detailed log of his diagnosis and struggle.<sup id="cite_ref-pmid16103678_94-1" class="reference"><a href="#cite_note-pmid16103678-94"><span>[</span>94<span>]</span></a></sup> His diary was published in 1919 as <i><a href="/wiki/The_Journal_of_a_Disappointed_Man" title="The Journal of a Disappointed Man" class="mw-redirect">The Journal of a Disappointed Man</a></i>.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95"><span>[</span>95<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Research">Research</span></h2>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Multiple_sclerosis_research" title="Multiple sclerosis research">Multiple sclerosis research</a></div>
<h3><span class="mw-headline" id="Medications">Medications</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Alemtuzumab_Fab_1CE1.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/32/Alemtuzumab_Fab_1CE1.png/220px-Alemtuzumab_Fab_1CE1.png" width="220" height="298" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/32/Alemtuzumab_Fab_1CE1.png/330px-Alemtuzumab_Fab_1CE1.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/32/Alemtuzumab_Fab_1CE1.png/440px-Alemtuzumab_Fab_1CE1.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Alemtuzumab_Fab_1CE1.png" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Chemical structure of <a href="/wiki/Alemtuzumab" title="Alemtuzumab">alemtuzumab</a></div>
</div>
</div>
<p>There is ongoing research looking for more effective, convenient, and tolerable treatments for relapsing-remitting MS; creation of therapies for the progressive subtypes; <a href="/wiki/Neuroprotection" title="Neuroprotection">neuroprotection</a> strategies; and effective symptomatic treatments.<sup id="cite_ref-pmid19597083_96-0" class="reference"><a href="#cite_note-pmid19597083-96"><span>[</span>96<span>]</span></a></sup></p>
<p>During the 2000s and 2010s, there has been approval of several oral drugs that are expected to gain in popularity and frequency of use.<sup id="cite_ref-pmid21425270_97-0" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup> Several more oral drugs are under investigation, one being <a href="/wiki/Laquinimod" title="Laquinimod">laquinimod</a>, which was announced in August 2012 and is in a third phase III trial after mixed results in the previous ones.<sup id="cite_ref-98" class="reference"><a href="#cite_note-98"><span>[</span>98<span>]</span></a></sup> Similarly, studies aimed to improve the efficacy and ease of use of already existing therapies are occurring. This includes the use of new preparations such as the <a href="/wiki/PEGylation" title="PEGylation">PEGylated</a> version of interferon-β-1a, which it is hoped may be given at less frequent doses with similar effects.<sup id="cite_ref-pmid22201341_99-0" class="reference"><a href="#cite_note-pmid22201341-99"><span>[</span>99<span>]</span></a></sup><sup id="cite_ref-PEG_100-0" class="reference"><a href="#cite_note-PEG-100"><span>[</span>100<span>]</span></a></sup> Request for approval of<i>peginterferon beta-1a</i> is expected during 2013.<sup id="cite_ref-PEG_100-1" class="reference"><a href="#cite_note-PEG-100"><span>[</span>100<span>]</span></a></sup></p>
<p><a href="/wiki/Monoclonal_antibodies" title="Monoclonal antibodies" class="mw-redirect">Monoclonal antibodies</a> have also raised high levels of interest. <a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>, <a href="/wiki/Daclizumab" title="Daclizumab">daclizumab</a>, and <a href="/wiki/CD20" title="CD20">CD20</a> monoclonal antibodies such as <a href="/wiki/Rituximab" title="Rituximab">rituximab</a>, <a href="/wiki/Ocrelizumab" title="Ocrelizumab">ocrelizumab</a> and <a href="/wiki/Ofatumumab" title="Ofatumumab">ofatumumab</a> have all shown some benefit and are under study as potential treatments.<sup id="cite_ref-pmid22224673_69-1" class="reference"><a href="#cite_note-pmid22224673-69"><span>[</span>69<span>]</span></a></sup> Their use has also been accompanied by the appearance of potentially dangerous adverse effects, the most important of which being opportunistic infections.<sup id="cite_ref-pmid21425270_97-1" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup> Related to these investigations is the development of a test for <a href="/wiki/JC_virus" title="JC virus">JC virus</a> antibodies, which might help to determine who is at greater risk of developing progressive multifocal leukoencephalopathy when taking natalizumab.<sup id="cite_ref-pmid21425270_97-2" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup> While monoclonal antibodies will probably have some role in the treatment of the disease in the future, it is believed that it will be small due to the risks associated with them.<sup id="cite_ref-pmid21425270_97-3" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup></p>
<p>Another research strategy is to evaluate the <a href="/wiki/Combination_therapy" title="Combination therapy">combined effectiveness</a> of two or more drugs.<sup id="cite_ref-pmid21111490_101-0" class="reference"><a href="#cite_note-pmid21111490-101"><span>[</span>101<span>]</span></a></sup> The main rationale for using a number of medications in MS is that the involved treatments target different mechanisms and, therefore, their use is not necessarily exclusive.<sup id="cite_ref-pmid21111490_101-1" class="reference"><a href="#cite_note-pmid21111490-101"><span>[</span>101<span>]</span></a></sup> <a href="/wiki/Synergy#Drug_synergy" title="Synergy">Synergies</a>, in which one drug improves the effect of another are also possible, but there can also be drawbacks such as the blocking of the action of the other or worsened side-effects.<sup id="cite_ref-pmid21111490_101-2" class="reference"><a href="#cite_note-pmid21111490-101"><span>[</span>101<span>]</span></a></sup> There have been several trials of combined therapy, yet none have shown positive enough results to be considered as a useful treatment for MS.<sup id="cite_ref-pmid21111490_101-3" class="reference"><a href="#cite_note-pmid21111490-101"><span>[</span>101<span>]</span></a></sup></p>
<p>Research on neuroprotection and regenerative treatments, such as <a href="/wiki/Stem_cell_therapy" title="Stem cell therapy">stem cell therapy</a>, while of high importance, are in the early stages.<sup id="cite_ref-pmid23039386_102-0" class="reference"><a href="#cite_note-pmid23039386-102"><span>[</span>102<span>]</span></a></sup> Likewise, there are not any effective treatments for the progressive variants of the disease. Many of the newest drugs as well as those under development are probably going to be evaluated as therapies for PPMS or SPMS.<sup id="cite_ref-pmid21425270_97-4" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Disease_biomarkers">Disease biomarkers</span></h3>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Journal.pone.0057573.g005_cropped.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/af/Journal.pone.0057573.g005_cropped.png/220px-Journal.pone.0057573.g005_cropped.png" width="220" height="262" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/af/Journal.pone.0057573.g005_cropped.png/330px-Journal.pone.0057573.g005_cropped.png 1.5x, //upload.wikimedia.org/wikipedia/commons/a/af/Journal.pone.0057573.g005_cropped.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Journal.pone.0057573.g005_cropped.png" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">MRI</a> brain scan produced using a <i>Gradient-echo phase sequence</i> showing an iron deposit in a white matter lesion (inside green box in the middle of the image; enhanced and marked by red arrow top-left corner)<sup id="cite_ref-pmid23516409_103-0" class="reference"><a href="#cite_note-pmid23516409-103"><span>[</span>103<span>]</span></a></sup></div>
</div>
</div>
<p>While diagnostic criteria are not expected to change in the near future, work to develop <a href="/wiki/Biomarker" title="Biomarker">biomarkers</a> that help with diagnosis and prediction of disease progression is ongoing.<sup id="cite_ref-pmid21425270_97-5" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup> New diagnostic methods that are being investigated include work with anti-myelin <a href="/wiki/Antibody" title="Antibody">antibodies</a>, and studies with serum and <a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">cerebrospinal fluid</a>, but none of them has yielded reliably positive results.<sup id="cite_ref-pmid19712003_104-0" class="reference"><a href="#cite_note-pmid19712003-104"><span>[</span>104<span>]</span></a></sup></p>
<p>At the current time, there are no laboratory investigations that can predict prognosis. Several promising approaches have been proposed including: <a href="/wiki/Interleukin-6" title="Interleukin-6" class="mw-redirect">interleukin-6</a>, <a href="/wiki/Nitric_oxide" title="Nitric oxide">nitric oxide</a> and <a href="/wiki/Nitric_oxide_synthase" title="Nitric oxide synthase">nitric oxide synthase</a>, <a href="/wiki/Osteopontin" title="Osteopontin">osteopontin</a>, and <a href="/wiki/Fetuin" title="Fetuin">fetuin</a>-A.<sup id="cite_ref-pmid19712003_104-1" class="reference"><a href="#cite_note-pmid19712003-104"><span>[</span>104<span>]</span></a></sup> Since disease progression is the result of degeneration of neurons, the roles of proteins showing loss of nerve tissue such as <a href="/wiki/Neurofilament" title="Neurofilament">neurofilaments</a>, <a href="/wiki/Tau_protein" title="Tau protein">tau</a>, and <a href="/wiki/N-acetylaspartate" title="N-acetylaspartate" class="mw-redirect">N-acetylaspartate</a> are under investigation.<sup id="cite_ref-pmid19712003_104-2" class="reference"><a href="#cite_note-pmid19712003-104"><span>[</span>104<span>]</span></a></sup> Other effects include looking for biomarkers that distinguish between those who will and will not respond to medications.<sup id="cite_ref-pmid19712003_104-3" class="reference"><a href="#cite_note-pmid19712003-104"><span>[</span>104<span>]</span></a></sup></p>
<p>Improvement in <a href="/wiki/Neuroimaging" title="Neuroimaging">neuroimaging</a> techniques such as <a href="/wiki/Positron_emission_tomography" title="Positron emission tomography">positron emission tomography</a> (PET) or <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> (MRI) carry a promise for better diagnosis and prognosis predictions, although the effect of such improvements in daily medical practice may take several decades.<sup id="cite_ref-pmid21425270_97-6" class="reference"><a href="#cite_note-pmid21425270-97"><span>[</span>97<span>]</span></a></sup> Regarding MRI, there are several techniques that have already shown some usefulness in research settings and could be introduced into clinical practice, such as double-inversion recovery sequences, <a href="/wiki/Magnetization_transfer" title="Magnetization transfer">magnetization transfer</a>, <a href="/wiki/Diffusion_MRI#Diffusion_tensor_imaging" title="Diffusion MRI">diffusion tensor</a>, and <a href="/wiki/Functional_magnetic_resonance_imaging" title="Functional magnetic resonance imaging">functional magnetic resonance imaging</a>.<sup id="cite_ref-pmid22159052_105-0" class="reference"><a href="#cite_note-pmid22159052-105"><span>[</span>105<span>]</span></a></sup> These techniques are more specific for the disease than existing ones, but still lack some standardization of acquisition protocols and the creation of normative values.<sup id="cite_ref-pmid22159052_105-1" class="reference"><a href="#cite_note-pmid22159052-105"><span>[</span>105<span>]</span></a></sup> There are other techniques under development that include contrast agents capable of measuring levels of peripheral <a href="/wiki/Macrophage" title="Macrophage">macrophages</a>, inflammation, or neuronal dysfunction,<sup id="cite_ref-pmid22159052_105-2" class="reference"><a href="#cite_note-pmid22159052-105"><span>[</span>105<span>]</span></a></sup> and techniques that measure iron deposition that could serve to determine the role of this feature in MS, or that of cerebral perfusion.<sup id="cite_ref-pmid22159052_105-3" class="reference"><a href="#cite_note-pmid22159052-105"><span>[</span>105<span>]</span></a></sup> Similarly, new PET <a href="/wiki/Radiotracer" title="Radiotracer" class="mw-redirect">radiotracers</a> might serve as markers of altered processes such as brain inflammation, cortical pathology, <a href="/wiki/Apoptosis" title="Apoptosis">apoptosis</a>, or remylienation.<sup id="cite_ref-pmid20636368_106-0" class="reference"><a href="#cite_note-pmid20636368-106"><span>[</span>106<span>]</span></a></sup> Antibiodies against the <a href="/wiki/Kir4.1" title="Kir4.1" class="mw-redirect">Kir4.1</a> potassium channel maybe related to MS.<sup id="cite_ref-107" class="reference"><a href="#cite_note-107"><span>[</span>107<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Chronic_cerebrospinal_venous_insufficiency">Chronic cerebrospinal venous insufficiency</span></h3>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Chronic_cerebrospinal_venous_insufficiency" title="Chronic cerebrospinal venous insufficiency">Chronic cerebrospinal venous insufficiency</a></div>
<p>In 2008, vascular surgeon <a href="/wiki/Paolo_Zamboni" title="Paolo Zamboni">Paolo Zamboni</a> suggested that MS involves narrowing of the veins draining the brain, which he referred to as <a href="/wiki/Chronic_cerebrospinal_venous_insufficiency" title="Chronic cerebrospinal venous insufficiency">chronic cerebrospinal venous insufficiency</a> (CCSVI). He found CCSVI in all patients with MS in his study, performed a surgical procedure, later called in the media the "liberation procedure" to correct it, and claimed that 73% of participants improved.<sup id="cite_ref-pmid19060024_108-0" class="reference"><a href="#cite_note-pmid19060024-108"><span>[</span>108<span>]</span></a></sup> This theory received significant attention in the media and among those with MS, especially in Canada.<sup id="cite_ref-pmid23402260_109-0" class="reference"><a href="#cite_note-pmid23402260-109"><span>[</span>109<span>]</span></a></sup> Concerns have been raised with Zamboni's research as it was neither blinded nor controlled, and its assumptions about the underlying cause of the disease is not backed by known data.<sup id="cite_ref-pmid20398855_110-0" class="reference"><a href="#cite_note-pmid20398855-110"><span>[</span>110<span>]</span></a></sup> Also, further studies have either not found a similar relationship or found one that is much less strong one,<sup id="cite_ref-pmid21161309_111-0" class="reference"><a href="#cite_note-pmid21161309-111"><span>[</span>111<span>]</span></a></sup> raising serious objections to the hypothesis.<sup id="cite_ref-Dorne_112-0" class="reference"><a href="#cite_note-Dorne-112"><span>[</span>112<span>]</span></a></sup> The "liberation procedure" has been criticized for resulting in serious complications and deaths with unproven benefits.<sup id="cite_ref-pmid20398855_110-1" class="reference"><a href="#cite_note-pmid20398855-110"><span>[</span>110<span>]</span></a></sup> It is, thus, as of 2013 not recommended for the treatment of MS.<sup id="cite_ref-113" class="reference"><a href="#cite_note-113"><span>[</span>113<span>]</span></a></sup> Additional research investigating the CCSVI hypothesis are underway.<sup id="cite_ref-a1_114-0" class="reference"><a href="#cite_note-a1-114"><span>[</span>114<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="See_also">See also</span></h2>
<ul>
<li><a href="/wiki/List_of_multiple_sclerosis_organizations" title="List of multiple sclerosis organizations">List of multiple sclerosis organizations</a></li>
<li><a href="/wiki/List_of_people_with_multiple_sclerosis" title="List of people with multiple sclerosis">List of people with multiple sclerosis</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-pmid18970977-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid18970977_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-33"><sup><i><b>ah</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-34"><sup><i><b>ai</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-35"><sup><i><b>aj</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-36"><sup><i><b>ak</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-37"><sup><i><b>al</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-38"><sup><i><b>am</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-39"><sup><i><b>an</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-40"><sup><i><b>ao</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-41"><sup><i><b>ap</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-42"><sup><i><b>aq</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-43"><sup><i><b>ar</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-44"><sup><i><b>as</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-45"><sup><i><b>at</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-46"><sup><i><b>au</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-47"><sup><i><b>av</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-48"><sup><i><b>aw</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-49"><sup><i><b>ax</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-50"><sup><i><b>ay</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-51"><sup><i><b>az</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-52"><sup><i><b>ba</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-53"><sup><i><b>bb</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-54"><sup><i><b>bc</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-55"><sup><i><b>bd</b></i></sup></a> <a href="#cite_ref-pmid18970977_1-56"><sup><i><b>be</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Compston A, Coles A (October 2008). "Multiple sclerosis". <i>Lancet</i> <b>372</b> (9648): 1502–17. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2808%2961620-7">10.1016/S0140-6736(08)61620-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18970977">18970977</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis&amp;rft.au=Compston+A%2C+Coles+A&amp;rft.aulast=Compston+A%2C+Coles+A&amp;rft.date=October+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2808%2961620-7&amp;rft_id=info%3Apmid%2F18970977&amp;rft.issue=9648&amp;rft.jtitle=Lancet&amp;rft.pages=1502%E2%80%9317&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=372" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11955556-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid11955556_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-pmid11955556_2-12"><sup><i><b>m</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Compston A, Coles A (April 2002). "Multiple sclerosis". <i>Lancet</i> <b>359</b> (9313): 1221–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2802%2908220-X">10.1016/S0140-6736(02)08220-X</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11955556">11955556</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis&amp;rft.au=Compston+A%2C+Coles+A&amp;rft.aulast=Compston+A%2C+Coles+A&amp;rft.date=April+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2802%2908220-X&amp;rft_id=info%3Apmid%2F11955556&amp;rft.issue=9313&amp;rft.jtitle=Lancet&amp;rft.pages=1221%E2%80%9331&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=359" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><span class="citation book">Murray ED, Buttner EA, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Daroff R, Fenichel G, Jankovic J, Mazziotta J. <i>Bradley's neurology in clinical practice.</i> (6th ed. ed.). Philadelphia, PA: Elsevier/Saunders. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1-4377-0434-4" title="Special:BookSources/1-4377-0434-4">1-4377-0434-4</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Bradley%27s+neurology+in+clinical+practice.&amp;rft.aulast=Murray+ED%2C+Buttner+EA%2C+Price+BH&amp;rft.au=Murray+ED%2C+Buttner+EA%2C+Price+BH&amp;rft.btitle=Depression+and+Psychosis+in+Neurological+Practice&amp;rft.date=2012&amp;rft.edition=6th+ed.&amp;rft.genre=bookitem&amp;rft.isbn=1-4377-0434-4&amp;rft.place=Philadelphia%2C+PA&amp;rft.pub=Elsevier%2FSaunders&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8780061-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid8780061_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-pmid8780061_4-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><span class="citation journal"><a href="/wiki/Fred_D._Lublin" title="Fred D. Lublin">Lublin FD</a>, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey". <i>Neurology</i> <b>46</b> (4): 907–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.46.4.907">10.1212/WNL.46.4.907</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8780061">8780061</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Defining+the+clinical+course+of+multiple+sclerosis%3A+results+of+an+international+survey&amp;rft.aulast=Lublin+FD%2C+Reingold+SC%3B+National+Multiple+Sclerosis+Society+%28USA%29+Advisory+Committee+on+Clinical+Trials+of+New+Agents+in+Multiple+Sclerosis&amp;rft.au=Lublin+FD%2C+Reingold+SC%3B+National+Multiple+Sclerosis+Society+%28USA%29+Advisory+Committee+on+Clinical+Trials+of+New+Agents+in+Multiple+Sclerosis&amp;rft.date=April+1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.46.4.907&amp;rft_id=info%3Apmid%2F8780061&amp;rft.issue=4&amp;rft.jtitle=Neurology&amp;rft.pages=907%E2%80%9311&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=46" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><span class="citation journal">Nakahara, J; Maeda, M; Aiso, S; Suzuki, N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.". <i>Clinical reviews in allergy &amp; immunology</i> <b>42</b> (1): 26–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs12016-011-8287-6">10.1007/s12016-011-8287-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22189514">22189514</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Current+concepts+in+multiple+sclerosis%3A+autoimmunity+versus+oligodendrogliopathy.&amp;rft.aufirst=J&amp;rft.aulast=Nakahara&amp;rft.au=Nakahara%2C+J&amp;rft.date=February+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs12016-011-8287-6&amp;rft_id=info%3Apmid%2F22189514&amp;rft.issue=1&amp;rft.jtitle=Clinical+reviews+in+allergy+%26+immunology&amp;rft.pages=26%E2%80%9334&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid17444504-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid17444504_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-pmid17444504_6-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Ascherio A, Munger KL (April 2007). "Environmental risk factors for multiple sclerosis. Part&#160;I: the role of infection". <i>Annals of Neurology</i> <b>61</b> (4): 288–99. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fana.21117">10.1002/ana.21117</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17444504">17444504</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Environmental+risk+factors+for+multiple+sclerosis.+Part%26nbsp%3BI%3A+the+role+of+infection&amp;rft.au=Ascherio+A%2C+Munger+KL&amp;rft.aulast=Ascherio+A%2C+Munger+KL&amp;rft.date=April+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.21117&amp;rft_id=info%3Apmid%2F17444504&amp;rft.issue=4&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=288%E2%80%9399&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8017890-7"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid8017890_7-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid8017890_7-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid8017890_7-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Weinshenker BG (1994). "Natural history of multiple sclerosis". <i>Annals of Neurology</i> <b>36</b> (Suppl): S6–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fana.410360704">10.1002/ana.410360704</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8017890">8017890</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Natural+history+of+multiple+sclerosis&amp;rft.aulast=Weinshenker+BG&amp;rft.au=Weinshenker+BG&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.410360704&amp;rft_id=info%3Apmid%2F8017890&amp;rft.issue=Suppl&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=S6%E2%80%9311&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=36" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Atlas2008-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Atlas2008_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Atlas2008_8-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation book">World Health Organization (2008). <a rel="nofollow" class="external text" href="http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdf"><i>Atlas: Multiple Sclerosis Resources in the World 2008</i></a>. Geneva: World Health Organization. pp.&#160;15–16. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/92-4-156375-3" title="Special:BookSources/92-4-156375-3">92-4-156375-3</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.aulast=World+Health+Organization&amp;rft.au=World+Health+Organization&amp;rft.btitle=Atlas%3A+Multiple+Sclerosis+Resources+in+the+World+2008&amp;rft.date=2008&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwhqlibdoc.who.int%2Fpublications%2F2008%2F9789241563758_eng.pdf&amp;rft.isbn=92-4-156375-3&amp;rft.pages=15%E2%80%9316&amp;rft.place=Geneva&amp;rft.pub=World+Health+Organization&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Milo2010-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Milo2010_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Milo2010_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Milo2010_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Milo2010_9-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Milo2010_9-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Milo2010_9-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Milo2010_9-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Milo2010_9-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Milo2010_9-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Milo2010_9-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Milo2010_9-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Milo2010_9-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Milo2010_9-12"><sup><i><b>m</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Milo R, Kahana E (March 2010). "Multiple sclerosis: geoepidemiology, genetics and the environment". <i>Autoimmun Rev</i> <b>9</b> (5): A387–94. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.autrev.2009.11.010">10.1016/j.autrev.2009.11.010</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19932200">19932200</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis%3A+geoepidemiology%2C+genetics+and+the+environment&amp;rft.aulast=Milo+R%2C+Kahana+E&amp;rft.au=Milo+R%2C+Kahana+E&amp;rft.date=March+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.autrev.2009.11.010&amp;rft_id=info%3Apmid%2F19932200&amp;rft.issue=5&amp;rft.jtitle=Autoimmun+Rev&amp;rft.pages=A387%E2%80%9394&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Charcot1-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Charcot1_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Charcot1_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Charcot1_10-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Clanet M (June 2008). <a rel="nofollow" class="external text" href="http://www.msforum.net/Site/ViewPDF/ViewPDF.aspx?ArticleID=E80DC748-5048-4BD2-9393-18BCAE0A1514&amp;doctype=Article">"Jean-Martin Charcot. 1825 to 1893"</a> (PDF). <i>Int MS J</i> <b>15</b> (2): 59–61. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18782501">18782501</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Jean-Martin+Charcot.+1825+to+1893&amp;rft.au=Clanet+M&amp;rft.aulast=Clanet+M&amp;rft.date=June+2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.msforum.net%2FSite%2FViewPDF%2FViewPDF.aspx%3FArticleID%3DE80DC748-5048-4BD2-9393-18BCAE0A1514%26doctype%3DArticle&amp;rft_id=info%3Apmid%2F18782501&amp;rft.issue=2&amp;rft.jtitle=Int+MS+J&amp;rft.pages=59%E2%80%9361&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span><br />
* <span class="citation journal">Charcot, J. (1868). "Histologie de la sclerose en plaques". <i>Gazette des hopitaux, Paris</i> <b>41</b>: 554–5.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Histologie+de+la+sclerose+en+plaques&amp;rft.au=Charcot%2C+J.&amp;rft.aulast=Charcot%2C+J.&amp;rft.date=1868&amp;rft.genre=article&amp;rft.jtitle=Gazette+des+hopitaux%2C+Paris&amp;rft.pages=554%E2%80%935&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=41" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><span class="citation journal">Kurtzke JF (1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". <i>Neurology</i> <b>33</b> (11): 1444–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.33.11.1444">10.1212/WNL.33.11.1444</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/6685237">6685237</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Rating+neurologic+impairment+in+multiple+sclerosis%3A+an+expanded+disability+status+scale+%28EDSS%29&amp;rft.au=Kurtzke+JF&amp;rft.aulast=Kurtzke+JF&amp;rft.date=1983&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.33.11.1444&amp;rft_id=info%3Apmid%2F6685237&amp;rft.issue=11&amp;rft.jtitle=Neurology&amp;rft.pages=1444%E2%80%9352&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10467378-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10467378_12-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Amato MP, Ponziani G (August 1999). "Quantification of impairment in MS: discussion of the scales in use". <i>Mult. Scler.</i> <b>5</b> (4): 216–9. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10467378">10467378</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Quantification+of+impairment+in+MS%3A+discussion+of+the+scales+in+use&amp;rft.au=Amato+MP%2C+Ponziani+G&amp;rft.aulast=Amato+MP%2C+Ponziani+G&amp;rft.date=August+1999&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F10467378&amp;rft.issue=4&amp;rft.jtitle=Mult.+Scler.&amp;rft.pages=216%E2%80%939&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12356200-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12356200_13-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Rudick RA, Cutter G, Reingold S (October 2002). "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials". <i>Mult. Scler.</i> <b>8</b> (5): 359–65. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12356200">12356200</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+multiple+sclerosis+functional+composite%3A+a+new+clinical+outcome+measure+for+multiple+sclerosis+trials&amp;rft.aulast=Rudick+RA%2C+Cutter+G%2C+Reingold+S&amp;rft.au=Rudick+RA%2C+Cutter+G%2C+Reingold+S&amp;rft.date=October+2002&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F12356200&amp;rft.issue=5&amp;rft.jtitle=Mult.+Scler.&amp;rft.pages=359%E2%80%9365&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Tsang2011-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tsang2011_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Tsang2011_14-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Tsang, BK; Macdonell, R (December 2011). "Multiple sclerosis- diagnosis, management and prognosis.". <i>Australian family physician</i> <b>40</b> (12): 948–55. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22146321">22146321</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis-+diagnosis%2C+management+and+prognosis.&amp;rft.aufirst=BK&amp;rft.aulast=Tsang&amp;rft.au=Tsang%2C+BK&amp;rft.date=December+2011&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22146321&amp;rft.issue=12&amp;rft.jtitle=Australian+family+physician&amp;rft.pages=948%E2%80%9355&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=40" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid16804331-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16804331_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16804331_15-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). "Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis". <i>Neuroepidemiology</i> <b>27</b> (1): 28–32. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1159%2F000094233">10.1159/000094233</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16804331">16804331</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Limited+impact+of+the+summer+heat+wave+in+France+%282003%29+on+hospital+admissions+and+relapses+for+multiple+sclerosis&amp;rft.aulast=Tataru+N%2C+Vidal+C%2C+Decavel+P%2C+Berger+E%2C+Rumbach+L&amp;rft.au=Tataru+N%2C+Vidal+C%2C+Decavel+P%2C+Berger+E%2C+Rumbach+L&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1159%2F000094233&amp;rft_id=info%3Apmid%2F16804331&amp;rft.issue=1&amp;rft.jtitle=Neuroepidemiology&amp;rft.pages=28%E2%80%9332&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17439878-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17439878_16-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Heesen C, Mohr DC, Huitinga I, <i>et al.</i> (March 2007). "Stress regulation in multiple sclerosis: current issues and concepts". <i>Mult. Scler.</i> <b>13</b> (2): 143–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F1352458506070772">10.1177/1352458506070772</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17439878">17439878</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Stress+regulation+in+multiple+sclerosis%3A+current+issues+and+concepts&amp;rft.au=Heesen+C%2C+Mohr+DC%2C+Huitinga+I%2C+%27%27et+al.%27%27&amp;rft.aulast=Heesen+C%2C+Mohr+DC%2C+Huitinga+I%2C+%27%27et+al.%27%27&amp;rft.date=March+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1352458506070772&amp;rft_id=info%3Apmid%2F17439878&amp;rft.issue=2&amp;rft.jtitle=Mult.+Scler.&amp;rft.pages=143%E2%80%938&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11205361-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11205361_17-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Martinelli V (2000). <a rel="nofollow" class="external text" href="http://link.springer-ny.com/link/service/journals/10072/bibs/00214%20Suppl%202/0021S849.htm">"Trauma, stress and multiple sclerosis"</a>. <i>Neurol. Sci.</i> <b>21</b> (4 Suppl 2): S849–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs100720070024">10.1007/s100720070024</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11205361">11205361</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Trauma%2C+stress+and+multiple+sclerosis&amp;rft.aulast=Martinelli+V&amp;rft.au=Martinelli+V&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flink.springer-ny.com%2Flink%2Fservice%2Fjournals%2F10072%2Fbibs%2F00214%2520Suppl%25202%2F0021S849.htm&amp;rft_id=info%3Adoi%2F10.1007%2Fs100720070024&amp;rft_id=info%3Apmid%2F11205361&amp;rft.issue=4+Suppl+2&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=S849%E2%80%9352&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15556803-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15556803_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15556803_18-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid15556803_18-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid15556803_18-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid15556803_18-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid15556803_18-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Marrie RA (December 2004). "Environmental risk factors in multiple sclerosis aetiology". <i>Lancet Neurol</i> <b>3</b> (12): 709–18. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2804%2900933-0">10.1016/S1474-4422(04)00933-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15556803">15556803</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Environmental+risk+factors+in+multiple+sclerosis+aetiology&amp;rft.aulast=Marrie+RA&amp;rft.au=Marrie+RA&amp;rft.date=December+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2804%2900933-0&amp;rft_id=info%3Apmid%2F15556803&amp;rft.issue=12&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=709%E2%80%9318&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18606967-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid18606967_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18606967_19-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid18606967_19-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Alonso A, Hernán MA (July 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". <i>Neurology</i> <b>71</b> (2): 129–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2F01.wnl.0000316802.35974.34">10.1212/01.wnl.0000316802.35974.34</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18606967">18606967</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Temporal+trends+in+the+incidence+of+multiple+sclerosis%3A+a+systematic+review&amp;rft.au=Alonso+A%2C+Hern%C3%A1n+MA&amp;rft.aulast=Alonso+A%2C+Hern%C3%A1n+MA&amp;rft.date=July+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2F01.wnl.0000316802.35974.34&amp;rft_id=info%3Apmid%2F18606967&amp;rft.issue=2&amp;rft.jtitle=Neurology&amp;rft.pages=129%E2%80%9335&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=71" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12127652-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12127652_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12127652_20-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Pugliatti M, Sotgiu S, Rosati G (July 2002). "The worldwide prevalence of multiple sclerosis". <i>Clin Neurol Neurosurg</i> <b>104</b> (3): 182–91. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0303-8467%2802%2900036-7">10.1016/S0303-8467(02)00036-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12127652">12127652</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+worldwide+prevalence+of+multiple+sclerosis&amp;rft.aulast=Pugliatti+M%2C+Sotgiu+S%2C+Rosati+G&amp;rft.au=Pugliatti+M%2C+Sotgiu+S%2C+Rosati+G&amp;rft.date=July+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0303-8467%2802%2900036-7&amp;rft_id=info%3Apmid%2F12127652&amp;rft.issue=3&amp;rft.jtitle=Clin+Neurol+Neurosurg&amp;rft.pages=182%E2%80%9391&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17492755-21"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid17492755_21-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17492755_21-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid17492755_21-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid17492755_21-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Ascherio A, Munger KL (June 2007). "Environmental risk factors for multiple sclerosis. Part&#160;II: Noninfectious factors". <i>Annals of Neurology</i> <b>61</b> (6): 504–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fana.21141">10.1002/ana.21141</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17492755">17492755</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Environmental+risk+factors+for+multiple+sclerosis.+Part%26nbsp%3BII%3A+Noninfectious+factors&amp;rft.au=Ascherio+A%2C+Munger+KL&amp;rft.aulast=Ascherio+A%2C+Munger+KL&amp;rft.date=June+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.21141&amp;rft_id=info%3Apmid%2F17492755&amp;rft.issue=6&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=504%E2%80%9313&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid20494325-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20494325_22-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ascherio A, Munger KL, Simon KC (June 2010). "Vitamin D and multiple sclerosis". <i>Lancet Neurol</i> <b>9</b> (6): 599–612. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2810%2970086-7">10.1016/S1474-4422(10)70086-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20494325">20494325</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Vitamin+D+and+multiple+sclerosis&amp;rft.au=Ascherio+A%2C+Munger+KL%2C+Simon+KC&amp;rft.aulast=Ascherio+A%2C+Munger+KL%2C+Simon+KC&amp;rft.date=June+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2810%2970086-7&amp;rft_id=info%3Apmid%2F20494325&amp;rft.issue=6&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=599%E2%80%93612&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19897699-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19897699_23-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). "Vitamin D: an evidence-based review". <i>J Am Board Fam Med</i> <b>22</b> (6): 698–706. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.3122%2Fjabfm.2009.06.090037">10.3122/jabfm.2009.06.090037</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19897699">19897699</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Vitamin+D%3A+an+evidence-based+review&amp;rft.au=Kulie+T%2C+Groff+A%2C+Redmer+J%2C+Hounshell+J%2C+Schrager+S&amp;rft.aulast=Kulie+T%2C+Groff+A%2C+Redmer+J%2C+Hounshell+J%2C+Schrager+S&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3122%2Fjabfm.2009.06.090037&amp;rft_id=info%3Apmid%2F19897699&amp;rft.issue=6&amp;rft.jtitle=J+Am+Board+Fam+Med&amp;rft.pages=698%E2%80%93706&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14747002-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14747002_24-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Dyment DA, Ebers GC, Sadovnick AD (February 2004). "Genetics of multiple sclerosis". <i>Lancet Neurol</i> <b>3</b> (92): 104–10. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2803%2900663-X">10.1016/S1474-4422(03)00663-X</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14747002">14747002</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Genetics+of+multiple+sclerosis&amp;rft.au=Dyment+DA%2C+Ebers+GC%2C+Sadovnick+AD&amp;rft.aulast=Dyment+DA%2C+Ebers+GC%2C+Sadovnick+AD&amp;rft.date=February+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2803%2900663-X&amp;rft_id=info%3Apmid%2F14747002&amp;rft.issue=92&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=104%E2%80%9310&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><span class="citation journal">Hassan-Smith, G; Douglas, MR (October 2011). "Epidemiology and diagnosis of multiple sclerosis.". <i>British journal of hospital medicine (London, England&#160;: 2005)</i> <b>72</b> (10): M146–51. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22041658">22041658</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Epidemiology+and+diagnosis+of+multiple+sclerosis.&amp;rft.aufirst=G&amp;rft.au=Hassan-Smith%2C+G&amp;rft.aulast=Hassan-Smith&amp;rft.date=October+2011&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22041658&amp;rft.issue=10&amp;rft.jtitle=British+journal+of+hospital+medicine+%28London%2C+England+%3A+2005%29&amp;rft.pages=M146%E2%80%9351&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid11603614-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11603614_26-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". <i>Neurol. Sci.</i> <b>22</b> (2): 117–39. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs100720170011">10.1007/s100720170011</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11603614">11603614</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+prevalence+of+multiple+sclerosis+in+the+world%3A+an+update&amp;rft.aulast=Rosati+G&amp;rft.au=Rosati+G&amp;rft.date=April+2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs100720170011&amp;rft_id=info%3Apmid%2F11603614&amp;rft.issue=2&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=117%E2%80%9339&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21247752-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21247752_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21247752_27-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid21247752_27-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid21247752_27-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Baranzini SE (June 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3105160">"Revealing the genetic basis of multiple sclerosis: are we there yet?"</a>. <i>Current Opinion in Genetics &amp; Development</i> <b>21</b> (3): 317–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.gde.2010.12.006">10.1016/j.gde.2010.12.006</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3105160">3105160</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21247752">21247752</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Revealing+the+genetic+basis+of+multiple+sclerosis%3A+are+we+there+yet%3F&amp;rft.au=Baranzini+SE&amp;rft.aulast=Baranzini+SE&amp;rft.date=June+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3105160&amp;rft_id=info%3Adoi%2F10.1016%2Fj.gde.2010.12.006&amp;rft_id=info%3Apmc%2F3105160&amp;rft_id=info%3Apmid%2F21247752&amp;rft.issue=3&amp;rft.jtitle=Current+Opinion+in+Genetics+%26+Development&amp;rft.pages=317%E2%80%9324&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8269393-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid8269393_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid8269393_28-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Kurtzke JF (October 1993). <a rel="nofollow" class="external text" href="http://cmr.asm.org/cgi/pmidlookup?view=long&amp;pmid=8269393">"Epidemiologic evidence for multiple sclerosis as an infection"</a>. <i>Clin. Microbiol. Rev.</i> <b>6</b> (4): 382–427. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1128%2FCMR.6.4.382">10.1128/CMR.6.4.382</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC358295">358295</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8269393">8269393</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Epidemiologic+evidence+for+multiple+sclerosis+as+an+infection&amp;rft.au=Kurtzke+JF&amp;rft.aulast=Kurtzke+JF&amp;rft.date=October+1993&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcmr.asm.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D8269393&amp;rft_id=info%3Adoi%2F10.1128%2FCMR.6.4.382&amp;rft_id=info%3Apmc%2F358295&amp;rft_id=info%3Apmid%2F8269393&amp;rft.issue=4&amp;rft.jtitle=Clin.+Microbiol.+Rev.&amp;rft.pages=382%E2%80%93427&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15721830-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15721830_29-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Gilden DH (March 2005). "Infectious causes of multiple sclerosis". <i><a href="/wiki/The_Lancet_Neurology" title="The Lancet Neurology" class="mw-redirect">The Lancet Neurology</a></i> <b>4</b> (3): 195–202. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2805%2901017-3">10.1016/S1474-4422(05)01017-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15721830">15721830</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Infectious+causes+of+multiple+sclerosis&amp;rft.au=Gilden+DH&amp;rft.aulast=Gilden+DH&amp;rft.date=March+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2805%2901017-3&amp;rft_id=info%3Apmid%2F15721830&amp;rft.issue=3&amp;rft.jtitle=The+Lancet+Neurology&amp;rft.pages=195%E2%80%93202&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18219824-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18219824_30-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Spitsin S, Koprowski H (2008). "Role of uric acid in multiple sclerosis". <i>Curr. Top. Microbiol. Immunol.</i> <b>318</b>: 325–42. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18219824">18219824</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Role+of+uric+acid+in+multiple+sclerosis&amp;rft.aulast=Spitsin+S%2C+Koprowski+H&amp;rft.au=Spitsin+S%2C+Koprowski+H&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F18219824&amp;rft.jtitle=Curr.+Top.+Microbiol.+Immunol.&amp;rft.pages=325%E2%80%9342&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=318" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17531860-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid17531860_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17531860_31-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Chari DM (2007). "Remyelination in multiple sclerosis". <i>Int. Rev. Neurobiol.</i> <b>79</b>: 589–620. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0074-7742%2807%2979026-8">10.1016/S0074-7742(07)79026-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17531860">17531860</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Remyelination+in+multiple+sclerosis&amp;rft.au=Chari+DM&amp;rft.aulast=Chari+DM&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0074-7742%2807%2979026-8&amp;rft_id=info%3Apmid%2F17531860&amp;rft.jtitle=Int.+Rev.+Neurobiol.&amp;rft.pages=589%E2%80%93620&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=79" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17351524-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17351524_32-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Pittock SJ, Lucchinetti CF (March 2007). "The pathology of MS: new insights and potential clinical applications". <i>Neurologist</i> <b>13</b> (2): 45–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1097%2F01.nrl.0000253065.31662.37">10.1097/01.nrl.0000253065.31662.37</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17351524">17351524</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+pathology+of+MS%3A+new+insights+and+potential+clinical+applications&amp;rft.aulast=Pittock+SJ%2C+Lucchinetti+CF&amp;rft.au=Pittock+SJ%2C+Lucchinetti+CF&amp;rft.date=March+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F01.nrl.0000253065.31662.37&amp;rft_id=info%3Apmid%2F17351524&amp;rft.issue=2&amp;rft.jtitle=Neurologist&amp;rft.pages=45%E2%80%9356&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23088946-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23088946_33-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ferré JC, Shiroishi MS, Law M (November 2012). "Advanced techniques using contrast media in neuroimaging". <i>Magn Reson Imaging Clin N Am</i> <b>20</b> (4): 699–713. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.mric.2012.07.007">10.1016/j.mric.2012.07.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23088946">23088946</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Advanced+techniques+using+contrast+media+in+neuroimaging&amp;rft.au=Ferr%C3%A9+JC%2C+Shiroishi+MS%2C+Law+M&amp;rft.aulast=Ferr%C3%A9+JC%2C+Shiroishi+MS%2C+Law+M&amp;rft.date=November+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.mric.2012.07.007&amp;rft_id=info%3Apmid%2F23088946&amp;rft.issue=4&amp;rft.jtitle=Magn+Reson+Imaging+Clin+N+Am&amp;rft.pages=699%E2%80%93713&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11794488-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11794488_34-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Trojano M, Paolicelli D (November 2001). <a rel="nofollow" class="external text" href="http://link.springer-ny.com/link/service/journals/10072/bibs/122%20Suppl%202000/122%20Suppl%2020S98.htm">"The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes"</a>. <i>Neurol. Sci.</i> <b>22</b> (Suppl 2): S98–102. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs100720100044">10.1007/s100720100044</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11794488">11794488</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+differential+diagnosis+of+multiple+sclerosis%3A+classification+and+clinical+features+of+relapsing+and+progressive+neurological+syndromes&amp;rft.aulast=Trojano+M%2C+Paolicelli+D&amp;rft.au=Trojano+M%2C+Paolicelli+D&amp;rft.date=November+2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flink.springer-ny.com%2Flink%2Fservice%2Fjournals%2F10072%2Fbibs%2F122%2520Suppl%25202000%2F122%2520Suppl%252020S98.htm&amp;rft_id=info%3Adoi%2F10.1007%2Fs100720100044&amp;rft_id=info%3Apmid%2F11794488&amp;rft.issue=Suppl+2&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=S98%E2%80%93102&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15177763-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15177763_35-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Poser CM, Brinar VV (June 2004). "Diagnostic criteria for multiple sclerosis: an historical review". <i>Clin Neurol Neurosurg</i> <b>106</b> (3): 147–58. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.clineuro.2004.02.004">10.1016/j.clineuro.2004.02.004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15177763">15177763</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Diagnostic+criteria+for+multiple+sclerosis%3A+an+historical+review&amp;rft.aulast=Poser+CM%2C+Brinar+VV&amp;rft.au=Poser+CM%2C+Brinar+VV&amp;rft.date=June+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clineuro.2004.02.004&amp;rft_id=info%3Apmid%2F15177763&amp;rft.issue=3&amp;rft.jtitle=Clin+Neurol+Neurosurg&amp;rft.pages=147%E2%80%9358&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11456302-36"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid11456302_36-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11456302_36-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid11456302_36-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid11456302_36-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">McDonald WI, Compston A, Edan G, <i>et al.</i> (July 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". <i>Annals of Neurology</i> <b>50</b> (1): 121–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fana.1032">10.1002/ana.1032</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11456302">11456302</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Recommended+diagnostic+criteria+for+multiple+sclerosis%3A+guidelines+from+the+International+Panel+on+the+diagnosis+of+multiple+sclerosis&amp;rft.aulast=McDonald+WI%2C+Compston+A%2C+Edan+G%2C+%27%27et+al.%27%27&amp;rft.au=McDonald+WI%2C+Compston+A%2C+Edan+G%2C+%27%27et+al.%27%27&amp;rft.date=July+2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.1032&amp;rft_id=info%3Apmid%2F11456302&amp;rft.issue=1&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=121%E2%80%937&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16283615-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16283615_37-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Polman CH, Reingold SC, Edan G, <i>et al.</i> (December 2005). "Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria<span style="padding-right:0.2em;">"</span>". <i>Annals of Neurology</i> <b>58</b> (6): 840–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fana.20703">10.1002/ana.20703</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16283615">16283615</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Diagnostic+criteria+for+multiple+sclerosis%3A+2005+revisions+to+the+%22McDonald+Criteria%22&amp;rft.aulast=Polman+CH%2C+Reingold+SC%2C+Edan+G%2C+%27%27et+al.%27%27&amp;rft.au=Polman+CH%2C+Reingold+SC%2C+Edan+G%2C+%27%27et+al.%27%27&amp;rft.date=December+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.20703&amp;rft_id=info%3Apmid%2F16283615&amp;rft.issue=6&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=840%E2%80%936&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=58" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18256986-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18256986_38-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Rashid W, Miller DH (February 2008). "Recent advances in neuroimaging of multiple sclerosis". <i>Semin Neurol</i> <b>28</b> (1): 46–55. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1055%2Fs-2007-1019127">10.1055/s-2007-1019127</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18256986">18256986</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Recent+advances+in+neuroimaging+of+multiple+sclerosis&amp;rft.aulast=Rashid+W%2C+Miller+DH&amp;rft.au=Rashid+W%2C+Miller+DH&amp;rft.date=February+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1055%2Fs-2007-1019127&amp;rft_id=info%3Apmid%2F18256986&amp;rft.issue=1&amp;rft.jtitle=Semin+Neurol&amp;rft.pages=46%E2%80%9355&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16945427-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16945427_39-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Link H, Huang YM (November 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". <i>J. Neuroimmunol.</i> <b>180</b> (1–2): 17–28. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.jneuroim.2006.07.006">10.1016/j.jneuroim.2006.07.006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16945427">16945427</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Oligoclonal+bands+in+multiple+sclerosis+cerebrospinal+fluid%3A+an+update+on+methodology+and+clinical+usefulness&amp;rft.aulast=Link+H%2C+Huang+YM&amp;rft.au=Link+H%2C+Huang+YM&amp;rft.date=November+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jneuroim.2006.07.006&amp;rft_id=info%3Apmid%2F16945427&amp;rft.issue=1%E2%80%932&amp;rft.jtitle=J.+Neuroimmunol.&amp;rft.pages=17%E2%80%9328&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=180" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10802774-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10802774_40-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Gronseth GS, Ashman EJ (May 2000). "Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". <i>Neurology</i> <b>54</b> (9): 1720–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.54.9.1720">10.1212/WNL.54.9.1720</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10802774">10802774</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Practice+parameter%3A+the+usefulness+of+evoked+potentials+in+identifying+clinically+silent+lesions+in+patients+with+suspected+multiple+sclerosis+%28an+evidence-based+review%29%3A+Report+of+the+Quality+Standards+Subcommittee+of+the+American+Academy+of+Neurology&amp;rft.au=Gronseth+GS%2C+Ashman+EJ&amp;rft.aulast=Gronseth+GS%2C+Ashman+EJ&amp;rft.date=May+2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.54.9.1720&amp;rft_id=info%3Apmid%2F10802774&amp;rft.issue=9&amp;rft.jtitle=Neurology&amp;rft.pages=1720%E2%80%935&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=54" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18219812-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18219812_41-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Pittock SJ, Rodriguez M (2008). "Benign multiple sclerosis: a distinct clinical entity with therapeutic implications". <i>Curr. Top. Microbiol. Immunol.</i> <b>318</b>: 1–17. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2F978-3-540-73677-6_1">10.1007/978-3-540-73677-6_1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18219812">18219812</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Benign+multiple+sclerosis%3A+a+distinct+clinical+entity+with+therapeutic+implications&amp;rft.aulast=Pittock+SJ%2C+Rodriguez+M&amp;rft.au=Pittock+SJ%2C+Rodriguez+M&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2F978-3-540-73677-6_1&amp;rft_id=info%3Apmid%2F18219812&amp;rft.jtitle=Curr.+Top.+Microbiol.+Immunol.&amp;rft.pages=1%E2%80%9317&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=318" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation book">Feinstein, A (2007). <i>The clinical neuropsychiatry of multiple sclerosis</i> (2nd ed. ed.). Cambridge: Cambridge University Press. p.&#160;20. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/052185234X" title="Special:BookSources/052185234X">052185234X</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.au=Feinstein%2C+A&amp;rft.aufirst=A&amp;rft.aulast=Feinstein&amp;rft.btitle=The+clinical+neuropsychiatry+of+multiple+sclerosis&amp;rft.date=2007&amp;rft.edition=2nd+ed.&amp;rft.genre=book&amp;rft.isbn=052185234X&amp;rft.pages=20&amp;rft.place=Cambridge&amp;rft.pub=Cambridge+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15847841-43"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15847841_43-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15847841_43-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (May 2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". <i>Lancet Neurol</i> <b>4</b> (5): 281–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2805%2970071-5">10.1016/S1474-4422(05)70071-5</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15847841">15847841</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Clinically+isolated+syndromes+suggestive+of+multiple+sclerosis%2C+part+I%3A+natural+history%2C+pathogenesis%2C+diagnosis%2C+and+prognosis&amp;rft.aulast=Miller+D%2C+Barkhof+F%2C+Montalban+X%2C+Thompson+A%2C+Filippi+M&amp;rft.au=Miller+D%2C+Barkhof+F%2C+Montalban+X%2C+Thompson+A%2C+Filippi+M&amp;rft.date=May+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2805%2970071-5&amp;rft_id=info%3Apmid%2F15847841&amp;rft.issue=5&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=281%E2%80%938&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16545751-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16545751_44-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (April 2006). "Secondary progressive multiple sclerosis: current knowledge and future challenges". <i>Lancet Neurol</i> <b>5</b> (4): 343–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2806%2970410-0">10.1016/S1474-4422(06)70410-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16545751">16545751</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Secondary+progressive+multiple+sclerosis%3A+current+knowledge+and+future+challenges&amp;rft.aulast=Rovaris+M%2C+Confavreux+C%2C+Furlan+R%2C+Kappos+L%2C+Comi+G%2C+Filippi+M&amp;rft.au=Rovaris+M%2C+Confavreux+C%2C+Furlan+R%2C+Kappos+L%2C+Comi+G%2C+Filippi+M&amp;rft.date=April+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2806%2970410-0&amp;rft_id=info%3Apmid%2F16545751&amp;rft.issue=4&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=343%E2%80%9354&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17884680-45"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid17884680_45-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17884680_45-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid17884680_45-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Miller DH, Leary SM (October 2007). "Primary-progressive multiple sclerosis". <i>Lancet Neurol</i> <b>6</b> (10): 903–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2807%2970243-0">10.1016/S1474-4422(07)70243-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17884680">17884680</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Primary-progressive+multiple+sclerosis&amp;rft.aulast=Miller+DH%2C+Leary+SM&amp;rft.au=Miller+DH%2C+Leary+SM&amp;rft.date=October+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2807%2970243-0&amp;rft_id=info%3Apmid%2F17884680&amp;rft.issue=10&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=903%E2%80%9312&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15727225-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15727225_46-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Stadelmann C, Brück W (November 2004). "Lessons from the neuropathology of atypical forms of multiple sclerosis". <i>Neurol. Sci.</i> <b>25</b> (Suppl 4): S319–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs10072-004-0333-1">10.1007/s10072-004-0333-1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15727225">15727225</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Lessons+from+the+neuropathology+of+atypical+forms+of+multiple+sclerosis&amp;rft.aulast=Stadelmann+C%2C+Br%C3%BCck+W&amp;rft.au=Stadelmann+C%2C+Br%C3%BCck+W&amp;rft.date=November+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs10072-004-0333-1&amp;rft_id=info%3Apmid%2F15727225&amp;rft.issue=Suppl+4&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=S319%E2%80%9322&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><span class="citation Journal">Burton, JM (12 December 2012). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.". <i><a href="/wiki/Cochrane_Library" title="Cochrane Library">Cochrane Database of Systematic Reviews</a></i> (12): <a rel="nofollow" class="external text" href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD006921/frame.html">CD006921</a>&#160;(Orig.&#160;rev.). <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD006921">10.1002/14651858.CD006921</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23235634">23235634</a>.</span></span></li>
<li id="cite_note-RCOP_acute-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-RCOP_acute_48-0">^</a></b></span> <span class="reference-text"><span class="citation book"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/books/NBK48919/pdf/TOC.pdf"><i>Multiple sclerosis&#160;: national clinical guideline for diagnosis and management in primary and secondary care</i></a> (pdf). London: Royal College of Physicians. 2004. pp.&#160;54–57. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1-86016-182-0" title="Special:BookSources/1-86016-182-0">1-86016-182-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21290636">21290636</a><span class="reference-accessdate">. Retrieved 6 February 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=Multiple+sclerosis+%3A+national+clinical+guideline+for+diagnosis+and+management+in+primary+and+secondary+care&amp;rft.date=2004&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK48919%2Fpdf%2FTOC.pdf&amp;rft_id=info%3Apmid%2F21290636&amp;rft.isbn=1-86016-182-0&amp;rft.pages=54%E2%80%9357&amp;rft.place=London&amp;rft.pub=Royal+College+of+Physicians&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-He2012-49"><span class="mw-cite-backlink">^ <a href="#cite_ref-He2012_49-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-He2012_49-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-He2012_49-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">He, D; Xu, Z; Dong, S; Zhang, H; Zhou, H; Wang, L; Zhang, S (12 December 2012). "Teriflunomide for multiple sclerosis". In Zhou, Hongyu. <i>Cochrane database of systematic reviews (Online)</i> <b>12</b>: CD009882. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD009882.pub2">10.1002/14651858.CD009882.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23235682">23235682</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Teriflunomide+for+multiple+sclerosis&amp;rft.aufirst=D&amp;rft.au=He%2C+D&amp;rft.aulast=He&amp;rft.date=12+December+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009882.pub2&amp;rft_id=info%3Apmid%2F23235682&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD009882&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-Aubagio-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-Aubagio_50-0">^</a></b></span> <span class="reference-text"><span class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm">"FDA approves new multiple sclerosis treatment Aubagio"</a> (Press release). US FDA. 12 September 2012<span class="reference-accessdate">. Retrieved 21 January 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=FDA+approves+new+multiple+sclerosis+treatment+Aubagio&amp;rft.date=12+September+2012&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm319277.htm&amp;rft.pub=US+FDA&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-fumarate-51"><span class="mw-cite-backlink">^ <a href="#cite_ref-fumarate_51-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-fumarate_51-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.biogenidec.com/press_release_details.aspx?ID=5981&amp;ReqId=1801165">"Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis"</a> (Press release). Biogen Idec. 27 March 2013<span class="reference-accessdate">. Retrieved 4 June 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=Biogen+Idec%E2%80%99s+TECFIDERA%E2%84%A2+%28Dimethyl+Fumarate%29+Approved+in+US+as+a+First-Line+Oral+Treatment+for+Multiple+Sclerosis&amp;rft.date=27+March+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.biogenidec.com%2Fpress_release_details.aspx%3FID%3D5981%26ReqId%3D1801165&amp;rft.pub=Biogen+Idec&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><span class="citation journal">Manouchehrinia, A; Constantinescu, CS (October 2012). "Cost-effectiveness of disease-modifying therapies in multiple sclerosis.". <i>Current neurology and neuroscience reports</i> <b>12</b> (5): 592–600. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs11910-012-0291-6">10.1007/s11910-012-0291-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22782520">22782520</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Cost-effectiveness+of+disease-modifying+therapies+in+multiple+sclerosis.&amp;rft.aufirst=A&amp;rft.aulast=Manouchehrinia&amp;rft.au=Manouchehrinia%2C+A&amp;rft.date=October+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs11910-012-0291-6&amp;rft_id=info%3Apmid%2F22782520&amp;rft.issue=5&amp;rft.jtitle=Current+neurology+and+neuroscience+reports&amp;rft.pages=592%E2%80%93600&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-Hassan2011-53"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hassan2011_53-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hassan2011_53-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Hassan-Smith, G; Douglas, MR (November 2011). "Management and prognosis of multiple sclerosis.". <i>British journal of hospital medicine (London, England&#160;: 2005)</i> <b>72</b> (11): M174–6. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22082979">22082979</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Management+and+prognosis+of+multiple+sclerosis.&amp;rft.aufirst=G&amp;rft.au=Hassan-Smith%2C+G&amp;rft.aulast=Hassan-Smith&amp;rft.date=November+2011&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22082979&amp;rft.issue=11&amp;rft.jtitle=British+journal+of+hospital+medicine+%28London%2C+England+%3A+2005%29&amp;rft.pages=M174%E2%80%936&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid21205679-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21205679_54-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". <i>Neurology</i> <b>76</b> (1 Suppl 1): S26–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.0b013e318205051d">10.1212/WNL.0b013e318205051d</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21205679">21205679</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Long-term+follow-up+of+clinical+trials+of+multiple+sclerosis+therapies&amp;rft.au=Freedman+MS&amp;rft.aulast=Freedman+MS&amp;rft.date=January+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.0b013e318205051d&amp;rft_id=info%3Apmid%2F21205679&amp;rft.issue=1+Suppl+1&amp;rft.jtitle=Neurology&amp;rft.pages=S26%E2%80%9334&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=76" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22284996-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22284996_55-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Qizilbash N, Mendez I, Sanchez-de la Rosa R (January 2012). "Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis". <i>Clin Ther</i> <b>34</b> (1): 159–176.e5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.clinthera.2011.12.006">10.1016/j.clinthera.2011.12.006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22284996">22284996</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Benefit-risk+analysis+of+glatiramer+acetate+for+relapsing-remitting+and+clinically+isolated+syndrome+multiple+sclerosis&amp;rft.aulast=Qizilbash+N%2C+Mendez+I%2C+Sanchez-de+la+Rosa+R&amp;rft.au=Qizilbash+N%2C+Mendez+I%2C+Sanchez-de+la+Rosa+R&amp;rft.date=January+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinthera.2011.12.006&amp;rft_id=info%3Apmid%2F22284996&amp;rft.issue=1&amp;rft.jtitle=Clin+Ther&amp;rft.pages=159%E2%80%93176.e5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=34" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21205678-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21205678_56-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". <i>Neurology</i> <b>76</b> (1 Suppl 1): S14–25. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.0b013e3182050388">10.1212/WNL.0b013e3182050388</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21205678">21205678</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Treatment+effects+of+immunomodulatory+therapies+at+different+stages+of+multiple+sclerosis+in+short-term+trials&amp;rft.au=Bates+D&amp;rft.aulast=Bates+D&amp;rft.date=January+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.0b013e3182050388&amp;rft_id=info%3Apmid%2F21205678&amp;rft.issue=1+Suppl+1&amp;rft.jtitle=Neurology&amp;rft.pages=S14%E2%80%9325&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=76" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22642799-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22642799_57-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Johnston J, So TY (June 2012). "First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview". <i>Drugs</i> <b>72</b> (9): 1195–211. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.2165%2F11634010-000000000-00000">10.2165/11634010-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22642799">22642799</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=First-line+disease-modifying+therapies+in+paediatric+multiple+sclerosis%3A+a+comprehensive+overview&amp;rft.au=Johnston+J%2C+So+TY&amp;rft.aulast=Johnston+J%2C+So+TY&amp;rft.date=June+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F11634010-000000000-00000&amp;rft_id=info%3Apmid%2F22642799&amp;rft.issue=9&amp;rft.jtitle=Drugs&amp;rft.pages=1195%E2%80%93211&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22014437-58"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22014437_58-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22014437_58-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid22014437_58-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid22014437_58-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Killestein J, Rudick RA, Polman CH (November 2011). "Oral treatment for multiple sclerosis". <i>Lancet Neurol</i> <b>10</b> (11): 1026–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2811%2970228-9">10.1016/S1474-4422(11)70228-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22014437">22014437</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Oral+treatment+for+multiple+sclerosis&amp;rft.au=Killestein+J%2C+Rudick+RA%2C+Polman+CH&amp;rft.aulast=Killestein+J%2C+Rudick+RA%2C+Polman+CH&amp;rft.date=November+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2811%2970228-9&amp;rft_id=info%3Apmid%2F22014437&amp;rft.issue=11&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=1026%E2%80%9334&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation book">Kellerman, Rick D.; Edward N. Hanley Jr MD (2011). <a rel="nofollow" class="external text" href="http://books.google.ca/books?id=pyKjGU5JdqQC&amp;pg=PT662"><i>Conn's Current Therapy 2012: Expert Consult - Online and Print</i></a>. Philadelphia: Saunders. p.&#160;627. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1-4557-0738-4" title="Special:BookSources/1-4557-0738-4">1-4557-0738-4</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.au=Kellerman%2C+Rick+D.%3B+Edward+N.+Hanley+Jr+MD&amp;rft.aulast=Kellerman%2C+Rick+D.%3B+Edward+N.+Hanley+Jr+MD&amp;rft.btitle=Conn%27s+Current+Therapy+2012%3A+Expert+Consult+-+Online+and+Print&amp;rft.date=2011&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.ca%2Fbooks%3Fid%3DpyKjGU5JdqQC%26pg%3DPT662&amp;rft.isbn=1-4557-0738-4&amp;rft.pages=627&amp;rft.place=Philadelphia&amp;rft.pub=Saunders&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-CochMit2013-60"><span class="mw-cite-backlink">^ <a href="#cite_ref-CochMit2013_60-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-CochMit2013_60-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Martinelli Boneschi, F; Vacchi, L; Rovaris, M; Capra, R; Comi, G (31 May 2013). "Mitoxantrone for multiple sclerosis.". <i>Cochrane database of systematic reviews (Online)</i> <b>5</b>: CD002127. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD002127.pub3">10.1002/14651858.CD002127.pub3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23728638">23728638</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Mitoxantrone+for+multiple+sclerosis.&amp;rft.aufirst=F&amp;rft.aulast=Martinelli+Boneschi&amp;rft.au=Martinelli+Boneschi%2C+F&amp;rft.date=31+May+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD002127.pub3&amp;rft_id=info%3Apmid%2F23728638&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD002127&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><span class="citation journal">Marriott, JJ; Miyasaki, JM; Gronseth, G; O'Connor, PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of, Neurology (4 May 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2871006">"Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology."</a>. <i>Neurology</i> <b>74</b> (18): 1463–70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1212%2FWNL.0b013e3181dc1ae0">10.1212/WNL.0b013e3181dc1ae0</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2871006">2871006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20439849">20439849</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Evidence+Report%3A+The+efficacy+and+safety+of+mitoxantrone+%28Novantrone%29+in+the+treatment+of+multiple+sclerosis%3A+Report+of+the+Therapeutics+and+Technology+Assessment+Subcommittee+of+the+American+Academy+of+Neurology.&amp;rft.aufirst=JJ&amp;rft.aulast=Marriott&amp;rft.au=Marriott%2C+JJ&amp;rft.date=4+May+2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2871006&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.0b013e3181dc1ae0&amp;rft_id=info%3Apmc%2F2871006&amp;rft_id=info%3Apmid%2F20439849&amp;rft.issue=18&amp;rft.jtitle=Neurology&amp;rft.pages=1463%E2%80%9370&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-Balak2012-62"><span class="mw-cite-backlink">^ <a href="#cite_ref-Balak2012_62-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Balak2012_62-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Balak, DM; Hengstman, GJ; Çakmak, A; Thio, HB (December 2012). "Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review.". <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> <b>18</b> (12): 1705–17. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F1352458512438239">10.1177/1352458512438239</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22371220">22371220</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Cutaneous+adverse+events+associated+with+disease-modifying+treatment+in+multiple+sclerosis%3A+a+systematic+review.&amp;rft.au=Balak%2C+DM&amp;rft.aufirst=DM&amp;rft.aulast=Balak&amp;rft.date=December+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1352458512438239&amp;rft_id=info%3Apmid%2F22371220&amp;rft.issue=12&amp;rft.jtitle=Multiple+sclerosis+%28Houndmills%2C+Basingstoke%2C+England%29&amp;rft.pages=1705%E2%80%9317&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid17131933-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17131933_63-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Sládková T, Kostolanský F (2006). "The role of cytokines in the immune response to influenza A virus infection". <i>Acta Virol.</i> <b>50</b> (3): 151–62. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17131933">17131933</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+role+of+cytokines+in+the+immune+response+to+influenza+A+virus+infection&amp;rft.aulast=Sl%C3%A1dkov%C3%A1+T%2C+Kostolansk%C3%BD+F&amp;rft.au=Sl%C3%A1dkov%C3%A1+T%2C+Kostolansk%C3%BD+F&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F17131933&amp;rft.issue=3&amp;rft.jtitle=Acta+Virol.&amp;rft.pages=151%E2%80%9362&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14974077-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14974077_64-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Munari L, Lovati R, Boiko A (2004). "Therapy with glatiramer acetate for multiple sclerosis". In Munari, Luca M. <i>Cochrane database of systematic reviews (Online)</i> (1): CD004678. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD004678">10.1002/14651858.CD004678</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14974077">14974077</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Therapy+with+glatiramer+acetate+for+multiple+sclerosis&amp;rft.aulast=Munari+L%2C+Lovati+R%2C+Boiko+A&amp;rft.au=Munari+L%2C+Lovati+R%2C+Boiko+A&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD004678&amp;rft_id=info%3Apmid%2F14974077&amp;rft.issue=1&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD004678&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15592724-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15592724_65-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Tremlett H, Oger J (November 2004). "Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis". <i>J. Neurol.</i> <b>251</b> (11): 1297–303. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs00415-004-0619-5">10.1007/s00415-004-0619-5</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15592724">15592724</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Hepatic+injury%2C+liver+monitoring+and+the+beta-interferons+for+multiple+sclerosis&amp;rft.aulast=Tremlett+H%2C+Oger+J&amp;rft.au=Tremlett+H%2C+Oger+J&amp;rft.date=November+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00415-004-0619-5&amp;rft_id=info%3Apmid%2F15592724&amp;rft.issue=11&amp;rft.jtitle=J.+Neurol.&amp;rft.pages=1297%E2%80%93303&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=251" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19882365-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19882365_66-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Comi G (October 2009). "Treatment of multiple sclerosis: role of natalizumab". <i>Neurol. Sci</i>. 30. Suppl 2 (S2): S155–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs10072-009-0147-2">10.1007/s10072-009-0147-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19882365">19882365</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Treatment+of+multiple+sclerosis%3A+role+of+natalizumab&amp;rft.au=Comi+G&amp;rft.aulast=Comi+G&amp;rft.date=October+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs10072-009-0147-2&amp;rft_id=info%3Apmid%2F19882365&amp;rft.issue=S2&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=S155%E2%80%938&amp;rft.series=30&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=Suppl+2" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><span class="citation journal">Hunt, D; Giovannoni, G (February 2012). "Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.". <i>Practical neurology</i> <b>12</b> (1): 25–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fpractneurol-2011-000092">10.1136/practneurol-2011-000092</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22258169">22258169</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Natalizumab-associated+progressive+multifocal+leucoencephalopathy%3A+a+practical+approach+to+risk+profiling+and+monitoring.&amp;rft.aufirst=D&amp;rft.au=Hunt%2C+D&amp;rft.aulast=Hunt&amp;rft.date=February+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1136%2Fpractneurol-2011-000092&amp;rft_id=info%3Apmid%2F22258169&amp;rft.issue=1&amp;rft.jtitle=Practical+neurology&amp;rft.pages=25%E2%80%9335&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-fumarateNDA-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-fumarateNDA_68-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf">"NDA 204063 - FDA Approved Labeling Text"</a>. US Food and Drug Agency. 27 March 2013<span class="reference-accessdate">. Retrieved 5 April 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=NDA+204063+-+FDA+Approved+Labeling+Text&amp;rft.date=27+March+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F204063lbl.pdf&amp;rft.pub=US+Food+and+Drug+Agency&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><br />
<span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204063Orig1s000ltr.pdf">"NDA Approval"</a>. US Food and Drug Agency. 27 March 2013<span class="reference-accessdate">. Retrieved 5 April 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=NDA+Approval&amp;rft.date=27+March+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fappletter%2F2013%2F204063Orig1s000ltr.pdf&amp;rft.pub=US+Food+and+Drug+Agency&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22224673-69"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22224673_69-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22224673_69-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Saidha S, Eckstein C, Calabresi PA (January 2012). "New and emerging disease modifying therapies for multiple sclerosis". <i>Annals of the New York Academy of Sciences</i> <b>1247</b>: 117–37. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1749-6632.2011.06272.x">10.1111/j.1749-6632.2011.06272.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22224673">22224673</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=New+and+emerging+disease+modifying+therapies+for+multiple+sclerosis&amp;rft.aulast=Saidha+S%2C+Eckstein+C%2C+Calabresi+PA&amp;rft.au=Saidha+S%2C+Eckstein+C%2C+Calabresi+PA&amp;rft.date=January+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1749-6632.2011.06272.x&amp;rft_id=info%3Apmid%2F22224673&amp;rft.jtitle=Annals+of+the+New+York+Academy+of+Sciences&amp;rft.pages=117%E2%80%9337&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1247" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16168933-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16168933_70-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kesselring J, Beer S (October 2005). "Symptomatic therapy and neurorehabilitation in multiple sclerosis". <i>Lancet Neurol</i> <b>4</b> (10): 643–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2805%2970193-9">10.1016/S1474-4422(05)70193-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16168933">16168933</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Symptomatic+therapy+and+neurorehabilitation+in+multiple+sclerosis&amp;rft.au=Kesselring+J%2C+Beer+S&amp;rft.aulast=Kesselring+J%2C+Beer+S&amp;rft.date=October+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2805%2970193-9&amp;rft_id=info%3Apmid%2F16168933&amp;rft.issue=10&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=643%E2%80%9352&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17443610-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17443610_71-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Khan F, Turner-Stokes L, Ng L, Kilpatrick T (2007). "Multidisciplinary rehabilitation for adults with multiple sclerosis". In Khan, Fary. <i>Cochrane Database Syst Rev</i> (2): CD006036. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD006036.pub2">10.1002/14651858.CD006036.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17443610">17443610</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multidisciplinary+rehabilitation+for+adults+with+multiple+sclerosis&amp;rft.au=Khan+F%2C+Turner-Stokes+L%2C+Ng+L%2C+Kilpatrick+T&amp;rft.aulast=Khan+F%2C+Turner-Stokes+L%2C+Ng+L%2C+Kilpatrick+T&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD006036.pub2&amp;rft_id=info%3Apmid%2F17443610&amp;rft.issue=2&amp;rft.jtitle=Cochrane+Database+Syst+Rev&amp;rft.pages=CD006036&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15859525-72"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15859525_72-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15859525_72-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005). "Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews". <i>Clinical rehabilitation</i> <b>19</b> (3): 247–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1191%2F0269215505cr870oa">10.1191/0269215505cr870oa</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15859525">15859525</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Evidence+of+the+efficacy+of+occupational+therapy+in+different+conditions%3A+an+overview+of+systematic+reviews&amp;rft.aulast=Steultjens+EM%2C+Dekker+J%2C+Bouter+LM%2C+Leemrijse+CJ%2C+van+den+Ende+CH&amp;rft.au=Steultjens+EM%2C+Dekker+J%2C+Bouter+LM%2C+Leemrijse+CJ%2C+van+den+Ende+CH&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1191%2F0269215505cr870oa&amp;rft_id=info%3Apmid%2F15859525&amp;rft.issue=3&amp;rft.jtitle=Clinical+rehabilitation&amp;rft.pages=247%E2%80%9354&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12917976-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12917976_73-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH (2003). "Occupational therapy for multiple sclerosis". In Steultjens, Esther EMJ. <i>Cochrane database of systematic reviews (Online)</i> (3): CD003608. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003608">10.1002/14651858.CD003608</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12917976">12917976</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Occupational+therapy+for+multiple+sclerosis&amp;rft.aulast=Steultjens+EM%2C+Dekker+J%2C+Bouter+LM%2C+Cardol+M%2C+Van+de+Nes+JC%2C+Van+den+Ende+CH&amp;rft.au=Steultjens+EM%2C+Dekker+J%2C+Bouter+LM%2C+Cardol+M%2C+Van+de+Nes+JC%2C+Van+den+Ende+CH&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003608&amp;rft_id=info%3Apmid%2F12917976&amp;rft.issue=3&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD003608&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17482708-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17482708_74-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Gallien P, Nicolas B, Robineau S, Pétrilli S, Houedakor J, Durufle A (2007). "Physical training and multiple sclerosis". <i>Ann Readapt Med Phys</i> <b>50</b> (6): 373–6, 369–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.annrmp.2007.04.004">10.1016/j.annrmp.2007.04.004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17482708">17482708</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Physical+training+and+multiple+sclerosis&amp;rft.au=Gallien+P%2C+Nicolas+B%2C+Robineau+S%2C+P%C3%A9trilli+S%2C+Houedakor+J%2C+Durufle+A&amp;rft.aulast=Gallien+P%2C+Nicolas+B%2C+Robineau+S%2C+P%C3%A9trilli+S%2C+Houedakor+J%2C+Durufle+A&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.annrmp.2007.04.004&amp;rft_id=info%3Apmid%2F17482708&amp;rft.issue=6&amp;rft.jtitle=Ann+Readapt+Med+Phys&amp;rft.pages=373%E2%80%936%2C+369%E2%80%9372&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><span class="citation journal">Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G (2005). "Exercise therapy for multiple sclerosis". In Kwakkel, Gert. <i>Cochrane Database of Systematic Reviews</i> (1): CD003980. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003980.pub2">10.1002/14651858.CD003980.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15674920">15674920</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Exercise+therapy+for+multiple+sclerosis&amp;rft.aulast=Rietberg+MB%2C+Brooks+D%2C+Uitdehaag+BMJ%2C+Kwakkel+G&amp;rft.au=Rietberg+MB%2C+Brooks+D%2C+Uitdehaag+BMJ%2C+Kwakkel+G&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003980.pub2&amp;rft_id=info%3Apmid%2F15674920&amp;rft.issue=1&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.pages=CD003980&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><span class="citation journal">Thomas PW, Thomas S, Hillier C, Galvin K, Baker R (2006). "Psychological interventions for multiple sclerosis". In Thomas, Peter W. <i>Cochrane Database of Systematic Reviews</i> (1): CD004431. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD004431.pub2">10.1002/14651858.CD004431.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16437487">16437487</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Psychological+interventions+for+multiple+sclerosis&amp;rft.aulast=Thomas+PW%2C+Thomas+S%2C+Hillier+C%2C+Galvin+K%2C+Baker+R&amp;rft.au=Thomas+PW%2C+Thomas+S%2C+Hillier+C%2C+Galvin+K%2C+Baker+R&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD004431.pub2&amp;rft_id=info%3Apmid%2F16437487&amp;rft.issue=1&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.pages=CD004431&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16420779-77"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16420779_77-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid16420779_77-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Huntley A (January 2006). "A review of the evidence for efficacy of complementary and alternative medicines in MS". <i>Int MS J</i> <b>13</b> (1): 5–12, 4. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16420779">16420779</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=A+review+of+the+evidence+for+efficacy+of+complementary+and+alternative+medicines+in+MS&amp;rft.au=Huntley+A&amp;rft.aulast=Huntley+A&amp;rft.date=January+2006&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F16420779&amp;rft.issue=1&amp;rft.jtitle=Int+MS+J&amp;rft.pages=5%E2%80%9312%2C+4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19222053-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19222053_78-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Olsen SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". <i>Occup Ther Int</i> <b>16</b> (1): 57–70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Foti.266">10.1002/oti.266</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19222053">19222053</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=A+review+of+complementary+and+alternative+medicine+%28CAM%29+by+people+with+multiple+sclerosis&amp;rft.aulast=Olsen+SA&amp;rft.au=Olsen+SA&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Foti.266&amp;rft_id=info%3Apmid%2F19222053&amp;rft.issue=1&amp;rft.jtitle=Occup+Ther+Int&amp;rft.pages=57%E2%80%9370&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><span class="citation journal">Jagannath, VA; Fedorowicz, Z; Asokan, GV; Robak, EW; Whamond, L (8 December 2010). "Vitamin D for the management of multiple sclerosis.". <i>Cochrane database of systematic reviews (Online)</i> (12): CD008422. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD008422.pub2">10.1002/14651858.CD008422.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21154396">21154396</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Vitamin+D+for+the+management+of+multiple+sclerosis.&amp;rft.aufirst=VA&amp;rft.au=Jagannath%2C+VA&amp;rft.aulast=Jagannath&amp;rft.date=8+December+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008422.pub2&amp;rft_id=info%3Apmid%2F21154396&amp;rft.issue=12&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD008422&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid17253500-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17253500_80-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Farinotti M, Simi S, Di Pietrantonj C, <i>et al.</i> (2007). "Dietary interventions for multiple sclerosis". In Farinotti, Mariangela. <i>Cochrane database of systematic reviews (Online)</i> (1): CD004192. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD004192.pub2">10.1002/14651858.CD004192.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17253500">17253500</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Dietary+interventions+for+multiple+sclerosis&amp;rft.au=Farinotti+M%2C+Simi+S%2C+Di+Pietrantonj+C%2C+%27%27et+al.%27%27&amp;rft.aulast=Farinotti+M%2C+Simi+S%2C+Di+Pietrantonj+C%2C+%27%27et+al.%27%27&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD004192.pub2&amp;rft_id=info%3Apmid%2F17253500&amp;rft.issue=1&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD004192&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21965673-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21965673_81-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M. (September 2011). "N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis.". <i>J Biol Chem</i> <b>286</b> (46): 40133–41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1074%2Fjbc.M111.277814">10.1074/jbc.M111.277814</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21965673">21965673</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=N-acetylglucosamine+inhibits+T-helper+1+%28Th1%29%2FT-helper+17+%28Th17%29+cell+responses+and+treats+experimental+autoimmune+encephalomyelitis.&amp;rft.au=Grigorian+A%2C+Araujo+L%2C+Naidu+NN%2C+Place+DJ%2C+Choudhury+B%2C+Demetriou+M.&amp;rft.aulast=Grigorian+A%2C+Araujo+L%2C+Naidu+NN%2C+Place+DJ%2C+Choudhury+B%2C+Demetriou+M.&amp;rft.date=September+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1074%2Fjbc.M111.277814&amp;rft_id=info%3Apmid%2F21965673&amp;rft.issue=46&amp;rft.jtitle=J+Biol+Chem&amp;rft.pages=40133%E2%80%9341&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=286" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><span class="citation journal">Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (2006). "Cannabis use in patients with multiple sclerosis". <i>Mult. Scler.</i> <b>12</b> (5): 646–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F1352458506070947">10.1177/1352458506070947</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17086912">17086912</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Cannabis+use+in+patients+with+multiple+sclerosis&amp;rft.au=Chong+MS%2C+Wolff+K%2C+Wise+K%2C+Tanton+C%2C+Winstock+A%2C+Silber+E&amp;rft.aulast=Chong+MS%2C+Wolff+K%2C+Wise+K%2C+Tanton+C%2C+Winstock+A%2C+Silber+E&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1352458506070947&amp;rft_id=info%3Apmid%2F17086912&amp;rft.issue=5&amp;rft.jtitle=Mult.+Scler.&amp;rft.pages=646%E2%80%9351&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14974004-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14974004_83-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Bennett M, Heard R (2004). "Hyperbaric oxygen therapy for multiple sclerosis". In Bennett, Michael H. <i>Cochrane database of systematic reviews (Online)</i> (1): CD003057. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003057.pub2">10.1002/14651858.CD003057.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14974004">14974004</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Hyperbaric+oxygen+therapy+for+multiple+sclerosis&amp;rft.au=Bennett+M%2C+Heard+R&amp;rft.aulast=Bennett+M%2C+Heard+R&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003057.pub2&amp;rft_id=info%3Apmid%2F14974004&amp;rft.issue=1&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD003057&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><span class="citation news">Adams, Tim (23 May 2010). <a rel="nofollow" class="external text" href="http://www.guardian.co.uk/lifeandstyle/2010/may/23/parasitic-hookworm-jasper-lawrence-tim-adams">"Gut instinct: the miracle of the parasitic hookworm"</a>. <i>The Observer</i>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Gut+instinct%3A+the+miracle+of+the+parasitic+hookworm&amp;rft.au=Adams%2C+Tim&amp;rft.aufirst=Tim&amp;rft.aulast=Adams&amp;rft.date=23+May+2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.guardian.co.uk%2Flifeandstyle%2F2010%2Fmay%2F23%2Fparasitic-hookworm-jasper-lawrence-tim-adams&amp;rft.jtitle=The+Observer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid3495637-85"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid3495637_85-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid3495637_85-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid3495637_85-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Phadke JG (May 1987). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1031962">"Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland"</a>. <i>J. Neurol. Neurosurg. Psychiatr.</i> <b>50</b> (5): 523–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fjnnp.50.5.523">10.1136/jnnp.50.5.523</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1031962">1031962</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3495637">3495637</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Survival+pattern+and+cause+of+death+in+patients+with+multiple+sclerosis%3A+results+from+an+epidemiological+survey+in+north+east+Scotland&amp;rft.aulast=Phadke+JG&amp;rft.au=Phadke+JG&amp;rft.date=May+1987&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1031962&amp;rft_id=info%3Adoi%2F10.1136%2Fjnnp.50.5.523&amp;rft_id=info%3Apmc%2F1031962&amp;rft_id=info%3Apmid%2F3495637&amp;rft.issue=5&amp;rft.jtitle=J.+Neurol.+Neurosurg.++Psychiatr.&amp;rft.pages=523%E2%80%9331&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11321195-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11321195_86-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Myhr KM, Riise T, Vedeler C, <i>et al</i> (February 2001). "Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension". <i>Mult. Scler.</i> <b>7</b> (1): 59–65. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11321195">11321195</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Disability+and+prognosis+in+multiple+sclerosis%3A+demographic+and+clinical+variables+important+for+the+ability+to+walk+and+awarding+of+disability+pension&amp;rft.aulast=Myhr+KM%2C+Riise+T%2C+Vedeler+C%2C+%27%27et+al%27%27&amp;rft.au=Myhr+KM%2C+Riise+T%2C+Vedeler+C%2C+%27%27et+al%27%27&amp;rft.date=February+2001&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F11321195&amp;rft.issue=1&amp;rft.jtitle=Mult.+Scler.&amp;rft.pages=59%E2%80%9365&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Loz2012-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-Loz2012_87-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lozano, R (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". <i>Lancet</i> <b>380</b> (9859): 2095–128. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2812%2961728-0">10.1016/S0140-6736(12)61728-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23245604">23245604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Global+and+regional+mortality+from+235+causes+of+death+for+20+age+groups+in+1990+and+2010%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010.&amp;rft.aufirst=R&amp;rft.aulast=Lozano&amp;rft.au=Lozano%2C+R&amp;rft.date=15+December+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2812%2961728-0&amp;rft_id=info%3Apmid%2F23245604&amp;rft.issue=9859&amp;rft.jtitle=Lancet&amp;rft.pages=2095%E2%80%93128&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=380" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid3066846-88"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid3066846_88-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid3066846_88-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Compston A (October 1988). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1032909">"The 150th anniversary of the first depiction of the lesions of multiple sclerosis"</a>. <i>J. Neurol. Neurosurg. Psychiatr.</i> <b>51</b> (10): 1249–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fjnnp.51.10.1249">10.1136/jnnp.51.10.1249</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1032909">1032909</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3066846">3066846</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+150th+anniversary+of+the+first+depiction+of+the+lesions+of+multiple+sclerosis&amp;rft.au=Compston+A&amp;rft.aulast=Compston+A&amp;rft.date=October+1988&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1032909&amp;rft_id=info%3Adoi%2F10.1136%2Fjnnp.51.10.1249&amp;rft_id=info%3Apmc%2F1032909&amp;rft_id=info%3Apmid%2F3066846&amp;rft.issue=10&amp;rft.jtitle=J.+Neurol.+Neurosurg.+Psychiatr.&amp;rft.pages=1249%E2%80%9352&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=51" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10603616-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10603616_89-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lassmann H (October 1999). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1692680">"The pathology of multiple sclerosis and its evolution"</a>. <i>Philosophical Transactions of the Royal Society B</i> <b>354</b> (1390): 1635–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1098%2Frstb.1999.0508">10.1098/rstb.1999.0508</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1692680">1692680</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10603616">10603616</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+pathology+of+multiple+sclerosis+and+its+evolution&amp;rft.au=Lassmann+H&amp;rft.aulast=Lassmann+H&amp;rft.date=October+1999&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1692680&amp;rft_id=info%3Adoi%2F10.1098%2Frstb.1999.0508&amp;rft_id=info%3Apmc%2F1692680&amp;rft_id=info%3Apmid%2F10603616&amp;rft.issue=1390&amp;rft.jtitle=Philosophical+Transactions+of+the+Royal+Society+B&amp;rft.pages=1635%E2%80%9340&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=354" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><span class="citation journal">Lassmann H (July 2005). "Multiple sclerosis pathology: evolution of pathogenetic concepts". <i><a href="/wiki/Brain_Pathology" title="Brain Pathology">Brain Pathology</a></i> <b>15</b> (3): 217–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1750-3639.2005.tb00523.x">10.1111/j.1750-3639.2005.tb00523.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16196388">16196388</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis+pathology%3A+evolution+of+pathogenetic+concepts&amp;rft.au=Lassmann+H&amp;rft.aulast=Lassmann+H&amp;rft.date=July+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1750-3639.2005.tb00523.x&amp;rft_id=info%3Apmid%2F16196388&amp;rft.issue=3&amp;rft.jtitle=Brain+Pathology&amp;rft.pages=217%E2%80%9322&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid390966-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid390966_91-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Medaer R (September 1979). "Does the history of multiple sclerosis go back as far as the 14th century?". <i>Acta Neurol. Scand.</i> <b>60</b> (3): 189–92. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1600-0447.1979.tb08970.x">10.1111/j.1600-0447.1979.tb08970.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/390966">390966</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Does+the+history+of+multiple+sclerosis+go+back+as+far+as+the+14th+century%3F&amp;rft.aulast=Medaer+R&amp;rft.au=Medaer+R&amp;rft.date=September+1979&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.1979.tb08970.x&amp;rft_id=info%3Apmid%2F390966&amp;rft.issue=3&amp;rft.jtitle=Acta+Neurol.+Scand.&amp;rft.pages=189%E2%80%9392&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=60" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16479124-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16479124_92-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Holmøy T (2006). "A Norse contribution to the history of neurological diseases". <i>Eur. Neurol.</i> <b>55</b> (1): 57–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1159%2F000091431">10.1159/000091431</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16479124">16479124</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=A+Norse+contribution+to+the+history+of+neurological+diseases&amp;rft.au=Holm%C3%B8y+T&amp;rft.aulast=Holm%C3%B8y+T&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1159%2F000091431&amp;rft_id=info%3Apmid%2F16479124&amp;rft.issue=1&amp;rft.jtitle=Eur.+Neurol.&amp;rft.pages=57%E2%80%938&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=55" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><span class="citation book">Firth, D (1948). <i>The Case of August D`Esté</i>. Cambridge: Cambridge University Press.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.aufirst=D&amp;rft.au=Firth%2C+D&amp;rft.aulast=Firth&amp;rft.btitle=The+Case+of+August+D%60Est%C3%A9&amp;rft.date=1948&amp;rft.genre=book&amp;rft.place=Cambridge&amp;rft.pub=Cambridge+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16103678-94"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16103678_94-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16103678_94-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Pearce JM (2005). "Historical descriptions of multiple sclerosis". <i>Eur. Neurol.</i> <b>54</b> (1): 49–53. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1159%2F000087387">10.1159/000087387</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16103678">16103678</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Historical+descriptions+of+multiple+sclerosis&amp;rft.aulast=Pearce+JM&amp;rft.au=Pearce+JM&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1159%2F000087387&amp;rft_id=info%3Apmid%2F16103678&amp;rft.issue=1&amp;rft.jtitle=Eur.+Neurol.&amp;rft.pages=49%E2%80%9353&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=54" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><span class="citation book">Barbellion, Wilhelm Nero Pilate (1919). <i>The Journal of a Disappointed Man</i>. New York: George H. Doran. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7012-1906-8" title="Special:BookSources/0-7012-1906-8">0-7012-1906-8</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.au=Barbellion%2C+Wilhelm+Nero+Pilate&amp;rft.aufirst=Wilhelm+Nero+Pilate&amp;rft.aulast=Barbellion&amp;rft.btitle=The+Journal+of+a+Disappointed+Man&amp;rft.date=1919&amp;rft.genre=book&amp;rft.isbn=0-7012-1906-8&amp;rft.place=New+York&amp;rft.pub=George+H.+Doran&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19597083-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19597083_96-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cohen JA (July 2009). "Emerging therapies for relapsing multiple sclerosis". <i>Arch. Neurol.</i> <b>66</b> (7): 821–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1001%2Farchneurol.2009.104">10.1001/archneurol.2009.104</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19597083">19597083</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Emerging+therapies+for+relapsing+multiple+sclerosis&amp;rft.au=Cohen+JA&amp;rft.aulast=Cohen+JA&amp;rft.date=July+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Farchneurol.2009.104&amp;rft_id=info%3Apmid%2F19597083&amp;rft.issue=7&amp;rft.jtitle=Arch.+Neurol.&amp;rft.pages=821%E2%80%938&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=66" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21425270-97"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21425270_97-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid21425270_97-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Miller AE (2011). "Multiple sclerosis: where will we be in 2020?". <i>Mt. Sinai J. Med.</i> <b>78</b> (2): 268–79. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fmsj.20242">10.1002/msj.20242</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21425270">21425270</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis%3A+where+will+we+be+in+2020%3F&amp;rft.aulast=Miller+AE&amp;rft.au=Miller+AE&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fmsj.20242&amp;rft_id=info%3Apmid%2F21425270&amp;rft.issue=2&amp;rft.jtitle=Mt.+Sinai+J.+Med.&amp;rft.pages=268%E2%80%9379&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=78" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><span class="citation news">Jeffrey, susan (9 August 2012). <a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/768902">"CONCERTO: A Third Phase 3 Trial for Laquinimod in MS"</a>. <i>Medscape Medical News</i><span class="reference-accessdate">. Retrieved 21 May 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=CONCERTO%3A+A+Third+Phase+3+Trial+for+Laquinimod+in+MS&amp;rft.aufirst=susan&amp;rft.au=Jeffrey%2C+susan&amp;rft.aulast=Jeffrey&amp;rft.date=9+August+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F768902&amp;rft.jtitle=Medscape+Medical+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22201341-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22201341_99-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kieseier BC, Calabresi PA (March 2012). "PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis". <i>CNS Drugs</i> <b>26</b> (3): 205–14. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.2165%2F11596970-000000000-00000">10.2165/11596970-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22201341">22201341</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=PEGylation+of+interferon-%CE%B2-1a%3A+a+promising+strategy+in+multiple+sclerosis&amp;rft.au=Kieseier+BC%2C+Calabresi+PA&amp;rft.aulast=Kieseier+BC%2C+Calabresi+PA&amp;rft.date=March+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F11596970-000000000-00000&amp;rft_id=info%3Apmid%2F22201341&amp;rft.issue=3&amp;rft.jtitle=CNS+Drugs&amp;rft.pages=205%E2%80%9314&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-PEG-100"><span class="mw-cite-backlink">^ <a href="#cite_ref-PEG_100-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-PEG_100-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.biogenidec.com/press_release_details.aspx?ID=5981&amp;ReqId=1777510">"Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis"</a> (Press release). Biogen Idec. 24 January 2013<span class="reference-accessdate">. Retrieved 21 May 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.btitle=Biogen+Idec+Announces+Positive+Top-Line+Results+from+Phase+3+Study+of+Peginterferon+Beta-1a+in+Multiple+Sclerosis&amp;rft.date=24+January+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.biogenidec.com%2Fpress_release_details.aspx%3FID%3D5981%26ReqId%3D1777510&amp;rft.pub=Biogen+Idec&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21111490-101"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21111490_101-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21111490_101-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid21111490_101-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid21111490_101-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Milo R, Panitch H (February 2011). "Combination therapy in multiple sclerosis". <i>J. Neuroimmunol.</i> <b>231</b> (1-2): 23–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.jneuroim.2010.10.021">10.1016/j.jneuroim.2010.10.021</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21111490">21111490</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Combination+therapy+in+multiple+sclerosis&amp;rft.aulast=Milo+R%2C+Panitch+H&amp;rft.au=Milo+R%2C+Panitch+H&amp;rft.date=February+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jneuroim.2010.10.021&amp;rft_id=info%3Apmid%2F21111490&amp;rft.issue=1-2&amp;rft.jtitle=J.+Neuroimmunol.&amp;rft.pages=23%E2%80%9331&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=231" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23039386-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23039386_102-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Luessi F, Siffrin V, Zipp F (September 2012). <a rel="nofollow" class="external text" href="http://www.expert-reviews.com/doi/full/10.1586/ern.12.59">"Neurodegeneration in multiple sclerosis: novel treatment strategies"</a>. <i>Expert Rev Neurother</i> <b>12</b> (9): 1061–76; quiz 1077. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1586%2Fern.12.59">10.1586/ern.12.59</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23039386">23039386</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Neurodegeneration+in+multiple+sclerosis%3A+novel+treatment+strategies&amp;rft.aulast=Luessi+F%2C+Siffrin+V%2C+Zipp+F&amp;rft.au=Luessi+F%2C+Siffrin+V%2C+Zipp+F&amp;rft.date=September+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.expert-reviews.com%2Fdoi%2Ffull%2F10.1586%2Fern.12.59&amp;rft_id=info%3Adoi%2F10.1586%2Fern.12.59&amp;rft_id=info%3Apmid%2F23039386&amp;rft.issue=9&amp;rft.jtitle=Expert+Rev+Neurother&amp;rft.pages=1061%E2%80%9376%3B+quiz+1077&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23516409-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23516409_103-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Mehta V, Pei W, Yang G, <i>et al.</i> (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3597727">"Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions"</a>. <i>PLoS ONE</i> <b>8</b> (3): e57573. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1371%2Fjournal.pone.0057573">10.1371/journal.pone.0057573</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3597727">3597727</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23516409">23516409</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Iron+is+a+sensitive+biomarker+for+inflammation+in+multiple+sclerosis+lesions&amp;rft.aulast=Mehta+V%2C+Pei+W%2C+Yang+G%2C+%27%27et+al.%27%27&amp;rft.au=Mehta+V%2C+Pei+W%2C+Yang+G%2C+%27%27et+al.%27%27&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3597727&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0057573&amp;rft_id=info%3Apmc%2F3597727&amp;rft_id=info%3Apmid%2F23516409&amp;rft.issue=3&amp;rft.jtitle=PLoS+ONE&amp;rft.pages=e57573&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19712003-104"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid19712003_104-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid19712003_104-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid19712003_104-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid19712003_104-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Harris VK, Sadiq SA (2009). "Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making". <i>Mol Diagn Ther</i> <b>13</b> (4): 225–44. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.2165%2F11313470-000000000-00000">10.2165/11313470-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19712003">19712003</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Disease+biomarkers+in+multiple+sclerosis%3A+potential+for+use+in+therapeutic+decision+making&amp;rft.au=Harris+VK%2C+Sadiq+SA&amp;rft.aulast=Harris+VK%2C+Sadiq+SA&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F11313470-000000000-00000&amp;rft_id=info%3Apmid%2F19712003&amp;rft.issue=4&amp;rft.jtitle=Mol+Diagn+Ther&amp;rft.pages=225%E2%80%9344&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22159052-105"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22159052_105-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22159052_105-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid22159052_105-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid22159052_105-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Filippi M, Rocca MA, De Stefano N, <i>et al.</i> (December 2011). "Magnetic resonance techniques in multiple sclerosis: the present and the future". <i>Arch. Neurol.</i> <b>68</b> (12): 1514–20. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1001%2Farchneurol.2011.914">10.1001/archneurol.2011.914</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22159052">22159052</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Magnetic+resonance+techniques+in+multiple+sclerosis%3A+the+present+and+the+future&amp;rft.au=Filippi+M%2C+Rocca+MA%2C+De+Stefano+N%2C+%27%27et+al.%27%27&amp;rft.aulast=Filippi+M%2C+Rocca+MA%2C+De+Stefano+N%2C+%27%27et+al.%27%27&amp;rft.date=December+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Farchneurol.2011.914&amp;rft_id=info%3Apmid%2F22159052&amp;rft.issue=12&amp;rft.jtitle=Arch.+Neurol.&amp;rft.pages=1514%E2%80%9320&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=68" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid20636368-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20636368_106-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kiferle L, Politis M, Muraro PA, Piccini P (February 2011). "Positron emission tomography imaging in multiple sclerosis-current status and future applications". <i>Eur. J. Neurol.</i> <b>18</b> (2): 226–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1468-1331.2010.03154.x">10.1111/j.1468-1331.2010.03154.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20636368">20636368</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Positron+emission+tomography+imaging+in+multiple+sclerosis-current+status+and+future+applications&amp;rft.au=Kiferle+L%2C+Politis+M%2C+Muraro+PA%2C+Piccini+P&amp;rft.aulast=Kiferle+L%2C+Politis+M%2C+Muraro+PA%2C+Piccini+P&amp;rft.date=February+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1468-1331.2010.03154.x&amp;rft_id=info%3Apmid%2F20636368&amp;rft.issue=2&amp;rft.jtitle=Eur.+J.+Neurol.&amp;rft.pages=226%E2%80%9331&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-107">^</a></b></span> <span class="reference-text"><span class="citation journal">Methner, A; Zipp, F (February 2013). "Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.". <i>Nature reviews. Neurology</i> <b>9</b> (2): 72–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1038%2Fnrneurol.2012.277">10.1038/nrneurol.2012.277</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23338282">23338282</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Multiple+sclerosis+in+2012%3A+Novel+therapeutic+options+and+drug+targets+in+MS.&amp;rft.aufirst=A&amp;rft.aulast=Methner&amp;rft.au=Methner%2C+A&amp;rft.date=February+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnrneurol.2012.277&amp;rft_id=info%3Apmid%2F23338282&amp;rft.issue=2&amp;rft.jtitle=Nature+reviews.+Neurology&amp;rft.pages=72%E2%80%933&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-pmid19060024-108"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19060024_108-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Zamboni P, Galeotti R, Menegatti E, <i>et al.</i> (April 2009). <a rel="nofollow" class="external text" href="http://jnnp.bmj.com/cgi/content/full/80/4/392">"Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis"</a>. <i>J. Neurol. Neurosurg. Psychiatr.</i> <b>80</b> (4): 392–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fjnnp.2008.157164">10.1136/jnnp.2008.157164</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2647682">2647682</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19060024">19060024</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Chronic+cerebrospinal+venous+insufficiency+in+patients+with+multiple+sclerosis&amp;rft.aulast=Zamboni+P%2C+Galeotti+R%2C+Menegatti+E%2C+%27%27et+al.%27%27&amp;rft.au=Zamboni+P%2C+Galeotti+R%2C+Menegatti+E%2C+%27%27et+al.%27%27&amp;rft.date=April+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjnnp.bmj.com%2Fcgi%2Fcontent%2Ffull%2F80%2F4%2F392&amp;rft_id=info%3Adoi%2F10.1136%2Fjnnp.2008.157164&amp;rft_id=info%3Apmc%2F2647682&amp;rft_id=info%3Apmid%2F19060024&amp;rft.issue=4&amp;rft.jtitle=J.+Neurol.+Neurosurg.+Psychiatr.&amp;rft.pages=392%E2%80%939&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=80" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23402260-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23402260_109-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Pullman D, Zarzeczny A, Picard A (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575396">"Media, politics and science policy: MS and evidence from the CCSVI Trenches"</a>. <i>BMC Med Ethics</i> <b>14</b>: 6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1186%2F1472-6939-14-6">10.1186/1472-6939-14-6</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575396">3575396</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23402260">23402260</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Media%2C+politics+and+science+policy%3A+MS+and+evidence+from+the+CCSVI+Trenches&amp;rft.aulast=Pullman+D%2C+Zarzeczny+A%2C+Picard+A&amp;rft.au=Pullman+D%2C+Zarzeczny+A%2C+Picard+A&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3575396&amp;rft_id=info%3Adoi%2F10.1186%2F1472-6939-14-6&amp;rft_id=info%3Apmc%2F3575396&amp;rft_id=info%3Apmid%2F23402260&amp;rft.jtitle=BMC+Med+Ethics&amp;rft.pages=6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=14" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid20398855-110"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid20398855_110-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid20398855_110-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Qiu J (May 2010). "Venous abnormalities and multiple sclerosis: another breakthrough claim?". <i>Lancet Neurol</i> <b>9</b> (5): 464–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1474-4422%2810%2970098-3">10.1016/S1474-4422(10)70098-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20398855">20398855</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Venous+abnormalities+and+multiple+sclerosis%3A+another+breakthrough+claim%3F&amp;rft.aulast=Qiu+J&amp;rft.au=Qiu+J&amp;rft.date=May+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2810%2970098-3&amp;rft_id=info%3Apmid%2F20398855&amp;rft.issue=5&amp;rft.jtitle=Lancet+Neurol&amp;rft.pages=464%E2%80%935&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21161309-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21161309_111-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ghezzi A, Comi G, Federico A (February 2011). "Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis". <i>Neurol. Sci.</i> <b>32</b> (1): 17–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs10072-010-0458-3">10.1007/s10072-010-0458-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21161309">21161309</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Chronic+cerebro-spinal+venous+insufficiency+%28CCSVI%29+and+multiple+sclerosis&amp;rft.au=Ghezzi+A%2C+Comi+G%2C+Federico+A&amp;rft.aulast=Ghezzi+A%2C+Comi+G%2C+Federico+A&amp;rft.date=February+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs10072-010-0458-3&amp;rft_id=info%3Apmid%2F21161309&amp;rft.issue=1&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=17%E2%80%9321&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=32" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Dorne-112"><span class="mw-cite-backlink"><b><a href="#cite_ref-Dorne_112-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Dorne H, Zaidat OO, Fiorella D, Hirsch J, Prestigiacomo C, Albuquerque F, Tarr RW. (October 2010). "Chronic cerebrospinal venous insufficiency and the doubtful promise of an endovascular treatment for multiple sclerosis". <i>J NeuroIntervent Surg</i> <b>2</b> (4): 309–311. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fjnis.2010.003947">10.1136/jnis.2010.003947</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21990639">21990639</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Chronic+cerebrospinal+venous+insufficiency+and+the+doubtful+promise+of+an+endovascular+treatment+for+multiple+sclerosis&amp;rft.au=Dorne+H%2C+Zaidat+OO%2C+Fiorella+D%2C+Hirsch+J%2C+Prestigiacomo+C%2C+Albuquerque+F%2C+Tarr+RW.&amp;rft.aulast=Dorne+H%2C+Zaidat+OO%2C+Fiorella+D%2C+Hirsch+J%2C+Prestigiacomo+C%2C+Albuquerque+F%2C+Tarr+RW.&amp;rft.date=October+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1136%2Fjnis.2010.003947&amp;rft_id=info%3Apmid%2F21990639&amp;rft.issue=4&amp;rft.jtitle=J+NeuroIntervent+Surg&amp;rft.pages=309%E2%80%93311&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-113"><span class="mw-cite-backlink"><b><a href="#cite_ref-113">^</a></b></span> <span class="reference-text"><span class="citation journal">Baracchini C, Atzori M, Gallo P (March 2013). "CCSVI and MS: no meaning, no fact". <i>Neurol. Sci.</i> <b>34</b> (3): 269–79. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs10072-012-1101-2">10.1007/s10072-012-1101-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22569567">22569567</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=CCSVI+and+MS%3A+no+meaning%2C+no+fact&amp;rft.au=Baracchini+C%2C+Atzori+M%2C+Gallo+P&amp;rft.aulast=Baracchini+C%2C+Atzori+M%2C+Gallo+P&amp;rft.date=March+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs10072-012-1101-2&amp;rft_id=info%3Apmid%2F22569567&amp;rft.issue=3&amp;rft.jtitle=Neurol.+Sci.&amp;rft.pages=269%E2%80%9379&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=34" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-a1-114"><span class="mw-cite-backlink"><b><a href="#cite_ref-a1_114-0">^</a></b></span> <span class="reference-text"><span class="citation journal">van Zuuren, EJ; Fedorowicz, Z; Pucci, E; Jagannath, VA; Robak, EW (12 December 2012). "Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients.". <i>Cochrane database of systematic reviews (Online)</i> <b>12</b>: CD009903. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD009903.pub2">10.1002/14651858.CD009903.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23235683">23235683</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=Percutaneous+transluminal+angioplasty+for+treatment+of+chronic+cerebrospinal+venous+insufficiency+%28CCSVI%29+in+multiple+sclerosis+patients.&amp;rft.aufirst=EJ&amp;rft.aulast=van+Zuuren&amp;rft.au=van+Zuuren%2C+EJ&amp;rft.date=12+December+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009903.pub2&amp;rft_id=info%3Apmid%2F23235683&amp;rft.jtitle=Cochrane+database+of+systematic+reviews+%28Online%29&amp;rft.pages=CD009903&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameters (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span></h2>
<ul>
<li><span class="citation journal">Langgartner M, Langgartner I, Drlicek M (April 2005). <a rel="nofollow" class="external text" href="http://bmj.bmjjournals.com/cgi/content/full/330/7496/885">"The patient's journey: multiple sclerosis"</a>. <i>BMJ</i> <b>330</b> (7496): 885–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fbmj.330.7496.885">10.1136/bmj.330.7496.885</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC556161">556161</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15831874">15831874</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+sclerosis&amp;rft.atitle=The+patient%27s+journey%3A+multiple+sclerosis&amp;rft.au=Langgartner+M%2C+Langgartner+I%2C+Drlicek+M&amp;rft.aulast=Langgartner+M%2C+Langgartner+I%2C+Drlicek+M&amp;rft.date=April+2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbmj.bmjjournals.com%2Fcgi%2Fcontent%2Ffull%2F330%2F7496%2F885&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.330.7496.885&amp;rft_id=info%3Apmc%2F556161&amp;rft_id=info%3Apmid%2F15831874&amp;rft.issue=7496&amp;rft.jtitle=BMJ&amp;rft.pages=885%E2%80%938&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=330" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
<h2><span class="mw-headline" id="External_links">External links</span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="http://www.dmoz.org/Health/Conditions_and_Diseases/Neurological_Disorders/Demyelinating_Diseases/Multiple_Sclerosis/">Multiple sclerosis</a> on the <a href="/wiki/Open_Directory_Project" title="Open Directory Project">Open Directory Project</a></li>
<li><a rel="nofollow" class="external text" href="http://www.atlasofms.org/">Database for analysis and comparison of global data on the epidemiology of MS</a></li>
</ul>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background: Silver;;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Demyelinating_diseases_of_CNS" title="Template:Demyelinating diseases of CNS"><span title="View this template" style=";background: Silver;;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Demyelinating_diseases_of_CNS" title="Template talk:Demyelinating diseases of CNS"><span title="Discuss this template" style=";background: Silver;;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Demyelinating_diseases_of_CNS&amp;action=edit"><span title="Edit this template" style=";background: Silver;;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><strong class="selflink">Multiple sclerosis</strong> and other <a href="/wiki/Demyelinating_disease" title="Demyelinating disease">demyelinating diseases</a> of <a href="/wiki/Central_nervous_system" title="Central nervous system">CNS</a> (<a href="/wiki/ICD-10_Chapter_VI:_Diseases_of_the_nervous_system#.28G35.E2.80.93G37.29_Demyelinating_diseases_of_the_central_nervous_system" title="ICD-10 Chapter VI: Diseases of the nervous system">G35–G37</a>, <a href="/wiki/List_of_ICD-9_codes_320%E2%80%93359:_diseases_of_the_nervous_system#Other_disorders_of_the_central_nervous_system_.28340.E2.80.93349.29" title="List of ICD-9 codes 320–359: diseases of the nervous system">340–341</a>)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Multiple_sclerosis_signs_and_symptoms" title="Multiple sclerosis signs and symptoms">Signs and symptoms</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Ataxia" title="Ataxia">Ataxia</a></li>
<li><a href="/wiki/Clinical_depression" title="Clinical depression" class="mw-redirect">Depression</a></li>
<li><a href="/wiki/Diplopia" title="Diplopia">Diplopia</a></li>
<li><a href="/wiki/Dysarthria" title="Dysarthria">Dysarthria</a></li>
<li><a href="/wiki/Dysphagia" title="Dysphagia">Dysphagia</a></li>
<li><a href="/wiki/Fatigue_(medical)" title="Fatigue (medical)">Fatigue</a></li>
<li><a href="/wiki/Urinary_incontinence" title="Urinary incontinence">Incontinence</a></li>
<li><a href="/wiki/Neurological_fatigue" title="Neurological fatigue" class="mw-redirect">Neurological fatigue</a></li>
<li><a href="/wiki/Nystagmus" title="Nystagmus">Nystagmus</a></li>
<li><a href="/wiki/Optic_neuritis" title="Optic neuritis">Optic neuritis</a></li>
<li><a href="/wiki/Pain" title="Pain">Pain</a></li>
<li><a href="/wiki/Uhthoff%27s_phenomenon" title="Uhthoff's phenomenon">Uhthoff's phenomenon</a></li>
<li><a href="/wiki/Dawson%27s_fingers" title="Dawson's fingers" class="mw-redirect">Dawson's fingers</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;">Diagnosis and evolution following</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/McDonald_criteria" title="McDonald criteria">McDonald criteria</a></li>
<li><a href="/wiki/Poser_criteria" title="Poser criteria">Poser criteria</a></li>
<li><a href="/wiki/Expanded_Disability_Status_Scale" title="Expanded Disability Status Scale">EDSS</a></li>
<li><a href="/wiki/Clinically_isolated_syndrome" title="Clinically isolated syndrome">Clinically isolated syndrome</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;">Investigation</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Pathophysiology_of_multiple_sclerosis" title="Pathophysiology of multiple sclerosis">Pathophysiology</a></li>
<li><a href="/wiki/Experimental_autoimmune_encephalomyelitis" title="Experimental autoimmune encephalomyelitis">Experimental autoimmune encephalomyelitis</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Treatment_of_multiple_sclerosis" title="Treatment of multiple sclerosis" class="mw-redirect">Treatment</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Interferon_beta_1a" title="Interferon beta 1a">Interferon beta 1a</a></li>
<li><a href="/wiki/Interferon_beta_1b" title="Interferon beta 1b">Interferon beta 1b</a></li>
<li><a href="/wiki/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li><a href="/wiki/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li><a href="/wiki/Natalizumab" title="Natalizumab">Natalizumab</a></li>
<li><a href="/wiki/Fingolimod" title="Fingolimod">Fingolimod</a></li>
<li><a href="/wiki/Teriflunomide" title="Teriflunomide">Teriflunomide</a></li>
<li><a href="/wiki/Dimethyl_fumarate" title="Dimethyl fumarate">Dimethyl fumarate</a></li>
<li><a href="/wiki/Therapies_under_investigation_for_multiple_sclerosis" title="Therapies under investigation for multiple sclerosis" class="mw-redirect">Therapies under investigation</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Idiopathic_inflammatory_demyelinating_diseases" title="Idiopathic inflammatory demyelinating diseases" class="mw-redirect">Borderline forms</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Acute_disseminated_encephalomyelitis" title="Acute disseminated encephalomyelitis">Acute disseminated encephalomyelitis</a></li>
<li><a href="/wiki/Balo_concentric_sclerosis" title="Balo concentric sclerosis">Balo concentric sclerosis</a></li>
<li><a href="/wiki/Neuromyelitis_optica" title="Neuromyelitis optica">Neuromyelitis optica</a></li>
<li><a href="/wiki/Marburg_multiple_sclerosis" title="Marburg multiple sclerosis">Marburg multiple sclerosis</a></li>
<li><a href="/wiki/Diffuse_myelinoclastic_sclerosis" title="Diffuse myelinoclastic sclerosis">Schilder's disease</a></li>
<li><a href="/wiki/Tumefactive_multiple_sclerosis" title="Tumefactive multiple sclerosis">Tumefactive multiple sclerosis</a> (Autoimmune <a href="/wiki/Peripheral_nervous_system" title="Peripheral nervous system">PNS</a> diseases like <a href="/wiki/Guillain-Barr%C3%A9_syndrome" title="Guillain-Barré syndrome" class="mw-redirect">Guillain-Barré syndrome</a> and <a href="/wiki/Chronic_inflammatory_demyelinating_polyneuropathy" title="Chronic inflammatory demyelinating polyneuropathy">CIDP</a> are normally set appart)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;">Other</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/List_of_people_with_multiple_sclerosis" title="List of people with multiple sclerosis">List of people with multiple sclerosis</a></li>
<li><a href="/wiki/List_of_multiple_sclerosis_organizations" title="List of multiple sclerosis organizations">List of multiple sclerosis organizations</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;;">
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;background:transparent;color:inherit;;">
<div style="padding:0px;;">
<table cellspacing="0" class="navbox-columns-table" style="text-align:left;width:100%;">
<tr style="vertical-align:top;">
<td style="padding:0px;text-align:center;background:#efefef;;;text-align:center;background:LemonChiffon;;width:10em;">
<div>
<p><a href="/wiki/Template:Medicine_navs" title="Template:Medicine navs">M</a>: <a href="/wiki/Central_nervous_system" title="Central nervous system">CNS</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:white;;width:10em;">
<div>
<p><a href="/wiki/Template:Nervous_system" title="Template:Nervous system">anat</a> (<a href="/wiki/Template:Meninges" title="Template:Meninges">n</a>/<a href="/wiki/Template:Spinal_cord" title="Template:Spinal cord">s</a>/<a href="/wiki/Template:Medulla" title="Template:Medulla">m</a>/<a href="/wiki/Template:Pons" title="Template:Pons">p</a>/<a href="/wiki/Template:Fourth_ventricle" title="Template:Fourth ventricle">4</a>/<a href="/wiki/Template:Mesencephalon" title="Template:Mesencephalon">e</a>/<a href="/wiki/Template:Cerebellum" title="Template:Cerebellum">b</a>/<a href="/wiki/Template:Diencephalon" title="Template:Diencephalon">d</a>/<a href="/wiki/Template:Cerebral_cortex" title="Template:Cerebral cortex">c</a>/<a href="/wiki/Template:Association_fibers" title="Template:Association fibers">a</a>/<a href="/wiki/Template:Commissural_fibers_and_septum" title="Template:Commissural fibers and septum">f</a>/<a href="/wiki/Template:Lateral_ventricles" title="Template:Lateral ventricles">l</a>/<a href="/wiki/Template:Rostral_basal_ganglia_and_associated_structures" title="Template:Rostral basal ganglia and associated structures">g</a>)/<a href="/wiki/Template:Nervous_system_physiology" title="Template:Nervous system physiology">phys</a>/<a href="/wiki/Template:Development_of_nervous_system" title="Template:Development of nervous system">devp</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:silver;;width:10em;">
<div>
<p><a href="/wiki/Template:CNS_diseases_of_the_nervous_system" title="Template:CNS diseases of the nervous system">noco</a> (<a href="/wiki/Template:Diseases_of_meninges" title="Template:Diseases of meninges">m</a>/<a href="/wiki/Template:Demyelinating_diseases_of_CNS" title="Template:Demyelinating diseases of CNS">d</a>/<a href="/wiki/Template:Seizures_and_epilepsy" title="Template:Seizures and epilepsy">e</a>/<a href="/wiki/Template:Headache" title="Template:Headache">h</a>/<a href="/wiki/Template:Cerebrovascular_diseases" title="Template:Cerebrovascular diseases">v</a>/<a href="/wiki/Template:Sleep" title="Template:Sleep">s</a>)/<a href="/wiki/Template:Congenital_malformations_and_deformations_of_nervous_system" title="Template:Congenital malformations and deformations of nervous system">cong</a>/<a href="/wiki/Template:Nervous_system_tumors" title="Template:Nervous system tumors">tumr</a>, <a href="/wiki/Template:Nervous_and_musculoskeletal_system_symptoms_and_signs" title="Template:Nervous and musculoskeletal system symptoms and signs">sysi</a>/<a href="/wiki/Template:Eponymous_medical_signs_for_nervous_system" title="Template:Eponymous medical signs for nervous system">epon</a>, <a href="/wiki/Template:Neurotrauma" title="Template:Neurotrauma">injr</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:#ccf;;width:10em;">
<div>
<p><a href="/wiki/Template:Neuro_procedures" title="Template:Neuro procedures">proc</a>, <a href="/wiki/ATC_code_N" title="ATC code N">drug</a> (<a href="/wiki/Template:General_anesthetics" title="Template:General anesthetics">N1A</a>/<a href="/wiki/Template:Analgesics" title="Template:Analgesics">2AB</a>/<a href="/wiki/Template:Antimigraine_preparations" title="Template:Antimigraine preparations">C</a>/<a href="/wiki/Template:Anticonvulsants" title="Template:Anticonvulsants">3</a>/<a href="/wiki/Template:Antiparkinson" title="Template:Antiparkinson">4</a>/<a href="/wiki/Template:Cholinergics" title="Template:Cholinergics">7A</a>/<a href="/wiki/Template:Antiaddictives" title="Template:Antiaddictives">B</a>/<a href="/wiki/Template:Antivertigo_preparations" title="Template:Antivertigo preparations">C</a>/<a href="/wiki/Template:Other_nervous_system_drugs" title="Template:Other nervous system drugs">D</a>)</p>
</div>
</td>
</tr>
</table>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background: Silver;;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:CNS_diseases_of_the_nervous_system" title="Template:CNS diseases of the nervous system"><span title="View this template" style=";background: Silver;;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:CNS_diseases_of_the_nervous_system" title="Template talk:CNS diseases of the nervous system"><span title="Discuss this template" style=";background: Silver;;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:CNS_diseases_of_the_nervous_system&amp;action=edit"><span title="Edit this template" style=";background: Silver;;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Pathology" title="Pathology">Pathology</a> of the <a href="/wiki/Nervous_system" title="Nervous system">nervous system</a>, primarily <a href="/wiki/Central_nervous_system_disease" title="Central nervous system disease">CNS</a> (<a href="/wiki/ICD-10_Chapter_VI:_Diseases_of_the_nervous_system" title="ICD-10 Chapter VI: Diseases of the nervous system">G04–G47</a>, <a href="/wiki/List_of_ICD-9_codes_320%E2%80%93359:_diseases_of_the_nervous_system" title="List of ICD-9 codes 320–359: diseases of the nervous system">323–349</a>)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Inflammation" title="Inflammation">Inflammation</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Human_brain" title="Human brain">Brain</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Encephalitis" title="Encephalitis">Encephalitis</a>
<ul>
<li><a href="/wiki/Viral_encephalitis" title="Viral encephalitis">Viral encephalitis</a></li>
<li><a href="/wiki/Herpesviral_encephalitis" title="Herpesviral encephalitis">Herpesviral encephalitis</a></li>
<li><a href="/wiki/Limbic_encephalitis" title="Limbic encephalitis">Limbic encephalitis</a></li>
<li><a href="/wiki/Encephalitis_lethargica" title="Encephalitis lethargica">Encephalitis lethargica</a></li>
</ul>
</li>
<li><a href="/wiki/Cavernous_sinus_thrombosis" title="Cavernous sinus thrombosis">Cavernous sinus thrombosis</a></li>
<li><a href="/wiki/Brain_abscess" title="Brain abscess">Brain abscess</a>
<ul>
<li><a href="/wiki/Amoebic_brain_abscess" title="Amoebic brain abscess">Amoebic</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Spinal_cord" title="Spinal cord">Spinal cord</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Myelitis" title="Myelitis">Myelitis</a>: <a href="/wiki/Poliomyelitis" title="Poliomyelitis">Poliomyelitis</a></li>
<li><a href="/wiki/Demyelinating_disease" title="Demyelinating disease">Demyelinating disease</a>
<ul>
<li><a href="/wiki/Transverse_myelitis" title="Transverse myelitis">Transverse myelitis</a></li>
</ul>
</li>
<li><a href="/wiki/Tropical_spastic_paraparesis" title="Tropical spastic paraparesis">Tropical spastic paraparesis</a></li>
<li><a href="/wiki/Epidural_abscess" title="Epidural abscess" class="mw-redirect">Epidural abscess</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;">Both/either</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Encephalomyelitis" title="Encephalomyelitis">Encephalomyelitis</a>
<ul>
<li><a href="/wiki/Acute_disseminated_encephalomyelitis" title="Acute disseminated encephalomyelitis">Acute disseminated</a></li>
</ul>
</li>
<li><a href="/wiki/Meningoencephalitis" title="Meningoencephalitis">Meningoencephalitis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Human_brain" title="Human brain">Brain</a>/<br />
<a href="/wiki/Encephalopathy" title="Encephalopathy">encephalopathy</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Neurodegenerative_disease" title="Neurodegenerative disease" class="mw-redirect">Degenerative</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Extrapyramidal_system" title="Extrapyramidal system">Extrapyramidal</a> and<br />
<a href="/wiki/Movement_disorder" title="Movement disorder">movement disorders</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Basal_ganglia_disease" title="Basal ganglia disease">Basal ganglia disease</a>
<ul>
<li><a href="/wiki/Parkinsonism" title="Parkinsonism">Parkinsonism</a>
<ul>
<li><a href="/wiki/Parkinson%27s_disease" title="Parkinson's disease">PD</a></li>
<li><a href="/wiki/Postencephalitic_parkinsonism" title="Postencephalitic parkinsonism">Postencephalitic</a></li>
<li><a href="/wiki/Neuroleptic_malignant_syndrome" title="Neuroleptic malignant syndrome">NMS</a></li>
</ul>
</li>
<li><a href="/wiki/Pantothenate_kinase-associated_neurodegeneration" title="Pantothenate kinase-associated neurodegeneration">PKAN</a></li>
<li><a href="/wiki/Tauopathy" title="Tauopathy">Tauopathy</a>
<ul>
<li><a href="/wiki/Progressive_supranuclear_palsy" title="Progressive supranuclear palsy">PSP</a></li>
</ul>
</li>
<li><a href="/wiki/Striatonigral_degeneration" title="Striatonigral degeneration" class="mw-redirect">Striatonigral degeneration</a></li>
<li><a href="/wiki/Hemiballismus" title="Hemiballismus">Hemiballismus</a></li>
<li><a href="/wiki/Huntington%27s_disease" title="Huntington's disease">HD</a></li>
<li><a href="/wiki/Olivopontocerebellar_atrophy" title="Olivopontocerebellar atrophy">OA</a></li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Dyskinesia" title="Dyskinesia">Dyskinesia</a>
<ul>
<li><a href="/wiki/Dystonia" title="Dystonia">Dystonia</a>
<ul>
<li><a href="/wiki/Status_dystonicus" title="Status dystonicus">Status dystonicus</a></li>
<li><a href="/wiki/Spasmodic_torticollis" title="Spasmodic torticollis">Spasmodic torticollis</a></li>
<li><a href="/wiki/Meige%27s_syndrome" title="Meige's syndrome">Meige's</a></li>
<li><a href="/wiki/Blepharospasm" title="Blepharospasm">Blepharospasm</a></li>
</ul>
</li>
<li><a href="/wiki/Athetosis" title="Athetosis">Athetosis</a></li>
<li><a href="/wiki/Chorea" title="Chorea">Chorea</a>
<ul>
<li><a href="/wiki/Choreoathetosis" title="Choreoathetosis">Choreoathetosis</a></li>
</ul>
</li>
<li><a href="/wiki/Myoclonus" title="Myoclonus">Myoclonus</a>
<ul>
<li><a href="/wiki/Myoclonic_epilepsy" title="Myoclonic epilepsy">Myoclonic epilepsy</a></li>
</ul>
</li>
<li><a href="/wiki/Akathisia" title="Akathisia">Akathisia</a></li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Tremor" title="Tremor">Tremor</a>
<ul>
<li><a href="/wiki/Essential_tremor" title="Essential tremor">Essential tremor</a></li>
<li><a href="/wiki/Intention_tremor" title="Intention tremor">Intention tremor</a></li>
</ul>
</li>
<li><a href="/wiki/Restless_legs_syndrome" title="Restless legs syndrome">Restless legs</a></li>
<li><a href="/wiki/Stiff_person_syndrome" title="Stiff person syndrome">Stiff person</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dementia" title="Dementia">Dementia</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Tauopathy" title="Tauopathy">Tauopathy</a>
<ul>
<li><a href="/wiki/Alzheimer%27s_disease" title="Alzheimer's disease">Alzheimer's</a>
<ul>
<li><a href="/wiki/Early-onset_Alzheimer%27s_disease" title="Early-onset Alzheimer's disease">Early-onset</a></li>
</ul>
</li>
<li><a href="/wiki/Primary_progressive_aphasia" title="Primary progressive aphasia">Primary progressive aphasia</a></li>
</ul>
</li>
<li><a href="/wiki/Frontotemporal_dementia" title="Frontotemporal dementia">Frontotemporal dementia</a>/<a href="/wiki/Frontotemporal_lobar_degeneration" title="Frontotemporal lobar degeneration">Frontotemporal lobar degeneration</a>
<ul>
<li><a href="/wiki/Pick%27s_disease" title="Pick's disease">Pick's</a></li>
<li><a href="/wiki/Dementia_with_Lewy_bodies" title="Dementia with Lewy bodies">Dementia with Lewy bodies</a></li>
</ul>
</li>
<li><a href="/wiki/Posterior_cortical_atrophy" title="Posterior cortical atrophy">Posterior cortical atrophy</a></li>
</ul>
<ul>
<li><a href="/wiki/Vascular_dementia" title="Vascular dementia">Vascular dementia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Mitochondrial_disease" title="Mitochondrial disease">Mitochondrial disease</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Leigh%27s_disease" title="Leigh's disease">Leigh's disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Demyelinating_disease" title="Demyelinating disease">Demyelinating</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/CNS_demyelinating_autoimmune_diseases" title="CNS demyelinating autoimmune diseases">autoimmune</a></i>
<ul>
<li><strong class="selflink">Multiple sclerosis</strong></li>
<li><a href="/wiki/Neuromyelitis_optica" title="Neuromyelitis optica">Neuromyelitis optica</a></li>
<li><a href="/wiki/Diffuse_myelinoclastic_sclerosis" title="Diffuse myelinoclastic sclerosis">Schilder's disease</a></li>
</ul>
</li>
<li><i><a href="/wiki/Hereditary_CNS_demyelinating_disease" title="Hereditary CNS demyelinating disease">hereditary</a></i>
<ul>
<li><a href="/wiki/Adrenoleukodystrophy" title="Adrenoleukodystrophy">Adrenoleukodystrophy</a></li>
<li><a href="/wiki/Alexander_disease" title="Alexander disease">Alexander</a></li>
<li><a href="/wiki/Canavan_disease" title="Canavan disease">Canavan</a></li>
<li><a href="/wiki/Krabbe_disease" title="Krabbe disease">Krabbe</a></li>
<li><a href="/wiki/Metachromatic_leukodystrophy" title="Metachromatic leukodystrophy">ML</a></li>
<li><a href="/wiki/Pelizaeus-Merzbacher_disease" title="Pelizaeus-Merzbacher disease" class="mw-redirect">PMD</a></li>
<li><a href="/wiki/Leukoencephalopathy_with_vanishing_white_matter" title="Leukoencephalopathy with vanishing white matter">VWM</a></li>
<li><a href="/wiki/Megalencephalic_leukoencephalopathy_with_subcortical_cysts" title="Megalencephalic leukoencephalopathy with subcortical cysts">MFC</a></li>
<li><a href="/wiki/CAMFAK_syndrome" title="CAMFAK syndrome">CAMFAK syndrome</a></li>
</ul>
</li>
<li><a href="/wiki/Central_pontine_myelinolysis" title="Central pontine myelinolysis">Central pontine myelinolysis</a></li>
<li><a href="/wiki/Marchiafava-Bignami_disease" title="Marchiafava-Bignami disease" class="mw-redirect">Marchiafava-Bignami disease</a></li>
<li><a href="/wiki/Alpers%27_disease" title="Alpers' disease">Alpers' disease</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;">Episodic/<br />
<a href="/wiki/Paroxysm" title="Paroxysm" class="mw-redirect">paroxysmal</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Epileptic_seizure" title="Epileptic seizure">Seizure</a>/<a href="/wiki/Epilepsy" title="Epilepsy">epilepsy</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Focal_seizures" title="Focal seizures" class="mw-redirect">Focal</a></li>
<li><a href="/wiki/Generalised_epilepsy" title="Generalised epilepsy">Generalised</a></li>
<li><a href="/wiki/Status_epilepticus" title="Status epilepticus">Status epilepticus</a></li>
<li><a href="/wiki/Myoclonic_epilepsy" title="Myoclonic epilepsy">Myoclonic epilepsy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Headache" title="Headache">Headache</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Migraine" title="Migraine">Migraine</a>
<ul>
<li><a href="/wiki/Familial_hemiplegic_migraine" title="Familial hemiplegic migraine">Familial hemiplegic</a></li>
</ul>
</li>
<li><a href="/wiki/Cluster_headache" title="Cluster headache">Cluster</a></li>
<li><a href="/wiki/Tension_headache" title="Tension headache">Tension</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Cerebrovascular_disease" title="Cerebrovascular disease">Cerebrovascular</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Transient_ischemic_attack" title="Transient ischemic attack">TIA</a>
<ul>
<li><a href="/wiki/Amaurosis_fugax" title="Amaurosis fugax">Amaurosis fugax</a></li>
<li><a href="/wiki/Transient_global_amnesia" title="Transient global amnesia">Transient global amnesia</a></li>
<li><a href="/wiki/Aphasia" title="Aphasia">Acute aphasia</a></li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Stroke" title="Stroke">Stroke</a>
<ul>
<li><a href="/wiki/Middle_cerebral_artery_syndrome" title="Middle cerebral artery syndrome">MCA</a></li>
<li><a href="/wiki/Anterior_cerebral_artery_syndrome" title="Anterior cerebral artery syndrome">ACA</a></li>
<li><a href="/wiki/Posterior_cerebral_artery_syndrome" title="Posterior cerebral artery syndrome">PCA</a></li>
<li><a href="/wiki/Foville%27s_syndrome" title="Foville's syndrome">Foville's</a></li>
<li><a href="/wiki/Millard-Gubler_syndrome" title="Millard-Gubler syndrome" class="mw-redirect">Millard-Gubler</a></li>
<li><a href="/wiki/Lateral_medullary_syndrome" title="Lateral medullary syndrome">Lateral medullary</a></li>
<li><a href="/wiki/Weber%27s_syndrome" title="Weber's syndrome">Weber's</a></li>
<li><a href="/wiki/Lacunar_stroke" title="Lacunar stroke">Lacunar stroke</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Sleep_disorder" title="Sleep disorder">Sleep disorders</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Insomnia" title="Insomnia">Insomnia</a></li>
<li><a href="/wiki/Hypersomnia" title="Hypersomnia">Hypersomnia</a></li>
<li><a href="/wiki/Sleep_apnea" title="Sleep apnea">Sleep apnea</a>
<ul>
<li><a href="/wiki/Obstructive_sleep_apnea" title="Obstructive sleep apnea">Obstructive</a></li>
<li><a href="/wiki/Ondine%27s_curse" title="Ondine's curse">Ondine's curse</a></li>
</ul>
</li>
<li><a href="/wiki/Narcolepsy" title="Narcolepsy">Narcolepsy</a></li>
<li><a href="/wiki/Cataplexy" title="Cataplexy">Cataplexy</a></li>
<li><a href="/wiki/Kleine-Levin_syndrome" title="Kleine-Levin syndrome" class="mw-redirect">Kleine-Levin</a></li>
<li><a href="/wiki/Circadian_rhythm_sleep_disorder" title="Circadian rhythm sleep disorder">Circadian rhythm sleep disorder</a>
<ul>
<li><a href="/wiki/Advanced_sleep_phase_disorder" title="Advanced sleep phase disorder">Advanced sleep phase disorder</a></li>
<li><a href="/wiki/Delayed_sleep_phase_disorder" title="Delayed sleep phase disorder">Delayed sleep phase disorder</a></li>
<li><a href="/wiki/Non-24-hour_sleep%E2%80%93wake_disorder" title="Non-24-hour sleep–wake disorder">Non-24-hour sleep–wake disorder</a></li>
<li><a href="/wiki/Jet_lag" title="Jet lag">Jet lag</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">CSF</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Intracranial_hypertension" title="Intracranial hypertension" class="mw-redirect">Intracranial hypertension</a>
<ul>
<li><a href="/wiki/Hydrocephalus" title="Hydrocephalus">Hydrocephalus</a>/<a href="/wiki/Normal_pressure_hydrocephalus" title="Normal pressure hydrocephalus">NPH</a></li>
<li><a href="/wiki/Choroid_plexus_papilloma" title="Choroid plexus papilloma">Choroid plexus papilloma</a></li>
<li><a href="/wiki/Idiopathic_intracranial_hypertension" title="Idiopathic intracranial hypertension">Idiopathic intracranial hypertension</a></li>
</ul>
</li>
<li><a href="/wiki/Cerebral_edema" title="Cerebral edema">Cerebral edema</a></li>
<li><a href="/wiki/Intracranial_hypotension" title="Intracranial hypotension" class="mw-redirect">Intracranial hypotension</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;">Other</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Brain_herniation" title="Brain herniation">Brain herniation</a></li>
<li><a href="/wiki/Reye%27s_syndrome" title="Reye's syndrome" class="mw-redirect">Reye's</a></li>
<li><a href="/wiki/Hepatic_encephalopathy" title="Hepatic encephalopathy">Hepatic encephalopathy</a></li>
<li><a href="/wiki/Toxic_encephalopathy" title="Toxic encephalopathy">Toxic encephalopathy</a></li>
<li><a href="/wiki/Hashimoto%27s_encephalopathy" title="Hashimoto's encephalopathy">Hashimoto's encephalopathy</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;"><a href="/wiki/Spinal_cord" title="Spinal cord">Spinal cord</a>/<br />
<a href="/wiki/Myelopathy" title="Myelopathy">myelopathy</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Syringomyelia" title="Syringomyelia">Syringomyelia</a></li>
<li><a href="/wiki/Syringobulbia" title="Syringobulbia">Syringobulbia</a></li>
<li><a href="/wiki/Morvan%27s_syndrome" title="Morvan's syndrome">Morvan's syndrome</a></li>
<li><a href="/wiki/Vascular_myelopathy" title="Vascular myelopathy">Vascular myelopathy</a>
<ul>
<li><a href="/wiki/Foix-Alajouanine_syndrome" title="Foix-Alajouanine syndrome" class="mw-redirect">Foix-Alajouanine syndrome</a></li>
</ul>
</li>
<li><a href="/wiki/Spinal_cord_compression" title="Spinal cord compression">Spinal cord compression</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LemonChiffon;">Both/either</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Neurodegenerative_disease" title="Neurodegenerative disease" class="mw-redirect">Degenerative</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Spinocerebellar_ataxia" title="Spinocerebellar ataxia">SA</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Friedreich%27s_ataxia" title="Friedreich's ataxia">Friedreich's ataxia</a></li>
<li><a href="/wiki/Ataxia_telangiectasia" title="Ataxia telangiectasia">Ataxia telangiectasia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LemonChiffon;">
<div style="padding:0em 0.75em;"><a href="/wiki/Motor_neuron_disease" title="Motor neuron disease">MND</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Upper_motor_neuron" title="Upper motor neuron">UMN</a> only:</i>
<ul>
<li><a href="/wiki/Primary_lateral_sclerosis" title="Primary lateral sclerosis">Primary lateral sclerosis</a></li>
<li><a href="/wiki/Pseudobulbar_palsy" title="Pseudobulbar palsy">Pseudobulbar palsy</a></li>
<li><a href="/wiki/Hereditary_spastic_paraplegia" title="Hereditary spastic paraplegia">Hereditary spastic paraplegia</a></li>
</ul>
</li>
</ul>
<ul>
<li><i><a href="/wiki/Lower_motor_neuron" title="Lower motor neuron">LMN</a> only:</i>
<ul>
<li><a href="/wiki/Distal_hereditary_motor_neuropathies" title="Distal hereditary motor neuropathies">Distal hereditary motor neuropathies</a></li>
<li><a href="/wiki/Spinal_muscular_atrophies" title="Spinal muscular atrophies">Spinal muscular atrophies</a>
<ul>
<li><a href="/wiki/Spinal_muscular_atrophy" title="Spinal muscular atrophy">SMA</a></li>
<li><a href="/wiki/X-linked_spinal_muscular_atrophy_type_1" title="X-linked spinal muscular atrophy type 1" class="mw-redirect">SMAX1</a></li>
<li><a href="/wiki/X-linked_spinal_muscular_atrophy_type_2" title="X-linked spinal muscular atrophy type 2">SMAX2</a></li>
<li><a href="/wiki/Distal_spinal_muscular_atrophy_type_1" title="Distal spinal muscular atrophy type 1">DSMA1</a></li>
<li><a href="/wiki/Congenital_distal_spinal_muscular_atrophy" title="Congenital distal spinal muscular atrophy">Congenital DSMA</a></li>
<li><a href="/wiki/Spinal_muscular_atrophy_with_pontocerebellar_hypoplasia" title="Spinal muscular atrophy with pontocerebellar hypoplasia" class="mw-redirect">SMA-PCH</a></li>
<li><a href="/wiki/Spinal_muscular_atrophy_with_lower_extremity_predominance" title="Spinal muscular atrophy with lower extremity predominance">SMA-LED</a></li>
<li><a href="/wiki/Spinal_muscular_atrophy_with_progressive_myoclonic_epilepsy" title="Spinal muscular atrophy with progressive myoclonic epilepsy">SMA-PME</a></li>
</ul>
</li>
<li><a href="/wiki/Progressive_muscular_atrophy" title="Progressive muscular atrophy">Progressive muscular atrophy</a></li>
<li><a href="/wiki/Progressive_bulbar_palsy" title="Progressive bulbar palsy">Progressive bulbar palsy</a>
<ul>
<li><a href="/wiki/Fazio%E2%80%93Londe_disease" title="Fazio–Londe disease">Fazio–Londe</a></li>
<li><a href="/wiki/Infantile_progressive_bulbar_palsy" title="Infantile progressive bulbar palsy">Infantile progressive bulbar palsy</a></li>
</ul>
</li>
</ul>
</li>
</ul>
<ul>
<li><i>both:</i>
<ul>
<li><a href="/wiki/Amyotrophic_lateral_sclerosis" title="Amyotrophic lateral sclerosis">Amyotrophic lateral sclerosis</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;;">
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;background:transparent;color:inherit;;">
<div style="padding:0px;;">
<table cellspacing="0" class="navbox-columns-table" style="text-align:left;width:100%;">
<tr style="vertical-align:top;">
<td style="padding:0px;text-align:center;background:#efefef;;;text-align:center;background:LemonChiffon;;width:10em;">
<div>
<p><a href="/wiki/Template:Medicine_navs" title="Template:Medicine navs">M</a>: <a href="/wiki/Central_nervous_system" title="Central nervous system">CNS</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:white;;width:10em;">
<div>
<p><a href="/wiki/Template:Nervous_system" title="Template:Nervous system">anat</a> (<a href="/wiki/Template:Meninges" title="Template:Meninges">n</a>/<a href="/wiki/Template:Spinal_cord" title="Template:Spinal cord">s</a>/<a href="/wiki/Template:Medulla" title="Template:Medulla">m</a>/<a href="/wiki/Template:Pons" title="Template:Pons">p</a>/<a href="/wiki/Template:Fourth_ventricle" title="Template:Fourth ventricle">4</a>/<a href="/wiki/Template:Mesencephalon" title="Template:Mesencephalon">e</a>/<a href="/wiki/Template:Cerebellum" title="Template:Cerebellum">b</a>/<a href="/wiki/Template:Diencephalon" title="Template:Diencephalon">d</a>/<a href="/wiki/Template:Cerebral_cortex" title="Template:Cerebral cortex">c</a>/<a href="/wiki/Template:Association_fibers" title="Template:Association fibers">a</a>/<a href="/wiki/Template:Commissural_fibers_and_septum" title="Template:Commissural fibers and septum">f</a>/<a href="/wiki/Template:Lateral_ventricles" title="Template:Lateral ventricles">l</a>/<a href="/wiki/Template:Rostral_basal_ganglia_and_associated_structures" title="Template:Rostral basal ganglia and associated structures">g</a>)/<a href="/wiki/Template:Nervous_system_physiology" title="Template:Nervous system physiology">phys</a>/<a href="/wiki/Template:Development_of_nervous_system" title="Template:Development of nervous system">devp</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:silver;;width:10em;">
<div>
<p><a href="/wiki/Template:CNS_diseases_of_the_nervous_system" title="Template:CNS diseases of the nervous system">noco</a> (<a href="/wiki/Template:Diseases_of_meninges" title="Template:Diseases of meninges">m</a>/<a href="/wiki/Template:Demyelinating_diseases_of_CNS" title="Template:Demyelinating diseases of CNS">d</a>/<a href="/wiki/Template:Seizures_and_epilepsy" title="Template:Seizures and epilepsy">e</a>/<a href="/wiki/Template:Headache" title="Template:Headache">h</a>/<a href="/wiki/Template:Cerebrovascular_diseases" title="Template:Cerebrovascular diseases">v</a>/<a href="/wiki/Template:Sleep" title="Template:Sleep">s</a>)/<a href="/wiki/Template:Congenital_malformations_and_deformations_of_nervous_system" title="Template:Congenital malformations and deformations of nervous system">cong</a>/<a href="/wiki/Template:Nervous_system_tumors" title="Template:Nervous system tumors">tumr</a>, <a href="/wiki/Template:Nervous_and_musculoskeletal_system_symptoms_and_signs" title="Template:Nervous and musculoskeletal system symptoms and signs">sysi</a>/<a href="/wiki/Template:Eponymous_medical_signs_for_nervous_system" title="Template:Eponymous medical signs for nervous system">epon</a>, <a href="/wiki/Template:Neurotrauma" title="Template:Neurotrauma">injr</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:#ccf;;width:10em;">
<div>
<p><a href="/wiki/Template:Neuro_procedures" title="Template:Neuro procedures">proc</a>, <a href="/wiki/ATC_code_N" title="ATC code N">drug</a> (<a href="/wiki/Template:General_anesthetics" title="Template:General anesthetics">N1A</a>/<a href="/wiki/Template:Analgesics" title="Template:Analgesics">2AB</a>/<a href="/wiki/Template:Antimigraine_preparations" title="Template:Antimigraine preparations">C</a>/<a href="/wiki/Template:Anticonvulsants" title="Template:Anticonvulsants">3</a>/<a href="/wiki/Template:Antiparkinson" title="Template:Antiparkinson">4</a>/<a href="/wiki/Template:Cholinergics" title="Template:Cholinergics">7A</a>/<a href="/wiki/Template:Antiaddictives" title="Template:Antiaddictives">B</a>/<a href="/wiki/Template:Antivertigo_preparations" title="Template:Antivertigo preparations">C</a>/<a href="/wiki/Template:Other_nervous_system_drugs" title="Template:Other nervous system drugs">D</a>)</p>
</div>
</td>
</tr>
</table>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background:Silver;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases"><span title="View this template" style=";background:Silver;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Hypersensitivity_and_autoimmune_diseases" title="Template talk:Hypersensitivity and autoimmune diseases"><span title="Discuss this template" style=";background:Silver;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Hypersensitivity_and_autoimmune_diseases&amp;action=edit"><span title="Edit this template" style=";background:Silver;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Immune_disorder" title="Immune disorder">Immune disorders</a>: <a href="/wiki/Hypersensitivity" title="Hypersensitivity">hypersensitivity</a> and <a href="/wiki/Autoimmune_disease" title="Autoimmune disease">autoimmune diseases</a> (<a href="/wiki/List_of_ICD-9_codes_240%E2%80%93279:_endocrine,_nutritional_and_metabolic_diseases,_and_immunity_disorders" title="List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders">279.5–6</a>)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Type_I_hypersensitivity" title="Type I hypersensitivity">Type I</a>/<a href="/wiki/Allergy" title="Allergy">allergy</a>/<a href="/wiki/Atopy" title="Atopy">atopy</a><br />
(<a href="/wiki/Immunoglobulin_E" title="Immunoglobulin E">IgE</a>)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Atopic_eczema" title="Atopic eczema" class="mw-redirect">Atopic eczema</a></li>
<li><a href="/wiki/Urticaria" title="Urticaria">Allergic urticaria</a></li>
<li><a href="/wiki/Allergic_rhinitis" title="Allergic rhinitis">Allergic rhinitis</a> (Hay fever)</li>
<li><a href="/wiki/Asthma" title="Asthma">Allergic asthma</a></li>
<li><a href="/wiki/Anaphylaxis" title="Anaphylaxis">Anaphylaxis</a></li>
<li><a href="/wiki/Food_allergy" title="Food allergy">Food allergy</a>
<ul>
<li><a href="/wiki/Milk_allergy" title="Milk allergy">Milk</a></li>
<li><a href="/wiki/Egg_allergy" title="Egg allergy">Egg</a></li>
<li><a href="/wiki/Peanut_allergy" title="Peanut allergy">Peanut</a></li>
<li><a href="/wiki/Tree_nut_allergy" title="Tree nut allergy">Tree nut</a></li>
<li><a href="/wiki/Seafood_allergy" title="Seafood allergy">Seafood</a></li>
<li><a href="/wiki/Soy_allergy" title="Soy allergy">Soy</a></li>
<li><a href="/wiki/Wheat_allergy" title="Wheat allergy">Wheat</a></li>
</ul>
</li>
<li><a href="/wiki/Penicillin_drug_reaction" title="Penicillin drug reaction">Penicillin allergy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>none</i></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Type_II_hypersensitivity" title="Type II hypersensitivity">Type II</a>/<a href="/wiki/Antibody-dependent_cell-mediated_cytotoxicity" title="Antibody-dependent cell-mediated cytotoxicity">ADCC</a><br />
<ul>
<li>
<ul>
<li><a href="/wiki/Immunoglobulin_M" title="Immunoglobulin M">IgM</a></li>
<li><a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG</a></li>
</ul>
</li>
</ul>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Pernicious_anemia" title="Pernicious anemia">Pernicious anemia</a></li>
<li><a href="/wiki/Hemolytic_disease_of_the_newborn" title="Hemolytic disease of the newborn">Hemolytic disease of the newborn</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Cytotoxicity" title="Cytotoxicity">Cytotoxic</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Autoimmune_hemolytic_anemia" title="Autoimmune hemolytic anemia">Autoimmune hemolytic anemia</a></li>
<li><a href="/wiki/Idiopathic_thrombocytopenic_purpura" title="Idiopathic thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</a></li>
<li><a href="/wiki/Bullous_pemphigoid" title="Bullous pemphigoid">Bullous pemphigoid</a></li>
<li><a href="/wiki/Pemphigus_vulgaris" title="Pemphigus vulgaris">Pemphigus vulgaris</a></li>
<li><a href="/wiki/Rheumatic_fever" title="Rheumatic fever">Rheumatic fever</a></li>
<li><a href="/wiki/Goodpasture%27s_syndrome" title="Goodpasture's syndrome" class="mw-redirect">Goodpasture's syndrome</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">"<a href="/wiki/Hypersensitivity#Type_V" title="Hypersensitivity">Type V</a>"/<a href="/wiki/Receptor_(biochemistry)" title="Receptor (biochemistry)">receptor</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Graves%27_disease" title="Graves' disease">Graves' disease</a></li>
<li><a href="/wiki/Myasthenia_gravis" title="Myasthenia gravis">Myasthenia gravis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Type_III_hypersensitivity" title="Type III hypersensitivity">Type III</a><br />
(<a href="/wiki/Immune_complex" title="Immune complex">Immune complex</a>)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Henoch%E2%80%93Sch%C3%B6nlein_purpura" title="Henoch–Schönlein purpura">Henoch–Schönlein purpura</a></li>
<li><a href="/wiki/Cutaneous_small-vessel_vasculitis" title="Cutaneous small-vessel vasculitis">Hypersensitivity vasculitis</a></li>
<li><a href="/wiki/Reactive_arthritis" title="Reactive arthritis">Reactive arthritis</a></li>
<li><a href="/wiki/Farmer%27s_lung" title="Farmer's lung">Farmer's lung</a></li>
<li><a href="/wiki/Acute_proliferative_glomerulonephritis" title="Acute proliferative glomerulonephritis">Post-streptococcal glomerulonephritis</a></li>
<li><a href="/wiki/Serum_sickness" title="Serum sickness">Serum sickness</a></li>
<li><a href="/wiki/Arthus_reaction" title="Arthus reaction">Arthus reaction</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Systemic_lupus_erythematosus" title="Systemic lupus erythematosus">Systemic lupus erythematosus</a></li>
<li><a href="/wiki/Subacute_bacterial_endocarditis" title="Subacute bacterial endocarditis">Subacute bacterial endocarditis</a></li>
<li><a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">Rheumatoid arthritis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Type_IV_hypersensitivity" title="Type IV hypersensitivity">Type IV</a>/<a href="/wiki/Cell-mediated_immunity" title="Cell-mediated immunity">cell-mediated</a><br />
(<a href="/wiki/T_cell" title="T cell">T cells</a>)</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Allergic_contact_dermatitis" title="Allergic contact dermatitis">Allergic contact dermatitis</a></li>
<li><a href="/wiki/Mantoux_test" title="Mantoux test">Mantoux test</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Diabetes_mellitus_type_1" title="Diabetes mellitus type 1">Diabetes mellitus type 1</a></li>
<li><a href="/wiki/Hashimoto%27s_thyroiditis" title="Hashimoto's thyroiditis">Hashimoto's thyroiditis</a></li>
<li><a href="/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" title="Guillain–Barré syndrome">Guillain–Barré syndrome</a></li>
<li><strong class="selflink">Multiple sclerosis</strong></li>
<li><a href="/wiki/Coeliac_disease" title="Coeliac disease">Coeliac disease</a></li>
<li><a href="/wiki/Giant-cell_arteritis" title="Giant-cell arteritis">Giant-cell arteritis</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;"><a href="/wiki/Graft-versus-host_disease" title="Graft-versus-host disease">GVHD</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Transfusion-associated_graft_versus_host_disease" title="Transfusion-associated graft versus host disease">Transfusion-associated graft versus host disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Unknown/<br />
multiple</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Hypersensitivity_pneumonitis" title="Hypersensitivity pneumonitis">Hypersensitivity pneumonitis</a>
<ul>
<li><a href="/wiki/Allergic_bronchopulmonary_aspergillosis" title="Allergic bronchopulmonary aspergillosis">Allergic bronchopulmonary aspergillosis</a></li>
</ul>
</li>
<li><a href="/wiki/Transplant_rejection" title="Transplant rejection">Transplant rejection</a></li>
<li><a href="/wiki/Latex_allergy" title="Latex allergy">Latex allergy</a> (I+IV)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:LightGreen;;">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Sj%C3%B6gren%27s_syndrome" title="Sjögren's syndrome">Sjögren's syndrome</a></li>
<li><a href="/wiki/Autoimmune_hepatitis" title="Autoimmune hepatitis">Autoimmune hepatitis</a></li>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome" title="Autoimmune polyendocrine syndrome">Autoimmune polyendocrine syndrome</a>
<ul>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome_type_1" title="Autoimmune polyendocrine syndrome type 1">APS1</a></li>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome_type_2" title="Autoimmune polyendocrine syndrome type 2">APS2</a></li>
</ul>
</li>
<li><a href="/wiki/Addison%27s_disease" title="Addison's disease">Autoimmune adrenalitis</a></li>
<li><a href="/wiki/Autoimmune_disease" title="Autoimmune disease">Systemic autoimmune disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;;">
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;background:transparent;color:inherit;;">
<div style="padding:0px;;">
<table cellspacing="0" class="navbox-columns-table" style="text-align:left;width:100%;">
<tr style="vertical-align:top;">
<td style="padding:0px;text-align:center;background:#efefef;;;text-align:center;background:LightGreen;;width:10em;">
<div>
<p><a href="/wiki/Template:Medicine_navs" title="Template:Medicine navs">M</a>: <a href="/wiki/Lymphocyte" title="Lymphocyte">LMC</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:white;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cell</a>/<a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">phys</a>/<a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">auag</a>/<a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">auab</a>/<a href="/wiki/Template:Complement_system" title="Template:Complement system">comp</a>, <a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">igrc</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:silver;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">imdf</a>/<a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">ipig</a>/<a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">hyps</a>/<a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">tumr</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:#ccf;;width:10em;">
<div>
<p><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">proc</a>, drug (<a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">L3</a>/<a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">4</a>)</p>
</div>
</td>
</tr>
</table>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<div style="display:none; right:10px;" class="metadata topicon nopopups" id="featured-star"><a href="/wiki/Wikipedia:Featured_articles" title="This is a featured article. Click here for more information."><img alt="This is a featured article. Click here for more information." src="//upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/15px-Cscr-featured.svg.png" width="15" height="14" srcset="//upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/23px-Cscr-featured.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/30px-Cscr-featured.svg.png 2x" /></a></div>
<p><span id="interwiki-pl-ga"></span> <span id="interwiki-bg-fa"></span> <span id="interwiki-cs-fa"></span> <span id="interwiki-de-fa"></span> <span id="interwiki-sr-fa"></span> <span id="interwiki-bs-fa"></span> <span id="interwiki-hr-fa"></span> <span id="interwiki-it-fa"></span> <span id="interwiki-pt-fa"></span></p>


<!-- 
NewPP limit report
Parsed by mw1188
CPU time usage: 3.908 seconds
Real time usage: 4.258 seconds
Preprocessor visited node count: 13363/1000000
Preprocessor generated node count: 62841/1500000
Post‐expand include size: 462400/2048000 bytes
Template argument size: 22799/2048000 bytes
Highest expansion depth: 14/40
Expensive parser function count: 7/500
Lua time usage: 0.435/10.000 seconds
Lua memory usage: 2.88 MB/50 MB
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:50603-0!*!0!!en!4!* and timestamp 20140326021423
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>								<div class="printfooter">
				Retrieved from "<a href="http://en.wikipedia.org/w/index.php?title=Multiple_sclerosis&amp;oldid=600986501">http://en.wikipedia.org/w/index.php?title=Multiple_sclerosis&amp;oldid=600986501</a>"				</div>
												<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Multiple_sclerosis" title="Category:Multiple sclerosis">Multiple sclerosis</a></li><li><a href="/wiki/Category:Epstein%E2%80%93Barr_virus-associated_diseases" title="Category:Epstein–Barr virus-associated diseases">Epstein–Barr virus-associated diseases</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Pages_containing_cite_templates_with_deprecated_parameters" title="Category:Pages containing cite templates with deprecated parameters">Pages containing cite templates with deprecated parameters</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_March_2014" title="Category:Use dmy dates from March 2014">Use dmy dates from March 2014</a></li><li><a href="/wiki/Category:Wikipedia_indefinitely_semi-protected_pages" title="Category:Wikipedia indefinitely semi-protected pages">Wikipedia indefinitely semi-protected pages</a></li><li><a href="/wiki/Category:Articles_with_Open_Directory_Project_links" title="Category:Articles with Open Directory Project links">Articles with Open Directory Project links</a></li><li><a href="/wiki/Category:Featured_articles" title="Category:Featured articles">Featured articles</a></li></ul></div></div>												<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
				<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
	<h3 id="p-personal-label">Personal tools</h3>
	<ul>
<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Multiple+sclerosis&amp;type=signup">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Multiple+sclerosis" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>	</ul>
</div>
				<div id="left-navigation">
					<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
	<h3 id="p-namespaces-label">Namespaces</h3>
	<ul>
					<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Multiple_sclerosis"  title="View the content page [c]" accesskey="c">Article</a></span></li>
					<li  id="ca-talk"><span><a href="/wiki/Talk:Multiple_sclerosis"  title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>
			</ul>
</div>
<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
	<h3 id="mw-vector-current-variant">
		</h3>
	<h3 id="p-variants-label"><span>Variants</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
				</div>
				<div id="right-navigation">
					<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
	<h3 id="p-views-label">Views</h3>
	<ul>
					<li id="ca-view" class="selected"><span><a href="/wiki/Multiple_sclerosis" >Read</a></span></li>
					<li id="ca-viewsource"><span><a href="/w/index.php?title=Multiple_sclerosis&amp;action=edit"  title="This page is protected.&#10;You can view its source [e]" accesskey="e">View source</a></span></li>
					<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Multiple_sclerosis&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
			</ul>
</div>
<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
	<h3 id="p-cactions-label"><span>Actions</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
<div id="p-search" role="search">
	<h3><label for="searchInput">Search</label></h3>
	<form action="/w/index.php" id="searchform">
					<div id="simpleSearch">
					<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />		</div>
	</form>
</div>
				</div>
			</div>
			<div id="mw-panel">
					<div id="p-logo" role="banner"><a style="background-image: url(//upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
				<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
	<h3 id='p-navigation-label'>Navigation</h3>
	<div class="body">
		<ul>
			<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
			<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
			<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li>
			<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
			<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			<li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li>
			<li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikimedia Shop</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
	<h3 id='p-interaction-label'>Interaction</h3>
	<div class="body">
		<ul>
			<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
			<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
			<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
			<li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
	<h3 id='p-tb-label'>Tools</h3>
	<div class="body">
		<ul>
			<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Multiple_sclerosis" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
			<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Multiple_sclerosis" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
			<li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li>
			<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li>
			<li id="t-permalink"><a href="/w/index.php?title=Multiple_sclerosis&amp;oldid=600986501" title="Permanent link to this revision of the page">Permanent link</a></li>
			<li id="t-info"><a href="/w/index.php?title=Multiple_sclerosis&amp;action=info">Page information</a></li>
			<li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q8277" title="Link to connected data repository item [g]" accesskey="g">Data item</a></li>
<li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Multiple_sclerosis&amp;id=600986501" title="Information on how to cite this page">Cite this page</a></li>		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
	<h3 id='p-coll-print_export-label'>Print/export</h3>
	<div class="body">
		<ul>
			<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Multiple+sclerosis">Create a book</a></li>
			<li id="coll-download-as-rl"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Multiple+sclerosis&amp;oldid=600986501&amp;writer=rl">Download as PDF</a></li>
			<li id="t-print"><a href="/w/index.php?title=Multiple_sclerosis&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
	<h3 id='p-lang-label'>Languages</h3>
	<div class="body">
		<ul>
			<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%A7%D9%84%D8%AA%D8%B5%D9%84%D8%A8_%D8%A7%D9%84%D9%84%D9%88%D9%8A%D8%AD%D9%8A" title="التصلب اللويحي – Arabic" lang="ar" hreflang="ar">العربية</a></li>
			<li class="interlanguage-link interwiki-bg"><a href="//bg.wikipedia.org/wiki/%D0%9C%D0%BD%D0%BE%D0%B6%D0%B5%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%B0_%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7%D0%B0" title="Множествена склероза – Bulgarian" lang="bg" hreflang="bg">Български</a></li>
			<li class="interlanguage-link interwiki-bs"><a href="//bs.wikipedia.org/wiki/Multipla_skleroza" title="Multipla skleroza – Bosnian" lang="bs" hreflang="bs">Bosanski</a></li>
			<li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Esclerosi_m%C3%BAltiple" title="Esclerosi múltiple – Catalan" lang="ca" hreflang="ca">Català</a></li>
			<li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Roztrou%C5%A1en%C3%A1_skler%C3%B3za" title="Roztroušená skleróza – Czech" lang="cs" hreflang="cs">Čeština</a></li>
			<li class="interlanguage-link interwiki-cy"><a href="//cy.wikipedia.org/wiki/Sglerosis_ymledol" title="Sglerosis ymledol – Welsh" lang="cy" hreflang="cy">Cymraeg</a></li>
			<li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Multipel_sklerose" title="Multipel sklerose – Danish" lang="da" hreflang="da">Dansk</a></li>
			<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Multiple_Sklerose" title="Multiple Sklerose – German" lang="de" hreflang="de">Deutsch</a></li>
			<li class="interlanguage-link interwiki-et"><a href="//et.wikipedia.org/wiki/Pol%C3%BCskleroos" title="Polüskleroos – Estonian" lang="et" hreflang="et">Eesti</a></li>
			<li class="interlanguage-link interwiki-el"><a href="//el.wikipedia.org/wiki/%CE%A0%CE%BF%CE%BB%CE%BB%CE%B1%CF%80%CE%BB%CE%AE_%CF%83%CE%BA%CE%BB%CE%AE%CF%81%CF%85%CE%BD%CF%83%CE%B7" title="Πολλαπλή σκλήρυνση – Greek" lang="el" hreflang="el">Ελληνικά</a></li>
			<li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Esclerosis_m%C3%BAltiple" title="Esclerosis múltiple – Spanish" lang="es" hreflang="es">Español</a></li>
			<li class="interlanguage-link interwiki-eo"><a href="//eo.wikipedia.org/wiki/Multloka_sklerozo" title="Multloka sklerozo – Esperanto" lang="eo" hreflang="eo">Esperanto</a></li>
			<li class="interlanguage-link interwiki-eu"><a href="//eu.wikipedia.org/wiki/Esklerosi_anizkoitz" title="Esklerosi anizkoitz – Basque" lang="eu" hreflang="eu">Euskara</a></li>
			<li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%81%D9%84%D8%AC_%DA%86%D9%86%D8%AF%DA%AF%D8%A7%D9%86%D9%87" title="فلج چندگانه – Persian" lang="fa" hreflang="fa">فارسی</a></li>
			<li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Scl%C3%A9rose_en_plaques" title="Sclérose en plaques – French" lang="fr" hreflang="fr">Français</a></li>
			<li class="interlanguage-link interwiki-ga"><a href="//ga.wikipedia.org/wiki/Scl%C3%A9ar%C3%B3is_iolrach" title="Scléaróis iolrach – Irish" lang="ga" hreflang="ga">Gaeilge</a></li>
			<li class="interlanguage-link interwiki-gl"><a href="//gl.wikipedia.org/wiki/Esclerose_m%C3%BAltiple" title="Esclerose múltiple – Galician" lang="gl" hreflang="gl">Galego</a></li>
			<li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EB%8B%A4%EB%B0%9C%EC%84%B1_%EA%B2%BD%ED%99%94%EC%A6%9D" title="다발성 경화증 – Korean" lang="ko" hreflang="ko">한국어</a></li>
			<li class="interlanguage-link interwiki-hi"><a href="//hi.wikipedia.org/wiki/%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A4%BF%E0%A4%AA%E0%A4%B2_%E0%A4%B8%E0%A5%8D%E0%A4%95%E0%A5%8D%E0%A4%B2%E0%A5%87%E0%A4%B0%E0%A5%8B%E0%A4%B8%E0%A4%BF%E0%A4%B8_(%E0%A4%AC%E0%A4%B9%E0%A5%81%E0%A4%B8%E0%A5%83%E0%A4%A4_%E0%A4%95%E0%A4%BE%E0%A4%A0%E0%A4%BF%E0%A4%A8%E0%A5%8D%E0%A4%AF)" title="मल्टिपल स्क्लेरोसिस (बहुसृत काठिन्य) – Hindi" lang="hi" hreflang="hi">हिन्दी</a></li>
			<li class="interlanguage-link interwiki-hr"><a href="//hr.wikipedia.org/wiki/Multipla_skleroza" title="Multipla skleroza – Croatian" lang="hr" hreflang="hr">Hrvatski</a></li>
			<li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Sklerosis_multipel" title="Sklerosis multipel – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li>
			<li class="interlanguage-link interwiki-is"><a href="//is.wikipedia.org/wiki/MS_(sj%C3%BAkd%C3%B3mur)" title="MS (sjúkdómur) – Icelandic" lang="is" hreflang="is">Íslenska</a></li>
			<li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Sclerosi_multipla" title="Sclerosi multipla – Italian" lang="it" hreflang="it">Italiano</a></li>
			<li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%98%D7%A8%D7%A9%D7%AA_%D7%A0%D7%A4%D7%95%D7%A6%D7%94" title="טרשת נפוצה – Hebrew" lang="he" hreflang="he">עברית</a></li>
			<li class="interlanguage-link interwiki-ku"><a href="//ku.wikipedia.org/wiki/Skleroza_en%C3%AEfireh" title="Skleroza enîfireh – Kurdish" lang="ku" hreflang="ku">Kurdî</a></li>
			<li class="interlanguage-link interwiki-lv"><a href="//lv.wikipedia.org/wiki/Izkais%C4%ABt%C4%81_skleroze" title="Izkaisītā skleroze – Latvian" lang="lv" hreflang="lv">Latviešu</a></li>
			<li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/I%C5%A1s%C4%97tin%C4%97_skleroz%C4%97" title="Išsėtinė sklerozė – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li>
			<li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Sclerosis_multiplex" title="Sclerosis multiplex – Hungarian" lang="hu" hreflang="hu">Magyar</a></li>
			<li class="interlanguage-link interwiki-mr"><a href="//mr.wikipedia.org/wiki/%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A4%BF%E0%A4%AA%E0%A4%B2_%E0%A4%B8%E0%A5%8D%E0%A4%95%E0%A5%8D%E0%A4%B2%E0%A5%87%E0%A4%B0%E0%A5%89%E0%A4%B8%E0%A4%BF%E0%A4%B8" title="मल्टिपल स्क्लेरॉसिस – Marathi" lang="mr" hreflang="mr">मराठी</a></li>
			<li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Multiple_sclerose" title="Multiple sclerose – Dutch" lang="nl" hreflang="nl">Nederlands</a></li>
			<li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E5%A4%9A%E7%99%BA%E6%80%A7%E7%A1%AC%E5%8C%96%E7%97%87" title="多発性硬化症 – Japanese" lang="ja" hreflang="ja">日本語</a></li>
			<li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Multippel_sklerose" title="Multippel sklerose – Norwegian (bokmål)" lang="no" hreflang="no">Norsk bokmål</a></li>
			<li class="interlanguage-link interwiki-oc"><a href="//oc.wikipedia.org/wiki/Escler%C3%B2si_multipla" title="Escleròsi multipla – Occitan" lang="oc" hreflang="oc">Occitan</a></li>
			<li class="interlanguage-link interwiki-or"><a href="//or.wikipedia.org/wiki/%E0%AC%AE%E0%AC%B2%E0%AD%8D%E0%AC%9F%E0%AC%BF%E0%AC%AA%E0%AD%8D%E0%AC%B2_%E0%AC%B8%E0%AD%8D%E0%AC%95%E0%AD%8D%E0%AC%B2%E0%AD%87%E0%AC%B0%E0%AD%8B%E0%AC%B8%E0%AC%BF%E0%AC%B8" title="ମଲ୍ଟିପ୍ଲ ସ୍କ୍ଲେରୋସିସ – Oriya" lang="or" hreflang="or">ଓଡ଼ିଆ</a></li>
			<li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Stwardnienie_rozsiane" title="Stwardnienie rozsiane – Polish" lang="pl" hreflang="pl">Polski</a></li>
			<li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Esclerose_m%C3%BAltipla" title="Esclerose múltipla – Portuguese" lang="pt" hreflang="pt">Português</a></li>
			<li class="interlanguage-link interwiki-ro"><a href="//ro.wikipedia.org/wiki/Scleroz%C4%83_multipl%C4%83" title="Scleroză multiplă – Romanian" lang="ro" hreflang="ro">Română</a></li>
			<li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%A0%D0%B0%D1%81%D1%81%D0%B5%D1%8F%D0%BD%D0%BD%D1%8B%D0%B9_%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7" title="Рассеянный склероз – Russian" lang="ru" hreflang="ru">Русский</a></li>
			<li class="interlanguage-link interwiki-sq"><a href="//sq.wikipedia.org/wiki/Multiple_skleroza" title="Multiple skleroza – Albanian" lang="sq" hreflang="sq">Shqip</a></li>
			<li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Multiple_sclerosis" title="Multiple sclerosis – Simple English" lang="simple" hreflang="simple">Simple English</a></li>
			<li class="interlanguage-link interwiki-sk"><a href="//sk.wikipedia.org/wiki/Skler%C3%B3za_multiplex" title="Skleróza multiplex – Slovak" lang="sk" hreflang="sk">Slovenčina</a></li>
			<li class="interlanguage-link interwiki-sl"><a href="//sl.wikipedia.org/wiki/Multipla_skleroza" title="Multipla skleroza – Slovenian" lang="sl" hreflang="sl">Slovenščina</a></li>
			<li class="interlanguage-link interwiki-ckb"><a href="//ckb.wikipedia.org/wiki/%D8%A6%DB%8E%D9%85_%D8%A6%DB%8E%D8%B3" title="ئێم ئێس – Sorani Kurdish" lang="ckb" hreflang="ckb">کوردی</a></li>
			<li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/Multipla_skleroza" title="Multipla skleroza – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li>
			<li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Multipla_skleroza" title="Multipla skleroza – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li>
			<li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/MS-tauti" title="MS-tauti – Finnish" lang="fi" hreflang="fi">Suomi</a></li>
			<li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Multipel_skleros" title="Multipel skleros – Swedish" lang="sv" hreflang="sv">Svenska</a></li>
			<li class="interlanguage-link interwiki-ta"><a href="//ta.wikipedia.org/wiki/%E0%AE%A4%E0%AE%A3%E0%AF%8D%E0%AE%9F%E0%AF%81%E0%AE%B5%E0%AE%9F_%E0%AE%AE%E0%AE%B0%E0%AE%AA%E0%AF%8D%E0%AE%AA%E0%AF%81_%E0%AE%A8%E0%AF%8B%E0%AE%AF%E0%AF%8D" title="தண்டுவட மரப்பு நோய் – Tamil" lang="ta" hreflang="ta">தமிழ்</a></li>
			<li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B9%82%E0%B8%A3%E0%B8%84%E0%B8%A1%E0%B8%B1%E0%B8%A5%E0%B8%95%E0%B8%B4%E0%B9%80%E0%B8%9E%E0%B8%B4%E0%B8%A5_%E0%B8%AA%E0%B9%80%E0%B8%81%E0%B8%A5%E0%B8%AD%E0%B9%82%E0%B8%A3%E0%B8%8B%E0%B8%B4%E0%B8%AA" title="โรคมัลติเพิล สเกลอโรซิส – Thai" lang="th" hreflang="th">ไทย</a></li>
			<li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Multipl_skleroz" title="Multipl skleroz – Turkish" lang="tr" hreflang="tr">Türkçe</a></li>
			<li class="interlanguage-link interwiki-uk"><a href="//uk.wikipedia.org/wiki/%D0%A0%D0%BE%D0%B7%D1%81%D1%96%D1%8F%D0%BD%D0%B8%D0%B9_%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7" title="Розсіяний склероз – Ukrainian" lang="uk" hreflang="uk">Українська</a></li>
			<li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96%E7%97%87" title="多发性硬化症 – Chinese" lang="zh" hreflang="zh">中文</a></li>
			<li class="uls-p-lang-dummy"><a href="#"></a></li>
			<li class="wbc-editpage"><a href="//www.wikidata.org/wiki/Q8277#sitelinks-wikipedia" title="Edit interlanguage links">Edit links</a></li>
		</ul>
	</div>
</div>
			</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 24 March 2014 at 05:00.<br /></li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy.</a> <br/>
Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a class="external" href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/wiki/Multiple_sclerosis" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
					<li id="footer-copyrightico">
						<a href="//wikimediafoundation.org/"><img src="//bits.wikimedia.org/images/wikimedia-button.png" width="88" height="31" alt="Wikimedia Foundation"/></a>
					</li>
					<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="//bits.wikimedia.org/static-1.23wmf18/skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" width="88" height="31" /></a>
					</li>
				</ul>
						<div style="clear:both"></div>
		</div>
		<script>/*<![CDATA[*/window.jQuery && jQuery.ready();/*]]>*/</script><script>if(window.mw){
mw.loader.state({"site":"loading","user":"ready","user.groups":"ready"});
}</script>
<script>if(window.mw){
mw.loader.load(["ext.cite","mediawiki.action.view.postEdit","mobile.desktop","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.DRN-wizard","ext.gadget.charinsert","mw.MwEmbedSupport.style","ext.wikimediaShopLink.core","ext.navigationTiming","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage","skins.vector.collapsibleNav"],null,true);
}</script>
<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=scripts&amp;skin=vector&amp;*"></script>
<!-- Served by mw1188 in 4.554 secs. -->
	</body>
</html>
